US20210401961A1 - Methods of tumor vaccination - Google Patents
Methods of tumor vaccination Download PDFInfo
- Publication number
- US20210401961A1 US20210401961A1 US17/342,893 US202117342893A US2021401961A1 US 20210401961 A1 US20210401961 A1 US 20210401961A1 US 202117342893 A US202117342893 A US 202117342893A US 2021401961 A1 US2021401961 A1 US 2021401961A1
- Authority
- US
- United States
- Prior art keywords
- tumor
- composition
- optionally
- antigen
- vaccination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 744
- 238000002255 vaccination Methods 0.000 title claims abstract description 230
- 238000000034 method Methods 0.000 title claims abstract description 131
- 239000000203 mixture Substances 0.000 claims abstract description 357
- 239000000427 antigen Substances 0.000 claims abstract description 290
- 108091007433 antigens Proteins 0.000 claims abstract description 285
- 102000036639 antigens Human genes 0.000 claims abstract description 285
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 186
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 186
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 186
- 230000028993 immune response Effects 0.000 claims abstract description 147
- 210000004443 dendritic cell Anatomy 0.000 claims description 96
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 94
- 230000002601 intratumoral effect Effects 0.000 claims description 79
- 238000002347 injection Methods 0.000 claims description 58
- 239000007924 injection Substances 0.000 claims description 58
- 241000700605 Viruses Species 0.000 claims description 45
- 238000007912 intraperitoneal administration Methods 0.000 claims description 40
- 239000002105 nanoparticle Substances 0.000 claims description 35
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 33
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 33
- 239000002671 adjuvant Substances 0.000 claims description 32
- 206010033128 Ovarian cancer Diseases 0.000 claims description 31
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 25
- 239000003085 diluting agent Substances 0.000 claims description 23
- 238000001990 intravenous administration Methods 0.000 claims description 22
- 208000005017 glioblastoma Diseases 0.000 claims description 20
- 244000309459 oncolytic virus Species 0.000 claims description 19
- 210000004789 organ system Anatomy 0.000 claims description 19
- 230000008685 targeting Effects 0.000 claims description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 16
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 102100035793 CD83 antigen Human genes 0.000 claims description 13
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- 238000007918 intramuscular administration Methods 0.000 claims description 13
- 238000010255 intramuscular injection Methods 0.000 claims description 13
- 239000007927 intramuscular injection Substances 0.000 claims description 13
- 238000007920 subcutaneous administration Methods 0.000 claims description 11
- 238000001361 intraarterial administration Methods 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 325
- 229920001184 polypeptide Polymers 0.000 abstract description 318
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 318
- 230000000890 antigenic effect Effects 0.000 abstract description 195
- 210000004027 cell Anatomy 0.000 description 106
- 230000002163 immunogen Effects 0.000 description 69
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 59
- 210000004881 tumor cell Anatomy 0.000 description 49
- 210000001744 T-lymphocyte Anatomy 0.000 description 48
- 241000699670 Mus sp. Species 0.000 description 45
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 43
- 239000002953 phosphate buffered saline Substances 0.000 description 29
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 238000002372 labelling Methods 0.000 description 25
- 230000036039 immunity Effects 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 22
- 230000003834 intracellular effect Effects 0.000 description 20
- 230000004614 tumor growth Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 238000010791 quenching Methods 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 230000002519 immonomodulatory effect Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 210000001672 ovary Anatomy 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 10
- -1 i.e. Polymers 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000000171 quenching effect Effects 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 102000005936 beta-Galactosidase Human genes 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 206010039491 Sarcoma Diseases 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000000172 cytosol Anatomy 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010003571 Astrocytoma Diseases 0.000 description 5
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 5
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 5
- 241000542855 Megathura crenulata Species 0.000 description 5
- 201000009906 Meningitis Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000588653 Neisseria Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 230000006057 immunotolerant effect Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000002539 nanocarrier Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000003504 photosensitizing agent Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 201000005505 Measles Diseases 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 208000000474 Poliomyelitis Diseases 0.000 description 4
- 241000702670 Rotavirus Species 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000001806 memory b lymphocyte Anatomy 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 241000203069 Archaea Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101710186862 Factor H binding protein Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 3
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102100035304 Lymphotactin Human genes 0.000 description 3
- 208000005647 Mumps Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 235000019892 Stellar Nutrition 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 208000010805 mumps infectious disease Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 101710188053 Protein D Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 101710132893 Resolvase Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 201000007180 bile duct carcinoma Diseases 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 201000004058 mixed glioma Diseases 0.000 description 2
- 208000001611 myxosarcoma Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 201000006845 reticulosarcoma Diseases 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 201000010965 sweat gland carcinoma Diseases 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 239000000277 virosome Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001372913 Maraba virus Species 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241000542857 Megathura Species 0.000 description 1
- 101100123569 Megathura crenulata KLH1 gene Proteins 0.000 description 1
- 101100123570 Megathura crenulata KLH2 gene Proteins 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241001212279 Neisseriales Species 0.000 description 1
- 101710171321 Neuraminyllactose-binding hemagglutinin Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010073338 Optic glioma Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039231 Rotaviral infections Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 241000776475 Terrabacteria group Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000007235 immunity generation Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 208000008511 optic nerve glioma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Definitions
- APC's antigen-presenting cells
- DCs dendritic cells
- the goal of such a vaccination strategy is to enlarge the pool of tumor-specific T-cells from the na ⁇ ve repertoire, but also to reverse tumor-associated dormancy or anergy through the presentation of tumor antigens, in an effort to break central tolerance to those antigens and to overcome blunting of the CD4 + and/or CD8 + T cell repertoire.
- the difficulty in designing therapeutic tumor vaccines lies in the propensity of the tumor to evade immune control by altering itself to reduce expression of the tumor antigens or by creating an environment (the tumor micro-environment or TME) that is inhibitory for T cells and other cells of the immune system.
- TME tumor micro-environment
- a novel vaccination strategy also referred to as ‘tumor-antigen independent vaccination,’ is provided herein.
- an immune response is raised against an antigen that is immunogenic in a subject (e.g., a human subject), wherein the antigen is of foreign (e.g., non-human) origin.
- Such an immunogen provides for a strong immune response, for instance by activating T-cells from the na ⁇ ve repertoire or by tapping into pre-existing immunity by re-activating memory T-cells and/or memory B-cells that were generated during a prior immune response that was not an immune response against the tumor, and in some cases, was an immune response that occurred prior to establishment of a tumor as the result of common vaccination against infectious diseases.
- This principle overcomes the restrictions of tumor antigen-based vaccination methods described above and is applicable over the entire patient population.
- tumor-antigen independent vaccinations find value in animal healthcare, where readily targetable tumor antigens are poorly available, and where there is a high need for cost efficient immune therapies that are applicable across various species of animals.
- a vaccination strategy comprises administration (e.g., a vaccination step) of an immunogenic composition (e.g., a vaccine composition) comprising an antigen that is foreign or exogenous to a subject (e.g., a human subject) as an immunogen.
- an immunogenic composition e.g., a vaccine composition
- the antigen is highly immunogenic, and can be an antigen that is not, or is only rarely, encountered by the immune system of the subject (e.g., a human subject) except via common vaccination against infectious diseases.
- a vaccination step is performed using a non-human antigen.
- a vaccination step is performed by using a non-tumor antigen.
- a vaccination strategy comprises actively marking a tumor cell (e.g., a tumor-marking step), or its direct or immediate environment (e.g., the tumor site or the tumor micro-environment (TME)) with the same antigen that was employed in the first aspect relating to vaccination.
- the tumor, or its direct environment e.g., the tumor site or the tumor micro-environment (TME)
- TEE tumor micro-environment
- the tumor, or its direct environment e.g., the tumor site or the tumor micro-environment (TME)
- a non-tumor antigen e.g., a non-human, non-tumor antigen
- any antigen that is immunogenic in a subject e.g., a human subject
- a subject e.g., a human subject
- foreign (e.g., non-human) origin e.g., by activating T-cells from the na ⁇ ve repertoire or by tapping into pre-existing immunity against antigens that are not antigens specific to the tumor of interest
- the step of administering the immunogenic composition can be performed prior to or subsequent to tumor marking.
- one or more vaccination steps are performed prior to a tumor-marking step.
- a method for generating an immune response against a tumor in a subject comprising: a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen, wherein the time between the vaccination step and the tumor-marking step is between about one day and about 6 months, is provided.
- the method further comprises one or more booster steps each comprising administering a booster composition to the subject, wherein the booster composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the one or more booster steps occur prior to the tumor-marking step.
- the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor.
- the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.
- the vaccination step comprises intradermally administering the first composition.
- the first composition is prepared for intradermal injection.
- the first composition comprises a diluent or solvent acceptable for intradermal injection.
- the vaccination step comprises intramuscularly administering the first composition.
- the first composition is prepared for intramuscular injection.
- the first composition comprises a diluent or solvent acceptable for intramuscular injection.
- the vaccination step comprises administering the first composition into an organ system that is different than the organ system in which the tumor resides. In certain exemplary embodiments, the vaccination step comprises administering the first composition at a site contralateral to the tumor.
- the vaccination step is performed subsequent to the tumor-marking step. In certain exemplary embodiments, the tumor-marking step is performed subsequent to the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
- the tumor is a solid tumor.
- the solid tumor is glioblastoma or ovarian cancer.
- the first composition comprises a dendritic cell comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell.
- the mature dendritic cell is derived from DCOne.
- the second composition is prepared for intratumoral administration.
- the second composition comprises a tumor targeting component.
- the tumor targeting component is a tumor-specific virus.
- the tumor-specific virus is an oncolytic virus.
- the tumor-specific virus comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the tumor targeting component is a tumor-specific nanoparticle.
- the tumor-specific nanoparticle comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the second composition comprises a dendritic cell comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell.
- the mature dendritic cell is derived from DCOne.
- the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- the subject is a non-tumor antigen-na ⁇ ve subject. In certain exemplary embodiments, the subject has previously been exposed to the non-tumor antigen. In certain exemplary embodiments, the subject has previously mounted an immune response against the non-tumor antigen.
- the subject is a human. In certain exemplary embodiments, the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
- a method for generating an immune response against a tumor in a subject comprising: a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor recall antigen or a nucleic acid encoding the non-tumor recall antigen; and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the recall antigen or a nucleic acid encoding the recall antigen, is provided.
- the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor.
- the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.
- the vaccination step comprises intradermally administering the first composition.
- the first composition is prepared for intradermal injection.
- the first composition comprises a diluent or solvent acceptable for intradermal injection.
- the vaccination step comprises intramuscularly administering the first composition.
- the first composition is prepared for intramuscular injection.
- the first composition comprises a diluent or solvent acceptable for intramuscular injection.
- the vaccination step comprises administering the first composition into an organ system that is different than the organ system in which the tumor resides. In certain exemplary embodiments, the vaccination step comprises administering the first composition at a site contralateral to the tumor.
- the vaccination step and the tumor-marking step are temporally separated. In certain exemplary embodiments, the vaccination step is performed subsequent to the tumor-marking step. In certain exemplary embodiments, the tumor-marking step is performed subsequent to the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
- the tumor is a solid tumor.
- the solid tumor is glioblastoma or ovarian cancer.
- the first composition comprises a dendritic cell comprising the recall antigen or a nucleic acid encoding the recall antigen.
- the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell.
- the mature dendritic cell is derived from DCOne.
- the second composition is prepared for intratumoral administration.
- the second composition comprises a tumor targeting component.
- the tumor targeting component is a tumor-specific virus.
- the tumor-specific virus is an oncolytic virus.
- the tumor-specific virus comprises the recall antigen or a nucleic acid encoding the recall antigen.
- the tumor targeting component is a tumor-specific nanoparticle.
- the tumor-specific nanoparticle comprises the recall antigen or a nucleic acid encoding the recall antigen.
- the second composition comprises a dendritic cell comprising the recall antigen or a nucleic acid encoding the recall antigen.
- the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell.
- the mature dendritic cell is derived from DCOne.
- the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- the subject has previously been exposed to the recall antigen. In certain exemplary embodiments, the subject has previously mounted an immune response against the recall antigen.
- the subject is a human. In certain exemplary embodiments, the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
- a method for generating an immune response against a tumor in a subject comprising: a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof; and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof, is provided.
- the method further comprises one or more booster steps each comprising administering a booster composition to the subject, wherein the booster composition comprises the diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof.
- the one or more booster steps occur prior to the tumor-marking step.
- the diphtheria toxin or detoxified variant thereof is CRM197.
- the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor.
- the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.
- the vaccination step comprises intradermally administering the first composition.
- he first composition is prepared for intradermal injection.
- the first composition comprises a diluent or solvent acceptable for intradermal injection.
- the vaccination step comprises intramuscularly administering the first composition.
- the first composition is prepared for intramuscular injection.
- the first composition comprises a diluent or solvent acceptable for intramuscular injection.
- the vaccination step comprises administering the first composition into an organ system that is different to the organ system in which the tumor resides. In certain exemplary embodiments, the vaccination step comprises administering the first composition at a site contralateral to the tumor.
- the vaccination step and the tumor-marking step are temporally separated. In certain exemplary embodiments, the vaccination step is performed subsequent to the tumor-marking step. In certain exemplary embodiments, the tumor-marking step is performed subsequent to the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
- the tumor is a solid tumor.
- the solid tumor is glioblastoma or ovarian cancer.
- the first composition comprises a dendritic cell comprising CRM197 or a nucleic acid encoding CRM197.
- the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell.
- the mature dendritic cell is derived from DCOne.
- the second composition is prepared for intratumoral administration.
- the second composition comprises a tumor targeting component.
- the tumor targeting component is a tumor-specific virus.
- the tumor-specific virus is an oncolytic virus.
- the tumor-specific virus comprises CRM197 or a nucleic acid encoding CRM197.
- the tumor targeting component is a tumor-specific nanoparticle.
- the tumor-specific nanoparticle comprises CRM197 or a nucleic acid encoding CRM197.
- the second composition comprises a dendritic cell comprising CRM197 or a nucleic acid encoding CRM197.
- the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell.
- the mature dendritic cell is derived from DCOne.
- the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- the subject is a human. In certain exemplary embodiments, the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
- a method for generating an immune response against a tumor in a subject comprising administering to the subject a non-tumor antigen or a nucleic acid encoding the non-tumor antigen at a tumor site, wherein the subject is previously vaccinated with the non-tumor antigen or a nucleic acid encoding the non-tumor antigen, is provided.
- a method for generating an immune response against a tumor in a subject comprising administering to the subject a recall antigen or a nucleic acid encoding the recall antigen at a tumor site, wherein the subject is previously vaccinated with the antigen or a nucleic acid encoding the antigen, and wherein the antigen is a non-tumor antigen, is provided.
- a method for generating an immune response against a tumor in a subject comprising administering to the subject a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof at a tumor site, wherein the subject is previously vaccinated with the diphtheria toxin or detoxified variant thereof or the nucleic acid encoding the diphtheria toxin or detoxified variant thereof, is provided.
- the diphtheria toxin or detoxified variant thereof is CRM197.
- FIG. 4A - FIG. 4B depict tumor growth inhibition in a humanized U87-MG glioblastoma model. Tumor size was monitored three times per week using a digital caliper ( FIG. 4A ). Tumor size at day 18 in vaccinated mice injected as indicated is shown in FIG. 4B .
- FIG. 5A - FIG. 5B depict tumor growth inhibition in a humanized A375 melanoma model. Tumor size was monitored three times per week using a digital caliper ( FIG. 5A ). Tumor size after day 30 in vaccinated mice injected as indicated is shown in FIG. 5B .
- FIG. 6A - FIG. 6D depict anti-KLH IgG ( FIG. 6C-6D ) and IgM ( FIG. 6A-6B ) levels in the serum of mice over time.
- Graphs represent the individual data of anti-KLH IgG and IgM per group (( FIG. 6A and FIG. 6C ) is the glioblastoma group, ( FIG. 6B and FIG. 6D ) is the melanoma group).
- Two-way ANOVA with Dunnet's multiple comparison test was used. * vs vehicle group, * ⁇ 0.05, ** ⁇ 0.01, *** ⁇ 0.001, **** ⁇ 0.0001).
- FIG. 8A - FIG. 8B depict tumor growth in a humanized OV90luc ovarian cancer mouse model.
- Tumor volumes (in mm 3 ) were calculated by the ellipsoid formula (L ⁇ W ⁇ H) ⁇ /6 ( FIG. 8A ).
- Bioluminescence intensity (photons/sec) is depicted ( FIG. 8B ).
- FIG. 9 depicts imaging data showing bioluminescence intensity (total photon flux (Optical) per animal) over time.
- the methods generally comprise a vaccination step comprising administering a first composition to a subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen, and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the same non-tumor antigen (or nucleic acid encoding the same non-tumor antigen).
- immune response includes T-cell mediated and/or B-cell mediated immune responses.
- exemplary immune functions of T cells include, e.g., cytokine production and induction of cytotoxicity in other cells.
- B-cell functions include antibody production.
- immune responses that are indirectly affected by T-cell activation e.g., antibody production and activation of cytokine responsive cells, e.g., macrophages.
- Immune cells involved in the immune response include lymphocytes, such as B cells and T cells (CD4 + and CD8 + cells); antigen presenting cells (e.g., professional antigen presenting cells such as dendritic cells, macrophages, B lymphocytes, Langerhans cells, and non-professional antigen presenting cells such as keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes); natural killer cells; myeloid cells, such as macrophages, eosinophils, mast cells, basophils, and granulocytes.
- the term refers to a T-cell mediated immune response.
- the immune response may in some embodiments be a T cell-dependent immune response.
- immune response against a tumor also includes immune responses against a non-human antigenic polypeptide that is introduced into the tumor micro-environment by intratumoral administration, such as intratumoral administration of (i) dendritic cells, including autologous or allogeneic dendritic cells, loaded with said polypeptide or (ii) viruses comprising a nucleic acid encoding said polypeptide.
- intratumoral administration such as intratumoral administration of (i) dendritic cells, including autologous or allogeneic dendritic cells, loaded with said polypeptide or (ii) viruses comprising a nucleic acid encoding said polypeptide.
- T-cell dependent immune response refers to an immune response wherein either T-cells, B-cells or both T- and B-cell populations are activated, and wherein T-cells further assist T and B cells and other immune cells in executing their function.
- tumor includes reference to cellular material, e.g., a tissue, proliferating at an abnormally high rate.
- a growth comprising neoplastic cells is a neoplasm, also known as a “tumor,” and generally forms a distinct tissue mass in a body of a subject.
- a tumor may show partial or total lack of structural organization and functional coordination with the normal tissue.
- a tumor is intended to encompass hematopoietic tumors as well as solid tumors.
- the tumor is a solid tumor.
- tumor includes reference to the tumor micro-environment or tumor site, i.e., the area within the tumor and the area directly outside the tumorous tissue.
- the tumor micro-environment or tumor site includes an area within the boundaries of the tumor tissue.
- the tumor micro-environment or tumor site includes the tumor interstitial compartment of a tumor, which is defined herein as all that is interposed between the plasma membrane of neoplastic cells and the vascular wall of the newly formed neovessels.
- tumor micro-environment or “tumor site” refers to a location within a subject in which a tumor resides, including the area immediately surrounding the tumor.
- a tumor may be benign (e.g., a benign tumor) or malignant (e.g., a malignant tumor or cancer).
- Malignant tumors can be broadly classified into three major types: those arising from epithelial structures are called carcinomas, those that originate from connective tissues such as muscle, cartilage, fat or bone are called sarcomas, and those affecting hematopoietic structures (structures pertaining to the formation of blood cells) including components of the immune system, are called leukemias and lymphomas.
- Other tumors include, but are not limited to, neurofibromatosis.
- the tumor is a glioblastoma.
- the tumor is an ovarian cancer (e.g., an epithelial ovarian cancer, which can be further subtyped into a serous, a clear cell, an endometrioid, a mucinous, or a mixed epithelial ovarian cancer).
- an ovarian cancer e.g., an epithelial ovarian cancer, which can be further subtyped into a serous, a clear cell, an endometrioid, a mucinous, or a mixed epithelial ovarian cancer.
- Solid tumors are abnormal masses of tissue that can be benign or malignant.
- solid tumors are named for the type of cells that form them (such as sarcomas, carcinomas, and lymphomas).
- solid tumors such as sarcomas and carcinomas, include, but are not limited to, liposarcoma, fibrosarcoma, chondrosarcoma, osteosarcoma, myxosarcoma, and other sarcomas, mesothelioma, synovioma, leiomyosarcoma, Ewing's tumor, colon carcinoma, rhabdomyosarcoma, pancreatic cancer, lymphoid malignancy, lung cancers, breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, adenocarcinoma, basal cell carcinoma, sweat gland carcinoma, squamous cell carcinoma, medullary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary thyroid carcinoma
- Carcinomas that can be amenable to therapy by a method disclosed herein include, but are not limited to, squamous cell carcinoma (various tissues), basal cell carcinoma (a form of skin cancer), esophageal carcinoma, bladder carcinoma, including transitional cell carcinoma (a malignant neoplasm of the bladder), hepatocellular carcinoma, colorectal carcinoma, bronchogenic carcinoma, lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung, colon carcinoma, thyroid carcinoma, gastric carcinoma, breast carcinoma, ovarian carcinoma, adrenocortical carcinoma, pancreatic carcinoma, sweat gland carcinoma, prostate carcinoma, papillary carcinoma, adenocarcinoma, sebaceous gland carcinoma, medullary carcinoma, papillary adenocarcinoma, ductal carcinoma in situ or bile duct carcinoma, cystadenocarcinoma, renal cell carcinoma, choriocarcinoma, Wilm's tumor, seminoma, embryonal carcinoma, cervical carcinoma, testicular carcinoma, na
- Sarcomas that can be amenable to therapy by a method disclosed herein include, but are not limited to, myxosarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, liposarcoma, fibrosarcoma, angiosarcoma, lymphangiosarcoma, endotheliosarcoma, osteosarcoma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, lymphangioendotheliosarcoma, synovioma, and other soft tissue sarcomas.
- the term “subject,” as used herein, refers to the recipient of a method as described herein, i.e., a recipient that can mount a cellular immune response, and is a mammal.
- the subject is a human.
- the subject is a domesticated animal, e.g., a horse, a cow, a pig, a sheep, a dog, a cat, etc.
- the subject is an animal suitable for veterinary healthcare, e.g., a zoo animal.
- the terms “patient” and “subject” may be used interchangeably.
- the subject is a human suffering from a tumor (e.g., a solid tumor).
- the subject is a domesticated animal suffering from a tumor (e.g., a solid tumor).
- the subject is an animal suitable for veterinary healthcare suffering from a tumor (e.g., a solid tumor).
- an “animal suitable for veterinary healthcare” is any animal that is suitable for treatment by a veterinarian, and includes, without limitation, wild animals, domesticated animals, and zoo animals that are capable of mounting a cellular immune response.
- polypeptide refers to a molecule composed of amino acid monomers linearly linked by amide bonds (peptide bonds). As used herein, the term is mutually inclusive of the terms “peptide” and “protein” and includes reference to parts of said polypeptides.
- nucleic acid refers to DNA and RNA including mRNA or cDNA, as well as synthetic congeners thereof.
- the nucleic acid can be a recombinant or synthetic nucleic acid.
- antigen refers generally to a biological molecule which contains at least one epitope specifically recognized by a T-cell receptor, an antibody, or other elements of specific humoral and/or cellular immunity. The whole molecule may be recognized, or one or more portions of the molecule, for instance following intracellular processing of a polypeptide into an MHC peptide antigen complex and subsequent antigen presentation.
- antigenic polypeptide is interchangeable with “polypeptide antigen.” This terminology includes antigenic parts of said polypeptides, for instance produced after intracellular processing of a polypeptide and in the context of a MHC peptide antigen complex.
- a “non-tumor antigen” refers to herein as an antigen that is not derived from a tumor.
- a non-tumor antigen may be a foreign antigen.
- a non-tumor antigen may be a bacterial toxin, e.g., a non-toxic variant of diphtheria toxin.
- antigen or “antigenic” may also be used to refer to a polypeptide that includes modifications, such as deletions, additions and substitutions to the native sequence, as long as the polypeptide maintains the ability to be specifically recognized by T-cell receptors and/or antibodies following vaccination with said polypeptide as an immunogen. These modifications may be deliberate, as through site-directed mutagenesis, or through particular synthetic procedures, or through a genetic engineering approach, or may be accidental, such as through mutations of hosts, which produce the antigens. Synthetic antigens are also included, for example, polyepitopes, flanking epitopes, and other recombinant or synthetically derived antigens (Bergmann et al. (1993) Eur. J. Immunol.
- the antigenic polypeptide contains at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 CD4 + T-helper cell epitope(s) and/or at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 CD8 + cytotoxic T-cell epitope(s).
- immunogenic composition refers to a substance which induces a specific immune response against an immunogen in a subject who is in need of an immune response against said immunogen.
- the composition may include an adjuvant and optionally one or more pharmaceutically-acceptable carriers, excipients and/or diluents.
- the immunogenic composition can be employed in prime-boost vaccination, such as at least 2, 3, 4 or at least 5 immunizations separated in time.
- the immunogenic composition can be an (allogeneic) dendritic cell comprising said immunogen.
- immunogen refers to a compound such as a polypeptide capable of eliciting an immune response that is specifically directed against an antigenic polypeptide as described herein.
- An immunogen is also an antigen, i.e., an antigenic polypeptide.
- an antigen is not necessarily an immunogen.
- the immunogen is used for vaccination (in an immunogenic composition such as a vaccine composition), and the antigenic polypeptide prepared for intratumoral delivery is instead used for marking a tumor as a target for an immune response to be elicited, or as a target for an immune response that is already elicited, in a subject.
- immunogen is also used to refer to a nucleic acid which encodes the non-human antigenic polypeptide as described herein.
- embodiments that describe the antigenic polypeptide also apply to an immunogen as described herein.
- non-human includes polypeptides that are not of human origin, including a bacterial polypeptide, a polypeptide of an organism of the Archaea domain, a fungal polypeptide and a viral polypeptide. Also included are plant polypeptides and non-human mammalian polypeptides such as polypeptides of non-human primates, rodents (e.g., mice and rats), rabbits, pigs, sheep, goats, cows, pigs, horses and donkeys, and birds (e.g., chickens, turkeys, ducks, geese and the like).
- rodents e.g., mice and rats
- rabbits, pigs, sheep, goats, cows, pigs, horses and donkeys e.g., chickens, turkeys, ducks, geese and the like.
- non-human also encompasses synthetic polypeptides, i.e., polypeptides that have an artificial sequence designed by man and that do not occur in nature or are not yet identified in nature.
- the term comprises human polypeptides comprising an amino acid alteration from the native sequence, the alteration providing for immunogenicity in a human subject.
- intratumoral refers to delivery or transport of the antigenic polypeptide, or the nucleic acid encoding said polypeptide, into a tumor.
- intratumoral delivery, or transport, of an antigenic polypeptide as described herein is by intratumoral administration, a route of administration generally known in the art.
- the antigen may be delivered to the tumor via a tumor-specific carrier, such as an oncolytic virus or a gene therapy vector, which have been broadly developed to deliver gene sequences to tumors.
- prepared for intratumoral delivery refers to an antigenic polypeptide as described herein, or a nucleic acid encoding said polypeptide as described herein, that is adapted for intratumoral delivery and/or is in a formulation that allows for intratumoral delivery.
- the preparation used for intratumoral delivery may be composed such that it has a beneficial effect on the interaction between the immune system and the tumor.
- dendritic cells such as autologous or allogeneic dendritic cells
- the polypeptide or nucleic acid as described herein can be comprised in a tumor-delivery vehicle such as a tumor-targeted vehicle including a tumor-specific virus such as an oncolytic virus (or any other virus that selectively replicates in tumor cells) that infects a tumor cell and which allows for (i) expression of said nucleic acid in a tumor cell, and (ii) (subsequently) intracellular processing and antigen presentation (MHC) of said (expressed) polypeptide by said tumor cell.
- a tumor-delivery vehicle such as a tumor-targeted vehicle including a tumor-specific virus such as an oncolytic virus (or any other virus that selectively replicates in tumor cells) that infects a tumor cell and which allows for (i) expression of said nucleic acid in a tumor cell, and (ii) (subsequently) intracellular processing and antigen presentation (MHC) of said (expressed) polypeptide by said tumor cell.
- MHC intracellular processing and antigen presentation
- the skilled person can apply other tumor-targeted delivery vehicles such as a tumor-specific nanoparticle or he can apply intratumoral administration through intratumoral injection in order to deliver said polypeptide or nucleic acid into a tumor.
- the polypeptide or nucleic acid prepared for intratumoral delivery as described herein is comprised in a tumor-targeted vehicle.
- extratumoral refers to a location, e.g., in the body of a subject, that is away (e.g., distal) from a tumor and immediately surrounding tissue (e.g., that may make up the tumor micro-environment).
- compositions for use as described herein elicit an immune response specifically directed against a tumor in a subject.
- specifically directed refers to an immune response that is specific for a tumor.
- the specificity is introduced by a step of marking a tumor with a non-human antigenic polypeptide as a target for an immune response, and by eliciting an immune response against an antigenic part of said non-human antigenic polypeptide (i.e., the target).
- the compositions for use as described herein is for use in eliciting an immune response against a tumor marked as a target for said immune response.
- the compositions for use as described herein is for use in eliciting an immune response against a tumor that is marked as a target for said immune response; wherein said target is a non-human antigenic polypeptide as described herein.
- the non-human antigenic polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery as described herein serves the purpose of marking the tumor as a target for an immune response (polypeptide/nucleic acid for marking a tumor).
- said polypeptide or said nucleic acid prepared for intratumoral delivery marks the tumor as a target for an immune response following intratumoral delivery.
- the term “vaccination step” refers to a step in a method (vaccination strategy) as described herein, wherein a composition comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide is administered to a subject at a site distal to a tumor site.
- a composition comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide is administered to a subject at a site distal to a tumor site.
- the composition in a vaccination step of a method as described herein, is administered at a site that is not the site in which the tumor resides (e.g., not the tumor site).
- the composition is administered at an extratumoral site.
- booster step refers to a step in a method (vaccination strategy) as described herein, wherein a booster composition comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding the antigenic polypeptide is administered to a subject at a site distal to a tumor site.
- a booster step is performed after a vaccination step, wherein the vaccination step results in an immune response against the antigen, and the booster step enhances the immune response against the antigen.
- a booster step results in an enhanced immune response in a subject having pre-existing immunity against, e.g., an antigenic polypeptide (e.g., a non-tumor antigen).
- the vaccination step in a method as described herein is a booster stem, e.g., when the subject has pre-existing immunity against, e.g., a non-tumor recall antigen.
- marking refers to active manipulation of the antigenic state of a tumor by intratumoral delivery of an antigenic polypeptide, or a nucleic acid encoding said polypeptide, as described herein.
- This provides for direct labelling of a tumor cell through intracellular delivery and subsequent processing and presentation of said polypeptide by said tumor cell, or provides for indirect labelling of a tumor via: (i) intracellular delivery and subsequent processing and presentation of said polypeptide by a non-tumor cell in said tumor; or (ii) extracellular delivery of said antigenic polypeptide to said tumor (i.e., extracellular to the cells present in said tumor before marking), for instance by using a dendritic cell that comprises a nucleic acid encoding said polypeptide or that is loaded with said antigenic polypeptide.
- tumor-marking step refers to a step in a method (e.g., a vaccination strategy) as described herein, wherein a composition comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide is administered to a subject at a tumor site.
- the tumor-marking step comprises the use of compositions, methods or technologies which facilitate the delivery of antigens into the cytosol of tumor cells.
- the immunogenic composition as described herein which also comprises said non-human antigenic polypeptide or a nucleic acid encoding said polypeptide, but as an immunogen (polypeptide/nucleic acid for eliciting an immune response), serves the purpose of eliciting an immune response against a tumor that is marked, or to be marked, with said non-human antigenic polypeptide.
- said immunogen is used to elicit an immune response against a tumor that is marked, or is to be marked, with said non-human antigenic polypeptide, or a nucleic acid encoding said antigenic polypeptide, prepared for intratumoral delivery.
- any antigenic polypeptide can be introduced into a tumor to generate a new antigenic target.
- any antigenic polypeptide can be introduced into a tumor to generate new antigenic target that is a B-cell epitope and/or T-cell epitope recognizable by an antibody and/or T-cell receptor, respectively, when an immune response against said target is elicited following administration of an immunological composition as described herein to a subject.
- the skilled person directly understands that: (i) the non-human antigenic polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery as described herein (polypeptide/nucleic acid for marking a tumor); and (ii) the non-human antigenic polypeptide, or a nucleic acid encoding said polypeptide, comprised as an immunogen in an immunogenic composition as described herein (polypeptide/nucleic acid for eliciting an immune response), are matched in that the immunogen, when administered, elicits an immune response that is directed against one or more (target) epitopes established by the polypeptide or nucleic acid for marking the tumor.
- the polypeptides under (i) and (ii) are immunologically matched in that a T-cell epitope and/or a B-cell epitope of the marking polypeptide in a tumor are recognized by, or are reactive with, a T-cell and/or B-cell response elicited by the polypeptide employed as an immunogen. It is thus understood that the polypeptides under (i) and (ii) are based on the same non-human antigenic polypeptide and optionally share an identical antigenic part thereof, optionally at least one B-cell and/or T-cell epitope thereof (i.e., are immunologically matched).
- the elicited immune response is specifically directed to the tumor marked as a target for said immune response.
- the formulations of the said polypeptide used for eliciting an immune response on the one hand and tumor marking on the other hand need not be the same. In fact, the skilled person appreciates that it might be beneficial to use different formulations of the said polypeptide for vaccination and tumor marking.
- T-cell mediated immune response refers to an immune response that is T-cell driven, and where elicitation of another or further immune response is dependent on activation of T-cells.
- the immune response is a T-cell mediated immune response/T-cell dependent immune response.
- T-cell mediated immune response/T-cell dependent immune response for instance through selection of an appropriate antigen of which many have been described in literature including but not limited to bacterial-, fungal-, mollusk-, snail-, insect- or plant-derived antigens to which measurable T cell responses have been documented, or by selecting an appropriate adjuvant or carrier such as a chemical adjuvant, biological adjuvant, protein, viral vaccine, dendritic cell vaccine or any other composition that can be administered as a vaccine composition (Bender et al., J. Exp.
- tumor-specific virus includes reference to any virus that has the capacity to selectively replicate in tumor cells.
- oncolytic virus refers to a virus that preferentially kills tumor cells as compared to normal cells.
- the term refers to viruses that can be engineered to carry a nucleic acid construct encoding a polypeptide, which is to be expressed in a tumor cell after infection of said tumor cell.
- nanoparticle refers to compositions that can carry a compound of interest, such as an antigenic polypeptide as described herein, and which can be functionalized on their surface with tumor-targeting or tumor-specific moieties.
- a compound of interest such as an antigenic polypeptide as described herein
- nanoparticles that can be engineered to actively target tumor cells are micelles and liposomes.
- dendritic cell refers to a professional antigen presenting cell (APC) that can take up an antigen such as an antigenic polypeptide into its cell, and presents the antigen, or an immunogenic part thereof together with an MHC class I complex or MHC class II complex.
- the term includes both immature dendritic cells (“imDC”) and mature dendritic cells (“mDC”), depending on maturity.
- the dendritic cell is a mature dendritic cell.
- the dendritic cell is a mature dendritic cell obtained from a cell of cell line DCOne as deposited under the conditions of the Budapest treaty with the DSMZ under accession number DSMZ ACC3189 on 15 Nov. 2012. The process of obtaining mature dendritic cells from the deposited DCOne cell line is for instance described in EP2931878B1.
- a first aspect relates to a vaccination step comprising the administration of (vaccination with) a first composition (e.g., an immunogenic composition) comprising a non-tumor antigen (e.g., a non-human antigenic polypeptide as an immunogen), or comprising a nucleic acid encoding a non-tumor antigen (e.g., a nucleic acid encoding a non-human antigenic polypeptide).
- the first composition comprises a non-tumor antigen or a nucleic acid encoding a non-tumor antigen.
- the first composition optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- a second aspect relates to a tumor-marking step comprising the administration of (vaccination with) a second composition (e.g., an immunogenic composition) comprising a non-tumor antigen (e.g., a non-human antigenic polypeptide as an immunogen), or comprising a nucleic acid encoding a non-tumor antigen (e.g., a nucleic acid encoding a non-human antigenic polypeptide).
- the second composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the second composition optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- the non-tumor antigen (e.g., non-human antigenic polypeptide) as disclosed herein serves two purposes.
- the first purpose is in generating an immune response.
- the immune response is a T-cell mediated immune response, against the antigen (e.g., non-human antigen, non-tumor antigen), by being incorporated in an immunogenic composition as an immunogen.
- the second purpose is in marking a tumor as a target for said immune response. The skilled person will directly understand that it is necessary that the tumor marking and mounting/generation of an immune response are matched in that the mounted immune response is directed against the tumor thus marked.
- “Matched” means that the immune response (to be) elicited is specifically directed against the antigenic polypeptide actively introduced into the tumor.
- the same or a corresponding antigenic epitope is used in marking the tumor and in elicitation of an immune response. Therefore, in certain embodiments, following the administration of a first composition (e.g., an immunogenic composition) as described herein to a subject, an immune response is elicited that is specifically directed against a tumor that is to be marked (or a tumor that is already marked) as a target for an immune response based on the same antigen.
- a first composition e.g., an immunogenic composition
- the antigenic polypeptide in the second composition for marking, and the antigenic polypeptide in the first composition are matched, in that the immune response that is elicited following administration of the first composition to a subject is directed against a tumor marked with said antigenic polypeptide following intratumoral delivery of the same, or at least immunogenically the same, antigenic polypeptide.
- the immune response elicited following administration of an immunogenic composition as described herein is specifically directed to at least one T-cell epitope and/or B-cell epitope with which the tumor is to be marked (or is marked).
- the non-human antigenic polypeptide in said immunogenic composition is a polypeptide corresponding to the polypeptide used for tumor marking as described herein.
- the immune response elicited following administration of a first composition is a T-cell mediated immune response or a T-cell-dependent immune response. It is within the skilled person's capabilities to identify appropriate immunogens and/or adjuvants that activate the cellular arm of immunity. References that aid the skilled person in selecting appropriate antigens are for instance Bender et al., J. Exp. Med, 182:1663-1671 (1995); Bennett et al., Nature, 393:478-480 (1998); Kalinski and Moser, Nature, 5:251-260 (2005); Van Tenderloo et al., PNAS, 107:31, p.
- suitable antigens include proteins of viral, bacterial, fungal origin; allergens, toxins and venoms, or model antigens of various sources such as chicken egg ovalbumin and keyhole limpet hemocyanin from the giant keyhole limpet, Megathura crenulata .
- a suitable antigen is of bacterial origin.
- a suitable antigen is a diphtheria toxin.
- a suitable antigen is a non-toxic variant of diphtheria toxin.
- a suitable antigen is CRM197.
- Other suitable antigenic polypeptides are polypeptides employed in a prior vaccination of a subject, such as recall antigens, which are described in more detail herein below. Common vaccines, used in such vaccinations, may include different antigenic polypeptides, which can be multivalent in that they comprise different microbial (recall) antigens with or without adjuvants.
- recall antigen refers to an antigen (e.g., antigenic polypeptide) which has previously (e.g., prior to the occurrence of a tumor in the subject or prior to a tumor-marking step) been encountered by a subject.
- Recall antigens are those which have previously been encountered by the subject and for which there exists pre-existing memory lymphocytes in the subject.
- a recall antigen refers to an antigen (e.g., antigenic polypeptide) for which pre-existing memory lymphocytes exist in the subject, e.g., as a result of prior infections or vaccinations.
- a recall antigen refers to an antigenic polypeptide which has previously been encountered by a subject via vaccination.
- the recall antigen is an antigenic polypeptide for which there is pre-existing immunity in said subject.
- the skilled person has multiple methods and means at his disposal that he can routinely apply in order to provide mounting of an immune response against a non-human antigenic polypeptide as an immunogen comprised in an immunogenic composition as described herein.
- references that aid the skilled person in selecting adjuvants that direct the immune response towards cellular immunity are for instance Pashine et al., Nature Medicine Supplement, 11: S63-S68 (2005) and Awate et al., Frontiers in Immunology, 4:114, p. 1-10 (2013), the disclosures of which are incorporated by reference herein in their entirety.
- adjuvants are aluminum mineral salts, oil-in-water emulsions, liposomes, toll-like receptor agonists or combinations thereof.
- adjuvants include liposomes, virosomes, MF59, Montanide, ISCOMs, QS-21, aluminum, ASO4, Poly I:C, MPL, GLA, imiquimod, CpG ODN, chitin, chitosan, ⁇ -glucan, or combinations thereof.
- compositions for use according to methods as described herein optionally comprise: a dendritic cell comprising the non-tumor antigen; a T-cell immune response-eliciting adjuvant; a T-cell immune response-eliciting virus or a virus-like particle comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen; or a combination thereof.
- compositions for use in a method as described herein also apply to aspects for instance the (i) non-tumor antigen (e.g., non-human antigenic polypeptide), or nucleic acid encoding the same for use in a method as described herein, (ii) immunogenic composition for use in a method as described herein, (iii) a method for eliciting an immune response, (iv) a method of treatment, and other aspects for use in a method as described herein where appropriate.
- non-tumor antigen e.g., non-human antigenic polypeptide
- nucleic acid encoding the same for use in a method as described herein
- immunogenic composition for use in a method as described herein e.g., a method for eliciting an immune response
- a method of treatment e.g., a method of treatment, and other aspects for use in a method as described herein where appropriate.
- a method of the present disclosure employs the use of a first composition and a second composition.
- the first composition comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide.
- the first composition comprises an antigenic polypeptide.
- the first composition comprises a nucleic acid encoding an antigenic polypeptide.
- the first composition comprises a non-tumor antigen.
- the first composition comprises a nucleic acid encoding a non-tumor antigen.
- the second composition comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide (i.e., the second composition comprises an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide which is the same as the antigenic polypeptide as in the first composition, or at least, immunologically the same antigenic polypeptide as in the first composition).
- the second composition comprises an antigenic polypeptide.
- the second composition comprises a nucleic acid encoding the antigenic polypeptide.
- the second composition comprises a non-tumor antigen.
- the second composition comprises a nucleic acid encoding a non-tumor antigen.
- the first composition and/or the second composition may comprise a dendritic cell comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide.
- the first composition comprises a dendritic cell comprising an antigenic polypeptide or a nucleic acid encoding an antigenic polypeptide.
- the second composition comprises a dendritic cell comprising an antigenic polypeptide or a nucleic acid encoding an antigenic polypeptide.
- the first composition comprises a dendritic cell comprising a non-tumor antigen or a nucleic acid encoding a non-tumor antigen.
- the second composition comprises a dendritic cell comprising a non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the dendritic cell is employed as a dendritic cell vaccine, provided that such cells are loaded with the antigenic polypeptide as described herein.
- a composition e.g., a first composition or a second composition
- a composition comprises a mature dendritic cell differentiated from a precursor cell line.
- a composition e.g., a first composition or a second composition
- the dendritic cell is a cell of cell line DCOne as deposited at the DSMZ under accession number DSMZ ACC3189 on 15 Nov. 2012.
- the first composition and/or the second composition each comprise a dendritic cell of cell line DCOne comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding the antigenic polypeptide. Loading strategies for dendritic cells are discussed herein.
- a pharmaceutically effective amount of a composition is administered.
- an “effective amount” or a “pharmaceutically effective amount” of, e.g., a first composition or a second composition refers to an amount effective, at dosages and for periods of time necessary to achieve an immune response.
- an effective amount is sufficient to induce an immune response against an antigenic polypeptide (e.g., non-tumor antigen), optionally comprised in a dendritic cell.
- An effective amount is sufficient to induce an immune response against a tumor that has been marked using an antigenic polypeptide (e.g., non-tumor antigen) as described herein.
- a first composition and/or a second composition as described herein may comprise any adjuvant known to those in the art.
- Adjuvants known in the art regardless of the route of administration, may be employed to improve/enhance the immunogenicity of an antigenic polypeptide (e.g., a non-tumor antigen) comprised within a composition of the present disclosure.
- Adjuvants enhance the immunogenicity of an antigen (e.g., a composition comprising a non-tumor antigen) but are not necessarily immunogenic themselves.
- Adjuvants have been used by those of skill in the art to improve immune responses to, e.g., vaccines.
- Adjuvants may be intrinsic or extrinsic.
- Intrinsic adjuvants may be derived from killed or attenuated bacteria used as vaccines.
- Extrinsic adjuvants maybe an immune modulating substance non-covalently linked to antigens and are formulated to enhance immune responses.
- the first composition and/or the second composition may comprise a T-cell immune response-eliciting adjuvant.
- T-cell immune response-eliciting refers to enhancing CD4+ and/or CD8+ T-cell immune responses or driving the immune response towards CD4+ and/or CD8+ T-cell activation.
- adjuvants such as liposomes, virosomes, MF59, Montanide, ISCOMs, QS-21, aluminum, ASO4, Poly I:C, MPL, GLA, imiquimod, CpG ODN, chitin, chitosan, ⁇ -glucan, or combinations thereof.
- adjuvants such as liposomes, virosomes, MF59, Montanide, ISCOMs, QS-21, aluminum, ASO4, Poly I:C, MPL, GLA, imiquimod, CpG ODN, chitin, chitosan, ⁇ -glucan, or combinations thereof.
- adjuvants may be used specifically for parenteral modes of administration.
- adjuvants include, e.g., aluminum compounds (such as aluminum phosphate and aluminum hydroxide).
- the antigen can be precipitated with, or adsorbed onto, an aluminum compound according to standard protocols.
- Other adjuvants for parenteral modes of administration, as well as intratumoral or peri-tumoral modes of administration, are known to those of skill in the art.
- a first composition and/or a second composition as described herein may comprise a virus, for example, a T-cell immune response-eliciting virus, or a virus-like particle (VLP), comprising an antigenic polypeptide (e.g., non-tumor antigen) or a nucleic acid encoding the antigenic polypeptide.
- a virus for example, a T-cell immune response-eliciting virus, or a virus-like particle (VLP), comprising an antigenic polypeptide (e.g., non-tumor antigen) or a nucleic acid encoding the antigenic polypeptide.
- viruses especially T-cell immune response-eliciting viruses or VLPs, have been described extensively for vaccination purposes.
- T-cell immune response-eliciting viruses or VLPs are for instance cowpox (vaccinia) viruses or derivatives thereof such as modified vaccinia virus Ankara (MVA), adenovirus or adeno-associated viruses and VLP's based on human papillomavirus, hepatitis B virus or VLP's engineered to present different tumor antigens.
- vaccinia cowpox
- MVA modified vaccinia virus Ankara
- VLP's based on human papillomavirus hepatitis B virus or VLP's engineered to present different tumor antigens.
- a composition as described herein may comprise an oncolytic virus.
- Viruses that have been clinically tested to be oncolytic include, without limitation, adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus, and vaccinia.
- the term “pharmaceutical composition” or “pharmaceutical formulation” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective (e.g., permit an antigenic polypeptide contained therein to be immunogenic), and which contains no additional unacceptably toxic components, with respect to toxicity when administered to a subject.
- a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation and/or composition, other than an active ingredient, which is nontoxic to a subject.
- Pharmaceutically acceptable carriers include, without limitation, a stabilizer, excipient, buffer, or preservative. In certain embodiments, the choice of carrier is determined in part by the particular method of administration. Accordingly, there are a variety of suitable formulations and compositions. Various formulations and compositions are known in the art that are suitable for, e.g., intratumoral administration, intramuscular administration, and other routes of administration.
- the pharmaceutical composition can contain preservatives.
- Suitable preservatives may include, e.g., propylparaben, methylparaben, benzalkonium chloride, and sodium benzoate.
- a mixture of two or more preservatives is used. The preservative or mixtures thereof are typically present in an amount of about 0.0001% to about 2% by weight of the total composition.
- Pharmaceutically acceptable carriers are generally nontoxic to subjects administered compositions according to methods described herein at the dosages and concentrations employed, and include, but are not limited to: buffers such as citrate, phosphate, and other organic acids; antioxidants including methionine and ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; hydrophilic polymers such as polyvinylpyrrolidone; proteins, such as gelatin, immunoglobulins, or serum albumin; preservatives (such as benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; octadecyldimethylbenzyl ammonium chloride; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; hexamethonium chloride; 3-pentano
- buffering agents are included in the compositions. Suitable buffering agents include, for example, sodium citrate, citric acid, potassium phosphate, phosphoric acid, and various other acids and salts. In certain embodiments, a mixture of two or more buffering agents is used. The buffering agent or mixtures thereof are typically present in an amount of about 0.001% to about 4% by weight of the total composition. Methods for preparing administrable pharmaceutical compositions are known to those in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).
- compositions and formulations described herein can include aqueous solutions.
- the formulation or composition may also contain more than one active ingredient useful for the particular indication, disease, or condition (e.g., tumor type) being treated using a method as described herein.
- active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
- Formulations and compositions include those for oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration.
- Formulations and compositions include those for any one of various routes of administration known in the art to those of skill in the art.
- the compositions are administered parenterally.
- parenteral includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration.
- compositions and formulations are provided as sterile liquid preparations, e.g., suspensions, emulsions, dispersions, viscous compositions, or isotonic aqueous solutions, which may in some embodiments be buffered to a selected pH.
- compositions and formulations are provided as gels, other viscous compositions, and solid compositions. Viscous compositions, can be formulated within the appropriate viscosity range to provide longer contact periods with specific tissues.
- Liquid or viscous compositions can comprise carriers, which can be a solvent or dispersing medium containing, e.g., saline, phosphate buffered saline, water, polyol (e.g., propylene glycol, liquid polyethylene glycol, glycerol) and suitable mixtures thereof.
- carriers can be a solvent or dispersing medium containing, e.g., saline, phosphate buffered saline, water, polyol (e.g., propylene glycol, liquid polyethylene glycol, glycerol) and suitable mixtures thereof.
- Sterile injectable solutions can be prepared by incorporating into the compositions a solvent, such as in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, dextrose, or the like.
- a suitable carrier such as sterile water, physiological saline, glucose, dextrose, or the like.
- the compositions can contain gelling or viscosity enhancing additives, pH buffering agents, auxiliary substances such as wetting, dispersing, or emulsifying agents (e.g., methylcellulose), flavoring agents, colors, and/or preservatives, depending upon the route of administration and the preparation desired. Standard texts available to those having knowledge in the art may in some aspects be consulted to prepare suitable preparations.
- compositions can be kept sterile from or of the action of microorganisms by various antibacterial and antifungal agents, e.g., chlorobutanol, parabens, phenol, and sorbic acid.
- Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- a composition for use in a method as described herein comprises an antigenic polypeptide (e.g., a non-tumor antigen), or a nucleic acid encoding the antigenic polypeptide.
- an antigenic polypeptide e.g., a non-tumor antigen
- the antigenic polypeptide is in a composition for intratumoral administration
- the antigenic polypeptide is tumor-targeted or prepared for intratumoral delivery, or the nucleic acid encoding the antigenic polypeptide, is either tumor-targeted or is prepared for intratumoral administration.
- tumor antigen-independent vaccination can be realized with multiple methods and means known in the art, both with regard to the marking of a tumor, as well as with the vaccination that mounts an immune response against a marked tumor as already described.
- marking or labelling of a tumor as a target for an immune response by employing a non-human antigenic polypeptide as described herein occurs in vivo, not in vitro or ex vivo.
- the antigenic polypeptide or nucleic acid as described herein can be prepared for intratumoral delivery in a variety of ways, generally well known in the art. For instance, preparing may involve tumor-targeting of said polypeptide or nucleic acid, e.g., by preparing a tumor-targeting composition comprising said polypeptide or nucleic acid.
- a tumor-targeting composition comprises the polypeptide or nucleic acid in such a way that it is rendered tumor-specific.
- intratumoral delivery is effectuated on the basis of specificity for tumor tissue as compared to non-tumor tissue. Tumor specificity also indicates that it may allow for homing to a tumor so as to provide for intratumoral delivery.
- the polypeptide prepared for intratumoral delivery, or the nucleic acid encoding said polypeptide is tumor-targeted by using one or more of, e.g., a tumor-specific virus, including an oncolytic virus, comprising a nucleic acid encoding said polypeptide; a tumor-specific nanoparticle comprising said polypeptide or a nucleic acid encoding said polypeptide.
- said polypeptide or nucleic acid is tumor-targeted by using a tumor-targeting antibody, peptide, small molecule, or nucleic acid aptamer fused to said polypeptide or nucleic acid.
- Another way of tumor-targeting a polypeptide or nucleic acid as described herein involves the preparation of an oncolytic virus that comprises a nucleic acid encoding an antigenic polypeptide as described herein, which is engineered to express said nucleic acid into a tumor cell.
- That oncolytic viruses can be used to specifically target tumor cells is extensively described in the art, for instance in Lawler et al., JAMA Oncol. 1; 3(6):841-849 (2017); Howells et al., Front Oncol. 7:195 (2017), the disclosures of which are incorporated by reference herein in their entireties.
- oncolytic viruses can be modified to engage tumor cells. It is also well-known in the art that oncolytic viruses can be used to deliver a nucleic acid construct encoding a polypeptide into a tumor cell, said virus being engineered to express said polypeptide into a tumor cell (Hutzler et al., Scientific Reports, 7: 16892 (2017); Grossardt et al., Human Gene Therapy, 24:644-654 (2013); Andtbacka et al., Journal of Clinical Oncology, 22:25, p.
- an antigenic polypeptide as described herein is presented by the MHC system of a tumor cell upon expression of said nucleic acid as described herein in a cell of said tumor to thereby mark said tumor as a target for an immune response.
- oncolytic viruses examples include Adenovirus, Herpes simplex virus, Pox virus, Coxsackie virus, Maraba virus, Poliovirus, Measles virus, Newcastle Disease virus (Lal and Rajala, Cancer Gene Therapy, DOI 10.1038/s41417-018-0018-1 (2016); Haddad, Frontiers in Immunology, 7:96 (2017); Bommareddy et al., Nature Reviews Immunology (2016), the disclosures of which are incorporated by reference herein in their entireties).
- a tumor-specific virus such as an oncolytic virus may be prepared in a pharmaceutical formulation adapted for parenteral administration.
- a pharmaceutical formulation generally comprises a carrier such as for instance an aqueous or oily solution, dispersion, emulsion and/or suspension.
- Parenteral administration involves the injection or infusion into a body tissue or body fluid, whereby in certain embodiments, a syringe, needle, or catheter is used.
- the carrier is an aqueous solution, and in certain embodiments, distilled sterile water, saline, buffered saline, or another pharmaceutically acceptable excipient for injection.
- parenteral modes of administration are intravenous, intra-arterial, intra-peritoneal, subcutaneous, intramuscular and intratumoral administration, which are well known to the person skilled in the art.
- a mode of administration of a tumor-specific virus such as an oncolytic virus is intravenous or intratumoral administration (Marelli et al., Frontiers in Immunology, 9:866 (2016), the disclosure of which is incorporated by reference herein in its entirety).
- the dose to be administered of a tumor-specific virus such as an oncolytic virus is a pharmaceutically effective dose, i.e., a dose sufficient to deliver an antigenic polypeptide or nucleic acid as described herein into a tumor. It is routine practice to determine a dosing regimen for a tumor-specific virus.
- An alternative way of tumor-targeting a polypeptide or nucleic acid as described herein involves the preparation of a tumor-specific nanoparticle comprising an antigenic polypeptide or nucleic acid as described herein, the latter being engineered to express said nucleic acid in a tumor cell after delivery.
- a nanoparticle which comprises a nanocarrier loaded or combined with for instance a polypeptide of interest, are extensively described in relation to specifically/selectively targeting (homing to) tumor cells and to subsequently deliver for instance a medicament such as a polypeptide to said tumor cell.
- tumor-specific delivery methods including, without limitation, use of nanoparticles, use of liposomes, and use of photochemical processes (e.g., photochemical internalization) may be used to enhance the delivery of an antigen (e.g., an antigenic polypeptide (e.g., a non-tumor antigen), or a nucleic acid encoding the antigenic polypeptide) into the cytosol of a tumor cell.
- an antigen e.g., an antigenic polypeptide (e.g., a non-tumor antigen), or a nucleic acid encoding the antigenic polypeptide
- Photochemical internalization refers to a delivery method which involves the use of light and a photosensitizing agent for introducing otherwise membrane-impermeable molecules into the cytosol of a target cell, but which does not necessarily result in destruction or death of the target cell.
- the molecule to be internalized or transferred is applied to the cells in combination with a photosensitizing agent. Exposure of the cells to light of a suitable wavelength activates the photosensitizing agent which in turn leads to disruption of the intracellular compartment membranes and the subsequent release of the molecule into the cytosol.
- the interaction between the photosensitizing agent and light is used to affect the cell such that intracellular uptake of the molecule is improved.
- photochemical internalization as well as various photosensitizing agents are described in PCT Publication Nos. WO 96/07432, WO 00/54708, WO 01/18636, WO 02/44396, WO 02/44395, and WO 03/020309, U.S. Pat. Nos. 6,680,301, 5,876,989, the disclosures of which are incorporated by reference herein in their entireties.
- photochemical internalization is used to deliver an antigen into the cytosol of a tumor cell.
- photochemical internalization is used to enhance the delivery of an antigen into the cytosol of a tumor cell.
- the nanoparticle, or nanocarrier as main part of the nanoparticle can be a polymeric nanoparticle, a micelle, a liposome, a nanogel or a carbon nanotube.
- a particle or carrier can be loaded with a compound of interest (such as a polypeptide) and actively targeted to a tumor by decorating such a particle or carrier with for instance antibodies or antibody fragments specific for a tumor antigen expressed on the surface of a tumor cell (see also the aforementioned references).
- Tumor-targeting moieties for a nanoparticle can in principle be any biological or chemical structure that displays affinity for a molecule expressed on a tumor cell, such as a peptide, oligopeptide or polypeptide, a protein, a hormone, a vitamin, an enzyme, a ligand of a tumor antigen or an antibody or antibody fragment that specifically binds to a tumor antigen.
- receptor-mediated endocytosis allows for uptake of a nanocarrier by a tumor cell, thereby providing intracellular delivery of for instance a polypeptide of interest, which can be intracellularly processed and subsequently presented as an antigen in an MHC complex by a tumor cell.
- receptor-mediated endocytosis allows for uptake of a nanocarrier by said cell, thereby providing intracellular delivery of for instance a polypeptide of interest in a tumor, which can be intracellularly processed and subsequently presented as an antigen in an MHC complex by said cell in said tumor.
- tumor-specific (or tumor-targeted) nanoparticles that can be employed for intratumoral delivery of an antigenic polypeptide or nucleic acid as described herein, are for instance poly(propylene) sulfide (PPS) nanoparticles, gold nanoparticles, PLGA nanoparticles, artificial exosomes, micelles or dendrimers.
- PPS poly(propylene) sulfide
- a tumor-specific nanoparticle as described herein is prepared in a pharmaceutical formulation adapted for parenteral administration.
- a pharmaceutical formulation generally comprises a carrier such as for instance an aqueous or oily solution, dispersion, emulsion and/or suspension.
- Parenteral administration involves the injection or infusion into a body tissue or body fluid, whereby in some cases, a syringe, needle, or catheter is used.
- the carrier is an aqueous solution, and in certain embodiments, the carrier is distilled sterile water, saline, buffered saline, or another pharmaceutically acceptable excipient for injection.
- parenteral modes of administration are intravenous, intra-arterial, intra-peritoneal, subcutaneous, intramuscular and intratumoral administration, which are well known to the person skilled in the art.
- a mode of administration of a tumor-specific nanoparticle is intravenous or intratumoral administration.
- the dose of tumor-specific nanoparticle to be administered is a pharmaceutically effective dose, i.e., a dose sufficient to deliver an antigenic polypeptide or nucleic acid as described herein into a tumor.
- a pharmaceutically effective dose i.e., a dose sufficient to deliver an antigenic polypeptide or nucleic acid as described herein into a tumor.
- the antigenic polypeptide or the nucleic acid as described herein are prepared for intratumoral delivery by being in a form that allows for intratumoral injection.
- tumor-targeted compositions as described herein can also be administered intratumorally.
- pharmaceutical formulations that are adapted for intratumoral injection, which may comprise a carrier such as for instance an aqueous or oily solution, dispersion, emulsion and/or suspensions.
- the antigenic polypeptide and/or nucleic acid are, In certain embodiments, comprised in a dendritic cell, or the antigenic polypeptide is in an aqueous suspension or solution.
- the antigenic polypeptide and/or nucleic acid can be comprised in a virus. It is thus explicitly envisaged herein that marking of a tumor with an antigenic polypeptide can occur at a tumor cell, but does not necessarily require intracellular processing and antigen presentation by a tumor cell itself.
- such intracellular processing can also be effectuated by other cell types in the tumor, including immune cells such as phagocytic cells—of which macrophages are an example—or fibroblasts.
- marking of a tumor can be performed by antigen processing through the MHC system of the dendritic cell itself which dendritic cell is intratumorally injected.
- dendritic cells in particular allogeneic dendritic cells, may attract endogenous immune cells including NK cells and cross-prime dendritic cells which enforces the immune response in the tumor (Laurell et al. 2017, J for Immunother. Of Cancer 5: 52, the disclosures of which is incorporated by reference herein in its entirety).
- the skilled person is well aware of methods and means relating to loading of dendritic cells with an antigenic polypeptide or with a nucleic acid, such as mRNA, encoding such a polypeptide. See for instance Van Nuffel et al., ISBT Science Series, 8, 161-164 (2013); WO 2014/006058 A1; WO 2009/034172 A1, the disclosures of which are incorporated by reference herein in their entireties.
- the skilled person is well aware of methods and means for intratumoral injection of dendritic cells. See for instance US 2004/0057935 A1; Cripe et al., Molecular Therapy, 23: 3, p.
- said polypeptide prepared for intratumoral delivery, or said nucleic acid encoding said polypeptide is for intratumoral administration and is in the form of a dendritic cell.
- the dendritic cell is a (mature) dendritic cell obtained from a cell of cell line DCOne as described herein, comprising said polypeptide or said nucleic acid encoding said polypeptide as described herein.
- a person skilled in the art can routinely define a dosing regimen that suits intratumoral administration of a dendritic cell comprising an antigenic polypeptide or a nucleic acid encoding said polypeptide (such as an mRNA) as described herein. The same applies to an aqueous suspension or solution comprising an antigenic polypeptide as described herein.
- tumor marking can be effectuated via multiple different methods and means, as long as the tumor is marked with an antigenic polypeptide as described herein.
- tumor marking does not have to be effectuated exclusively by intracellular processing of antigenic polypeptides by tumor cells or other cell types in the tumor.
- the antigenic polypeptides prepared for intratumoral delivery are extracellular in the tumor and are thus not internalized by cells in said tumor.
- the presence of an extracellular antigenic polypeptide in the tumor will attract immune cells activated prior to marking by a vaccination step as described herein. In certain embodiments, such a vaccination step, and subsequent generation of immunity, is performed prior to tumor marking.
- polypeptide, or nucleic acid encoding said polypeptide, prepared for intratumoral delivery are, in certain embodiments, accompanied by immuno-modulatory compounds, such as a chemokine and/or cytokine, that modulates the tumor, in certain embodiments, the tumor site or TME, to increase susceptibility to an immune response, in some cases to convert at least partially an immuno-tolerant tumor environment into an immuno-sensitive tumor environment or to facilitate (optimal) T-cell functionality in the tumor site or TME.
- immuno-modulatory compounds such as a chemokine and/or cytokine
- Such an immunomodulatory compound is in some cases included in an tumor-specific virus, tumor-specific nano-particle, dendritic cell, or aqueous suspension or solution as described herein, either in the form of a polypeptide, or as a nucleic acid encoding such an polypeptide.
- examples of such immunomodulatory compounds are e.g., GM-CSF, CCRS, XCL1, CCL20 and CCL21 (Mohan et al., Immunobiology, 223:477-485 (2016); He et al., Journal of Experimental & Clinical Cancer Research, 29:37 (2010); Nguyen-Hoai et al., Cancer Gene Therapy, 19: 69-76 (2012), the disclosures of which are incorporated by reference herein in their entireties).
- said antigenic polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery is in a composition that also comprises an immuno-modulatory compound (such as an immuno-modulatory polypeptide or a nucleic acid encoding said immuno-modulatory polypeptide), that converts at least partially an immuno-tolerant tumor site or TME into an immuno-sensitive tumor site or TME, and/or facilitates T-cell functionality in the tumor site or TME.
- said immuno-modulatory compound is an immunomodulatory polypeptide, or a nucleic acid encoding said immuno-modulatory polypeptide.
- the immuno-modulatory polypeptide is, or encodes for, GM-CSF, CCRS, XCL1 or CCL20, human GM-CSF, CCRS, XCL1 or CCL20.
- such an immuno-modulatory compound facilitates T-cell functionality in the tumor site or TME.
- immuno-tolerant TME refers to a well-established phenomenon wherein the environment within a tumor provides for tolerance of, or insensitivity to, an antitumor immune response.
- a tumor site or TME is immuno-tolerant if it is more tolerant of, or more insensitive to, an immune response directed against a tumor in said TME, as compared to an immune response directed against a target in an environment outside said tumor, such as for instance an environment in or near healthy cells or healthy tissue.
- immuno-sensitive TME or “immuno-sensitive tumor site,” as used herein, refers to a situation wherein a tumor is sensitive or susceptible to an antitumor immune response.
- tumor antigen includes both tumor associated antigens (TAAs) and tumor specific antigens (TSAs), including tumor neo-antigens.
- TAAs tumor associated antigens
- TSAs tumor specific antigens
- a tumor associated antigen is an antigen that is expressed on the surface of a tumor cell in higher amounts than is observed on normal cells or an antigen that is expressed on normal cells during fetal development.
- a tumor specific antigen is an antigen that is unique to tumor cells and is not expressed on normal cells.
- tumor antigen includes TAAs or TSAs that have been already identified and those that have yet to be identified.
- any antigenic polypeptide can be employed insofar it is immunogenic in a human subject. This includes both antigenic polypeptides of human and non-human origin. Therefore, an antigenic polypeptide can be a human or non-human antigenic polypeptide that is immunogenic in a human subject. In certain embodiments, the antigenic polypeptide is non-human. It is nonetheless explicitly envisaged herein that in aspects and/or embodiments that recite the term “non-human antigenic polypeptide,” that aspect or embodiment can be amended so as to refer to “human antigenic polypeptide,” or the term “human antigenic polypeptide” can be added in such aspects and/or embodiments.
- Human antigenic polypeptides that are immunogenic in a human subject are for instance embryonic, ovarian or testis polypeptides. This applies for instance to NY-ESO-1, WT-1 and the MAGE antigens (see for instance Cheever et al, Clin Cancer Res; 15:5323-5337 (2009); Vigneron et al, Cancer Immunity, 13:15 (2013) the disclosures of which are incorporated by reference herein in their entireties).
- the non-human antigenic polypeptides that are to be employed as the immunogen and marker in aspects of a method as described herein are not previously encountered by a subject as part of an immune response against a tumor.
- the antigenic polypeptides are non-tumor antigens.
- the antigenic polypeptides are antigens that have not previously been encountered by the immune system of the subject and to which a subject is thus immunologically na ⁇ ve, or are antigenic polypeptides previously encountered by a subject, but not as part of an immune response against a tumor, and in some cases for which protective immunity (memory T-cells and/or B-cells) exists.
- an non-human antigenic polypeptide as described herein is rarely if ever encountered (by the immune system) by a large portion of the human population intended for potential vaccination or is an antigenic polypeptide against which immunity pre-exists (is present in a subject), wherein said immunity is not directed against a tumor.
- the latter form of immunity can for instance be provided by a prior vaccination against an infectious disease earlier in life, including vaccination against hepatitis, such as hepatitis A and/or B, diphtheria, tetanus, pertussis, influenza, Haemophilus influenzae type b, polio (poliomyelitis), measles, mumps, rubella, varicella, human papillomavirus, Streptococcus pneumoniae (pneumonia), Neisseria meningitides (meningitis) or rotaviruses (rotaviral infection).
- hepatitis such as hepatitis A and/or B, diphtheria, tetanus, pertussis, influenza, Haemophilus influenzae type b, polio (poliomyelitis), measles, mumps, rubella, varicella, human papillomavirus, Streptococcus pneumoniae (pneumonia), Neisseria
- non-human antigenic polypeptides for use according to a method as described herein are immunogenic polypeptides of one or more of hepatitis, including hepatitis A and/or B, diphtheria, tetanus, pertussis, influenza, Haemophilus influenzae type b, polio, measles, mumps, rubella, varicella, human papillomavirus, Streptococcus pneumoniae, Neisseria meningitides or rotaviruses.
- a non-human antigen polypeptide as described herein is a microbial polypeptide employed in a prior vaccination of said subject.
- the prior vaccination was against an infectious disease.
- the prior vaccination was against hepatitis A and/or B; diphtheria; tetanus; pertussis; influenza; Haemophilus influenzae type b; polio; measles; mumps; rubella; varicella; human papillomavirus, Streptococcus pneumoniae, Neisseria meningitides or rotaviruses.
- polypeptide employed in a prior vaccination could be administered in different forms, such as part of (i) subunit vaccine, (ii) inactivated or attenuated micro-organism, (iii) toxoid vaccine (i.e., vaccine comprising inactivated toxins), etc.
- a non-human antigenic polypeptide as described herein is a polypeptide selected from the group formed by VP3 from hepatitis A virus, including VP3 as identified in UniProtKB Acc. No. P08617, last modified: Aug. 1, 1988—v1; tetanus toxin from Clostridium tetani , including tetanus toxin as identified in UniProtKB Acc. No. P04958, last modified Jan. 23, 2007—v2; pertussis toxin from Bordetella pertussis , including pertussis toxin as identified in UniProtKB Acc. No. P04977, last modified: Aug.
- glycoprotein E1 or E2 from rubella virus including glycoprotein E1 or E2 as identified in UniprotKb Acc. No. P08563, last modified: May 30, 2006—v2; immediate early 62 (1E62) protein from varicella zoster virus, including 1E62 protein as identified in UniprotKb Acc. No. P09310, last modified: Jul. 1, 1989—v1; E6 or E7 protein from HPV16 or HPV18, including E6 or E7 protein as identified in UniprotKb Acc. Nos. P03126 (last modified: Jul. 21, 1986-v1), P03129 (last modified: Jul. 21, 1986—v1), P06463 (last modified: Jan.
- B2CQ00 (last modified May 20, 2008—v1) or nadA as identified in UniprotKb Acc. No. Q9K105 (last modified Oct. 1, 2000—v1); VP8 or VP6 from rotaviruses, including VP8 as identified in UniprotKb Acc. No. P12473 (last modified: Mar. 24, 2009—v2) or VP6 as identified in UniprotKb Acc. No. P04509 (last modified: May 30, 2000—v2); and diphtheria toxin from Corynebacterium diphtheria , including a detoxified variant thereof referred to as CRM-197.
- an antigenic polypeptide as described herein is a recall antigen. In certain embodiments, an antigenic polypeptide as described herein is a microbial recall antigen.
- the antigenic polypeptide chosen is matched with existing immunity (e.g., memory immunity in the form of memory T-cells and/or B-cells) in a subject, such that vaccination with such an antigenic polypeptide as immunogen, and tumor marking with such an antigenic polypeptide, taps into said pre-existing immunity (i.e., activates memory T-cells and/or B-cells to mount an immune response against said tumor).
- existing immunity e.g., memory immunity in the form of memory T-cells and/or B-cells
- pre-existing immunity i.e., activates memory T-cells and/or B-cells to mount an immune response against said tumor.
- the pre-existing immunity was generated early in life of the subject, e.g., at a time between the age of 0-20 years, at a time between the age of 1-12 or 1-6 years. In certain embodiments, the pre-existing immunity was generated at a time between the age of about 0-1 years, about 0-2 years, about 0-3 years, about 1-3 years, about 2-4 years, about 3-5 years, about 4-6 years, about 5-7 years, about 6-8 years, about 7-9 years, about 8-10 years, about 9-11 years, about 10-12 years, about 11-13 years, about 12-14 years, about 13-15 years, about 14-16 years, about 15-17 years, about 16-18 years, about 17-19 years, about 18-20 years, at a time before the age of 1, at a time before the age of 2, at a time before the age of 3, at a time before the age of 4, at a time before the age of 5, at a time before the age of 6, at a time before the age of 7, at a time before the age of 8,
- dormant immune cells are reactivated by at least one immunization with an immunogenic composition as described herein.
- the antigenic polypeptide used in aspects of a method as described herein is not previously encountered by a subject as part of an immune response against a tumor, is (i) not (or rarely) encountered by a human subject as part of an immune response, or (ii) is encountered as part of an immune response, but not an immune response against a tumor, and wherein protective immunity is present in a subject.
- the antigenic polypeptide as described herein mounts an immune response in cancer patients, e.g., patients suffering from a tumor.
- the antigenic polypeptide mounts an immune response in at least 90% of the patients intended for potential vaccination using a method as described herein.
- the antigenic polypeptide mounts an immune response in at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the patients intended for potential vaccination using a method as described herein.
- the immune response thus mounted in cancer patients can be a de novo response due to the fact that the patients' immune system has not previously encountered this immunogen.
- the antigenic polypeptide is a non-mammalian polypeptide, such as a microbial polypeptide, or a synthetic polypeptide.
- the antigenic polypeptide is selected from the group formed by keyhole limpet hemocyanin (KLH), green fluorescent protein (GFP) including enhanced green fluorescent protein (eGFP), luciferase, beta-galactosidase and a diphtheria toxin.
- KLH keyhole limpet hemocyanin
- GFP green fluorescent protein
- eGFP enhanced green fluorescent protein
- luciferase luciferase
- beta-galactosidase and a diphtheria toxin.
- microbial polypeptide refers to a polypeptide of a micro-organism, which includes bacteria, archaea, protists, fungi, unicellular plants and viruses.
- the antigenic polypeptide (e.g., non-human antigenic polypeptide) is a bacterial polypeptide, a polypeptide originating from an organism of the Archaea domain, a fungal polypeptide or a viral polypeptide.
- the antigenic polypeptide is a plant polypeptide.
- a non-human mammalian polypeptide such as a polypeptide of a non-human primate, a rodent (e.g., mice and rats), a rabbit, a pig, a sheep, a goat, a cow, a horse and a donkey, a birds (e.g., a chicken, a turkey, a duck, a goose and the like).
- the antigenic polypeptide can also be a polypeptide of a snail or other mollusk, e.g., one of the genus of Megathura , or Megathura crenulata.
- antigenic polypeptides that are not mammalian polypeptides find certain use in a method as described herein, since non-mammalian antigenic polypeptides are more immunogenic than mammalian polypeptides when administered to a human subject.
- suitable non-mammalian antigenic polypeptides are for instance green fluorescent protein (GFP) including enhanced green fluorescent protein (eGFP), luciferase and beta-galactosidase.
- KLH Keyhole Limpet Hemocyanin
- KLH Keyhole Limpet Hemocyanin
- KLH can be either KLH1 (amino acid sequence is provided in UniProtKB—Q53IP9, last modified: Feb. 19, 2014—v2) or KLH2 (amino acid sequence is provided in UniProtKB—Q1MVA1, last modified: May 30, 2006—v1).
- KLH is an example of a highly immunogenic antigen, which has been widely used as a universal immunogen and vaccine carrier.
- an antigenic polypeptide is a diphtheria toxin, which term includes detoxified variants thereof such as cross-reacting material (CRM)-197.
- the antigenic polypeptide e.g., non-tumor antigen
- CRM197 cross-reacting material
- diphtheria toxin has the amino acid sequence as indicated in SEQ ID NO:1.
- a detoxified variant of diphtheria toxin is CRM-197, which has the amino acid sequence as indicated in SEQ ID NO:1, except for glycine (G) at amino acid residue position 52 being substituted with glutamic acid (E).
- the term also includes variants of diphtheria toxin that have at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:1 or to a part of SEQ ID NO:1 having a continuous stretch of least 100, at least 200 or at least 300 amino acid residues.
- the continuous stretch is in—or is—the amino acid region indicated by positions 1-385 of SEQ ID NO:1.
- such variants include proteins having the amino acid sequence of SEQ ID NO:1, except that 1-50, 1-20, or 1-10, amino acid residues are deleted, inserted or substituted. Such variants may exhibit antigenicity and/or immunogenicity as described herein.
- % sequence identity is defined herein as the percentage of amino acids in an amino acid sequence that is identical with the amino acids in an amino acid sequence of interest, after aligning the sequences and optionally introducing gaps, if necessary, to achieve the maximum percent sequence identity. Methods and computer programs for alignments are well known in the art. Sequence identity is calculated over substantially the whole length, in some cases, the whole (full) length, of an amino acid sequence of interest. The skilled person understands that consecutive amino acid residues in one amino acid sequence are compared to consecutive amino acid residues in another amino acid sequence.
- the tumor in methods as described herein wherein diphtheria toxin is employed for intratumoral delivery of an antigenic polypeptide, the tumor is a tumor that expresses the HB-EGF receptor.
- a tumor that expresses the HB-EGF receptor is selected from the group consisting of an ovarian tumor; a lung tumor; a bladder tumor; a gastric tumor; a pancreatic tumor; a breast tumor; a liver tumor (e.g., hepatocellular carcinoma); a brain tumor (e.g., glioblastoma, astrocytoma, brain stem glioma, mixed glioma, oligodendroglioma, optic nerve glioma, and other tumors that originate in the brain, e.g., anaplastic astrocytoma, fibrillary astrocytoma, pilocytic astrocytoma); a neuroblastoma; a lymphoma including Hodgkin
- the tumor that expresses the HB-EGF receptor is a malignant tumor selected from the group formed by ovarian cancer; lung cancer; bladder cancer; gastric cancer; pancreatic cancer; breast cancer; hepatocellular carcinoma; brain cancer (e.g., glioblastoma); neuroblastoma; lymphoma including Hodgkin lymphoma or non-Hodgkin lymphoma, histiocytic lymphoma or anaplastic large cell lymphoma; and leukemia, e.g., AML, CML or ALL.
- nucleic acids encoding the antigenic polypeptide as described herein.
- a nucleic acid encoding CRM197 for use in a method as described herein is provided.
- Amino acid sequences of proteins or polypeptides as described herein can be produced by methods and means generally available in the art. For instance, the person skilled in the art will understand how to generate a DNA sequence that encodes a fusion protein as described herein and how to manufacture and isolate a nucleic acid molecule with said DNA sequence using generally known recombinant DNA techniques.
- the sequence of the nucleic acid molecule is codon-optimized for expression in a host cell. In this way codons are used that are favored for high level expression in a specific host cell.
- nucleic acid molecules are inserted in an expression vector using recombinant DNA techniques known by the person skilled in the art.
- Expression vectors direct the expression of a fusion protein as described herein in a host cell.
- these expression vectors are replicable in a host cell, either as episomes or as part of the chromosomal DNA.
- the expression vector comprises (i) a strong promoter/enhancer, such as the CMV or SV40 promoter, (ii) an optimal translation initiation sequence, such as a ribosomal binding site and start codon, and/or a KOZAK consensus sequence and (iii) a transcription termination sequence, including a poly(A) signal when the protein is expressed in eukaryotic cells.
- Suitable expression vectors include plasmids and viral vectors such as adenoviruses, adeno-associated viruses and retroviruses.
- viral vectors such as adenoviruses, adeno-associated viruses and retroviruses.
- the expression vector to be used is dependent on the host cell that is used for expression of a recombinant protein.
- an expression vector is suited for expression of a nucleic acid in a prokaryotic cell including a bacterial cell, or in a eukaryotic host cell, such as a yeast cell and a mammalian cell.
- a suitable example is mammalian expression vector pCMV4.
- a nucleic acid molecule may be inserted in the genome of a host cell.
- the insertion is at a locus or within a region that ensures expression of a nucleic acid molecule as described herein in the host cell.
- Suitable host cells include prokaryotic and eukaryotic cells, such as bacterial cells, yeast cells, insect cells, animal cells, mammalian cells, murine cells, rat cells, sheep cells, simian cells and human cells.
- suitable eukaryotic host cells include, but are not limited to HEK 293 cells, the hamster cell line CHO and BHK-21; the murine host cells NIH3T3, NSO and C127; the simian host cells COS and Vero; and the human host cells HeLa, PER.C6, U-937 and Hep G2.
- Suitable cells are available from public sources such as ATCC and Life Technologies. A number of transfection techniques are known in the art, see, e.g., Graham et al., 1973.
- the person skilled in the art may employ techniques as described in these references to introduce one or more exogenous nucleic acid molecules into suitable host cells.
- An example of a host cell for the production of a fusion protein as described herein is a HEK 293 cell.
- the antigenic polypeptide as described herein can also be a synthetic polypeptide, e.g., a synthetic polypeptide that is designed for eliciting a strong cellular immune response upon administration to a human subject.
- the antigenic polypeptide when for administration as an immunogen, it may comprise a further polypeptide or conjugation partner so as to enhance elicitation of an immune response.
- said immunogen can be a fusion polypeptide comprising said antigenic polypeptide and for instance a carrier protein.
- a tumor e.g., a solid tumor
- methods for generating an immune response against a tumor in a subject comprise a vaccination step comprising distally administering a first composition, and a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition.
- Such methods comprise a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the first composition and the second composition are described elsewhere herein.
- the vaccination step comprises administering the first composition to a site that is away from the tumor. In certain embodiments, the vaccination step comprises administering the first composition to a site distal to the tumor. In certain embodiments, distal administration of an immunogenic composition (e.g., a first composition) in a vaccination step as described herein is through the parenteral route, which includes intravenous, intra-arterial, subcutaneous, intradermal, intranodal, intralymphatic and intramuscular administration, which are all well known to the person skilled in the art.
- an immunogenic composition e.g., a first composition
- distal administration of an immunogenic composition is delivered by a mode selected from the group consisting of intramuscular injection, subcutaneous injection, intravenous injection, intraarterial injection, intraperitoneal injection, intrasternal injection, intradermal injection, transcutaneous injection, transdermal injection, and delivery to the interstitial space of a tissue
- the vaccination step comprises administration of the first composition, wherein the administration is not intratumoral, but instead is extratumoral and is in some cases intramuscular, intradermal, intravenous, intranodal or intralymphatic, intradermal, intravenous or a combination thereof. In certain embodiments, the vaccination step comprising administering the first composition intramuscularly at a site distal to the tumor site.
- the vaccination step comprises distally administering the first composition at a site at least about 0.1 mm, at least about 0.2 mm, at least about 0.3 mm, at least about 0.4 mm, at least about 0.5 mm, at least about 0.6 mm, at least about 0.7 mm, at least about 0.8 mm, at least about 0.9 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, at least about 6 mm, at least about 7 mm, at least about 8 mm, at least about 9 mm, at least about 10 mm, at least about 15 mm, at least about 20 mm, at least about 25 mm, at least about 30 mm, at least about 35 mm, at least about 40 mm, at least about 45 mm, at least about 50 mm, at least about 60 mm, at least about 70 mm, at least about 80 mm, at least about 90 mm, at least about 10 cm, at least
- the vaccination step comprises administering a first composition to the subject at a site distal to a tumor site, therein the site distal to the tumor site is at least about 0.1 mm, at least about 0.2 mm, at least about 0.3 mm, at least about 0.4 mm, at least about 0.5 mm, at least about 0.6 mm, at least about 0.7 mm, at least about 0.8 mm, at least about 0.9 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, at least about 6 mm, at least about 7 mm, at least about 8 mm, at least about 9 mm, at least about 10 mm, at least about 15 mm, at least about 20 mm, at least about 25 mm, at least about 30 mm, at least about 35 mm, at least about 40 mm, at least about 45 mm, at least about 50 mm, at least about 60 mm, at least about 70 mm, at least
- the vaccination step comprises distally administering the first composition at a site in an organ system that is different to the organ system in which the tumor resides. In certain embodiments, the vaccination step comprises administering a first composition into an organ system that is different than the organ system in which the tumor resides. For example, if the tumor resides at or in an ovary (e.g., an epithelial ovarian cancer), the vaccination step comprises distally administering the first composition at a site in an organ system that is not the ovary, e.g., the liver, kidney, etc.
- ovary e.g., an epithelial ovarian cancer
- the vaccination step comprises distally administering the first composition at a site in an organ system that is not the ovary, e.g., the liver, kidney, etc.
- organ or “organ system” as used herein refers to a group of tissues with similar functions.
- organ systems include, without limitation, the muscular system, the digestive system (e.g., stomach, small intestine, large intestine, liver, pancreas, etc.), the respiratory system (e.g., lungs), the urinary system (e.g., kidneys, bladder, etc.), the reproductive organs (e.g., male and female reproductive system, ovaries, placenta, prostate, etc.), the endocrine system, the circulatory system, the nervous system (e.g., central and peripheral nervous systems), and the integumentary system (e.g., skin, subcutaneous tissue).
- the muscular system e.g., the digestive system (e.g., stomach, small intestine, large intestine, liver, pancreas, etc.), the respiratory system (e.g., lungs), the urinary system (e.g., kidneys, bladder, etc.), the reproductive organs (e.g., male and female reproductive system, ovaries, placenta, prostate, etc.), the en
- the vaccination step comprises distally administering the first composition at a site contralateral to the tumor site.
- the vaccination comprises administering a first composition at a site contralateral to the tumor (a site in which the tumor resides).
- the vaccination step comprises distally administering the first composition at or in the contralateral ovary.
- the vaccination step comprises distally administering the first composition to the right ovary.
- the vaccination step comprises administering a first composition at or in the contralateral ovary.
- the vaccination step comprises administering a first composition to the right ovary.
- a method as described herein comprises one or more vaccination steps.
- a second, a third, a fourth, a fifth, a sixth, a seventh, or more vaccination steps are performed.
- the skilled artisan will recognize that any, if any, subsequent vaccination steps are performed, the subsequent vaccination steps are envisioned to incorporate any of the embodiments of a vaccination step described herein.
- the tumor-marking step comprises intratumorally or peri-tumorally administering the second composition. In certain embodiments, the tumor-marking step comprises administering a second composition to the subject at the tumor site. In certain embodiments, the tumor-marking step comprises administering a second composition into the tumor or proximal to the tumor. Accordingly, use of an antigenic polypeptide described herein prepared for intratumoral delivery as described herein, is provided.
- Also provided is a method for eliciting an immune response against a subject suffering from a tumor comprising the steps of administering to a subject suffering from a tumor a pharmaceutically effective amount of an antigenic polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery; and administering to said subject a pharmaceutically effective amount of an immunogenic composition comprising said polypeptide as an immunogen, or comprising a nucleic acid encoding said immunogen, and optionally one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- Such a method may further comprise the step of allowing an MHC peptide antigen complex to be produced from said polypeptide following intratumoral delivery of said polypeptide, or said nucleic acid encoding said polypeptide, prepared for intratumoral delivery.
- administration of the first composition and the second composition according to a method as described herein elicits a T cell mediated immune response against the antigenic polypeptide or the MHC peptide antigen complex.
- Also provided herein is a method for treating a tumor in a subject in need, comprising: (1) a vaccination step comprising distally administering a first composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide.
- a method for treating a tumor in a subject in need comprising: (1) a vaccination step comprising distally administering a first composition comprising a non-tumor antigen or a nucleic acid encoding the non-tumor antigen, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- Also provided herein is a method for treating a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- a method for treating a tumor in a subject in need comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- Also provided herein is a method for generating an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising distally administering a first composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide.
- a method for generating an immune response against a tumor in a subject in need comprising: (1) a vaccination step comprising distally administering a first composition comprising a non-tumor antigen or a nucleic acid encoding the non-tumor antigen, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- Also provided herein is a method for generating an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- a method for generating an immune response against a tumor in a subject in need comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- a method for eliciting or directing an immune response against a tumor in a subject in need comprising: (1) a vaccination step comprising distally administering a first composition comprising a non-tumor antigen or a nucleic acid encoding the non-tumor antigen, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- a method for eliciting or directing an immune response against a tumor in a subject in need comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- the antigenic polypeptide of a method as described herein is CRM197.
- a method for treating a tumor in a subject in need comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises CRM197 or a nucleic acid encoding CRM197; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises CRM197 or a nucleic acid encoding CRM197.
- Also provided herein is a method for generating an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises CRM197 or a nucleic acid encoding CRM197; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises CRM197 or a nucleic acid encoding CRM197.
- the vaccination step and the tumor-marking step are temporally separated. Accordingly, in certain embodiments, the vaccination step is performed prior to the tumor-marking step. In certain embodiments, the tumor-marking step is performed subsequent to the vaccination step. In certain embodiments, a certain time has elapsed after the vaccination step before the tumor-marking step is performed. In certain embodiments, the amount of time elapsed after the vaccination step is sufficient for the subject to mount an immune response to the antigenic polypeptide comprised within the administered first composition. In certain embodiments, the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step.
- a primary immune response can be mounted as a result of the vaccination step. In the case of a primary immune response, it may take about 7 days to about 21 days to mount the primary immune response.
- a secondary immune response can be mounted as a result of the vaccination step, e.g., in response to an antigenic polypeptide for which the subject has pre-existing immunity against. In the case of a secondary immune response, it may take about 2 days to about 3 days to mount the secondary immune response.
- the time between the vaccination step and the tumor-marking step is from about 1 day to about 21 days, from about 1 day to about 22 days, from about 1 day to about 23 days, from about 1 day to about 24 days, from about 1 day to about 3 weeks, from about 1 day to about 4 weeks, from about 1 day to about 5 weeks, from about 1 day to about 10 weeks, from about 1 day to about 15 weeks, from about 1 day to about 20 weeks, from about 1 day to about 25 weeks, from about 1 day to about 30 weeks, from about 1 day to about 35 weeks, from about 1 day to about 40 weeks, from about 1 day to about 45 weeks, from about 1 day to about 50 weeks, from about 1 day to about 1 year, from about 1 day to about 2 years, from about 1 day to about 3 years, from about 1 day to about 4 years, from about 1 day to about 5 years, from about 1 day to about 10 years, from about 1 day to about 15 years, from about 1 day to about 20 years, from about 1 day to about 25 years, from about 1 day to about 30 years, from about 1 day to about
- the time between a vaccination step and the tumor-marking step is about 1 day to about 1 month, 14 days to about 2 months, 1 month to about 3 months, 2 months to about 5 months, 4 months to about 6 months, 5 months to about 7 months, 6 months to about 8 months, 7 months to about 9 months, 8 months to about 10 months, 9 months to about 11 months, 10 months to about 12 months, 11 months to about 13 months, 12 months to about 14 months, 13 months to about 15 months, 14 months to about 16 months, 15 months to about 17 months, 16 months to about 18 months, 17 months to about 19 months, 18 months to about 20 months, 19 months to about 21 months, 20 months to about 22 months, 21 months to about 23 months, 22 months to about 24 months, 3 months to about 1 year, 6 months to about 1 year, 1 year to about 2 years, 1.5 years to about 3 years, 2 years to about 3.5 years, 2.5 years to about 4 years, 3 years to about 4.5 years, 3.5 years to about 5 years, 4 years to about 5.5 years, 4.5 years to about 6
- the time between the vaccination step and the tumor-marking step is about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks about 50 weeks, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 10 years, about 15 years, about 20 years, about 25 years, about 30 years, or more, and any intervening amount of time thereof.
- the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days. In certain embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 3 days. In certain embodiments, the time between the vaccination step and the tumor-marking step is about 7 days to about 21 days.
- SEQ ID NO: 1 Diphtheria toxin GADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGI QKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNE NPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKE LGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPF AEGSSSVEYINNWEQAKALSVELEINFETRGKRGQ DAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIR DKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQ YLEEFHQTALEHPELSELKTVTGTNPVFAGANYAA WAVNVAQVIDSETADNLEKTTAALSILPGIGSVMG IADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGEL VDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHK TQPFLHDGYAVSWNTVEDSIIRTGFQ
- DCOne progenitors (as deposited with the DSMZ under accession number DSMZ ACC3189 on 15 Nov. 2012) were differentiated and matured according to the procedure described in WO2009019320 A2, the disclosure of which is incorporated by reference herein in its entirety. Cells were counted and phenotypic analysis of DCOne mDC cells was performed using flow cytometry (FACSVerse; BDBiosciences).
- OV90 ovarian cancer cell were cultured in medium199/MCDB105 medium (1:1) containing 15% FBS and 2% P/S) in an incubator at 37° C. with 5% CO 2 OV90 cells were obtained from ATCC.
- Uptake by DCOne mDC was assessed for three different foreign antigens at a final concentration of 10 ⁇ g/mL for 4 hours and 24 hours during maturation. 750.000 cells were seeded into 6 well plates for each condition.
- the antigens used were CRM197-Alexa488, subunit KLH-FITC and ⁇ -galactosidase-FITC.
- CRM197-Alexa488 was purchased from Fina Biosolutions.
- Subunit KLH was purchased from Stellar Biotechnologies Inc.
- ⁇ -galactosidase was purchased from Roche.
- Subunit KLH and ⁇ -galactosidase were conjugated in-house to fluorochrome fluorescein isothiocyanate (FITC) using a FITC labelling kit according to manufacturer's protocol. Uptake of foreign antigens was assessed by flow cytometry. 0.08% Trypan blue was used to quench externally bound protein, to visualize only the internalized protein.
- FITC fluorochrome fluorescein isothiocyanate
- the labelling of OV90 ovarian cancer cells was assessed for three different foreign proteins at a final concentration of 10 ⁇ g/mL for 4 hours and 24 hours. 100.000 cells were seeded into 96 well plates for each condition. The proteins used were CRM197-Alexa488, Subunit KLH-FITC and ⁇ -galactosidase-FITC. Labelling of tumor cells in vitro was assessed by flow cytometry as mentioned above for DCOne mDC cells.
- mice Four-week-old immunodeficient female NOD/Shi-scid/IL-2Rynull immunodeficient mouse strain (NCG; Taconic) were engrafted with intravenous (IV) injection of 5e4 cord blood-derived CD34+ hematopoietic stem and progenitor cells (French Blood Bank) two days after chemical myeloablative treatment.
- IV intravenous
- Humanized mice were enhanced for dendritic cell populations with a GM-CSF/IL3/1L4 hydrodynamic boost and Flt3L recombinant protein.
- mice were inoculated subcutaneously in the right flank with 1e 6 U87-MG glioblastoma cells/mouse (Sigma Aldrich) for tumor engraftment.
- Approximately 15 days after tumor engraftment mice were randomised and divided into different vaccination groups including 5 mice per group. All mice received 1 intraperitoneal (i.p.) vaccination and one intratumoral (i.t.) injection marking the tumor
- mice received 100 ⁇ g KLH per i.p. injection or a 100 ⁇ l PBS i.p. injection, and were injected with 200.000 KLH-loaded DCOne mDCs i.t. or 100 ⁇ g KLH in 50 ⁇ l i.t. according to following schedule:
- Subunit KLH was purchased from Stellar Biotechnologies Inc. Tumor growth reduction and induction of immune responses were measured.
- mice After humanization with CD34 + stem cells and hydrodynamic boost with cytokines as described above, mice were inoculated subcutaneously in the right flank with 2e 6 A375 melanoma cells/mouse (Sigma Aldrich) for tumor engraftment. Approximately 15 days after tumor engraftment mice were randomized and divided into different vaccination groups including 5 mice per group. The mice received two intraperitoneal (i.p.) vaccinations and thereafter one intratumoral (i.t.) injection for marking the tumor.
- i.p. intraperitoneal vaccinations
- intratumoral i.t.
- mice received 100 ⁇ g KLH in 100 ⁇ l per i.p. injection or a 100 ⁇ l PBS i.p. injection, and were injected with 200.000 KLH-loaded DCOne mDCs or 100 ⁇ g KLH in 50 ⁇ l i.t. according to the following schedule:
- Subunit KLH was purchased from Stellar Biotechnologies Inc. Tumor growth reduction and vaccination induced immune responses were measured.
- DCOne mDC cells were loaded with fluorochrome-conjugated subunit KLH during maturation process for 4 hours and 24 hours as described in the material and methods section.
- the internalization of subunit KLH was analysed using flow cytometer. Trypan blue quenches the cell surface-bound antigen and was used to distinguish between surface-bound antigen and internalized antigen.
- the observed internalization of subunit KLH-FITC by DCOne mDC after 4 hrs was 54.6 ⁇ 8.8%, and 49.9 ⁇ 9.8% with trypan blue and after 24 hours 86.1 ⁇ 7.0%, and 81.7 ⁇ 8.0% with trypan blue indicating effective antigen uptake by DCOne mDC ( FIG. 1A ).
- OV90 ovarian carcinoma cells were cultured with subunit KLH-FITC for 4 hours and 24 hours as described in the material and methods section. It was observed that 13.5 ⁇ 2.6%, labelling of OV90 for 4 hours of which 7.5 ⁇ 1.0% of cells with intracellular antigen as demonstrated by quenching of surface-bound subunit KLH-FITC signal with trypan blue, and after 24 hours 16.5 ⁇ 11.5% of OV90 cells were labelled with antigen with 9.5 ⁇ 3.8% of antigen inside the cells ( FIG. 1B ).
- DCOne mDCs were incubated with ⁇ -galactosidase-FITC for 4 hrs and 24 hrs as described in the materials and methods section.
- the uptake of ⁇ -galactosidase-FITC was measured using flow cytometry in the absence or presence of trypan blue in order to distinguish between extracellularly bound and internalized ⁇ -galactosidase-FITC.
- FIG. 2A depicts that after 4 hrs incubation 39.7 ⁇ 10.7% of DCOne mDC have internalized ⁇ -galactosidase-FITC as the trypan blue quenching hardly affected the signal (34.5 ⁇ 10.2%) indicating intracellular localization of ⁇ -galactosidase-FITC in DCOne mDC.
- the labelling of ovarian cancer cell line OV-90 with ⁇ -galactosidase-FITC after 4 hours and 24 hours was 11.3 ⁇ 8.9% (6.0 ⁇ 4.6% with trypan blue) and 10.4 ⁇ 4.2%, (6.5 ⁇ 3.6% with trypan blue) respectively showing both surface-bound and intracellular presence of ⁇ -galactosidase-FITC ( FIG. 2B ).
- DCOne mDC cells were cultured with CRM197-Alexa488 for 4 and 24 hours as described in the materials and methods section. After 4 and 24 hours uptake of antigen CRM-197 by DCOne mDCs were analysed using a flow cytometer in the presence and absence of trypan blue as mentioned in above sections. 90.6 ⁇ 5.4% and 99.4 ⁇ 0.1% of DCOne mDC were observed to have had efficiently internalized CRM-197 after 4 and 24 hours, respectively. Trypan blue quenching did not affect these results (87.6 ⁇ 8.0 and 99.5 ⁇ 0.2% respectively; FIG. 7A ).
- the percentage of CRM197-Alexa488 uptake after 4 hours by OV90 tumor cells was 82.0 ⁇ 2.5%, and after 24 hours labelling increased up to 98.2 ⁇ 0.1% ( FIG. 3 ).
- the trypan blue quenching did not affect the signal indicating that CRM-197 is predominantly present inside the cell (72.7 ⁇ 11.9% and 97.6 ⁇ 1.4% with trypan blue after 4 and 24 hours respectively).
- DCOne mDCs The in vitro data of uptake of foreign proteins by DCOne mDCs showed that DCOne mDCs were very efficient in internalizing foreign protein. All foreign proteins tested, CRM197, KLH and ⁇ -galactosidase were taken up very well by DCOne mDCs. DCOne cells can thus be used as a carrier for vaccination and/or intratumoral delivery of foreign proteins.
- the U87-MG mice received one i.p. vaccination of either PBS or KLH and one i.t. injection to mark the tumor either with KLH or KLH-loaded DCOne mDCs.
- Tumor growth was monitored three times per week using a digital caliper ( FIG. 4A ).
- a slowed tumor growth was observed in vaccinated mice as compared to the mice injected with PBS, with i.t. injection of KLH-loaded DCOne having the strongest effect ( FIG. 4B ).
- DCOne progenitor cells (as deposited with the DSMZ under accession number DSMZ ACC3189 on 15 Nov. 2012) were differentiated and matured according to the procedure described in PCT Publication No. WO 2009/019320, incorporated herein by reference in its entirety. Cells were counted and phenotypic analysis of DCOne mDC cells was performed using flow cytometry (FACSVerse; BDBiosciences).
- DCOne AML progenitor cells were cultured in MEM ⁇ containing 10% FBS and 2% P/S in an incubator at 37° C. with 5% CO 2 .
- OV90 ovarian cancer cells were cultured in medium199/MCDB105 medium (1:1) containing 15% FBS and 2% P/S in an incubator at 37° C. with 5% CO2.
- OV90 cells were obtained from ATCC.
- U87MG glioblastoma cancer cells were cultured in EMEM medium containing 10% FBS and 2% P/S in an incubator at 37° C. with 5% CO2.
- U87MG cells were obtained from Merck.
- Uptake by DCOne mDC cells was assessed for foreign antigen at a final concentration of 10 ⁇ g/mL for 4 hours and 24 hours during maturation. 750,000 cells were seeded into 6-well plates for each condition. The foreign antigen used was CRM197-Alexa488 (Fina Biosolutions). Uptake of foreign antigens was assessed by flow cytometry. 0.08% Trypan blue was used to quench externally bound protein, to visualize only the internalized protein.
- DCOne progenitor AML cells The labelling of DCOne progenitor AML cells, OV90 ovarian cancer cells and U87MG glioblastoma cancer cells was assessed at a final concentration of 10 ⁇ g/mL for 4 hours and 24 hours. 100,000 cells were seeded into 96 well plates for each condition. The foreign antigen used was CRM197-Alexa488 (Fina Biosolutions). Labelling of tumor cells in vitro was assessed by flow cytometry as mentioned above for DCOne mDCs.
- NSGS were engrafted with intravenous (IV) injection of 5e4 cord blood-derived CD34+ hematopoietic stem and progenitor cells.
- Mice were inoculated subcutaneously with 5e6 OV90luc ovarian cancer cells expressing luciferase for tumor engraftment. Mice were randomized by tumor volume and divided into different vaccination groups including 5 mice per group. The average tumour size at start of vaccination was 80 mm 3 . All mice received 2 intraperitoneal (i.p.) vaccinations and one intratumoral (i.t.) injection marking the tumor.
- mice received 50 ⁇ g CRM197 per i.p. injection or a PBS i.p. injection, and were injected with 25 ⁇ g CRM197 i.t. according to the following schedule:
- CRM197 was purchased from Fina Biosolutions. Tumor growth reduction (caliper measurement and BLI imaging) and induction of immune responses were measured.
- DCOne mDC cells were cultured with CRM197-Alexa488 for 4 and 24 hours as described in the materials and methods section. After 4 and 24 hours uptake of antigen CRM-197 by DCOne mDC cells were analysed using a flow cytometer in the presence and absence of trypan blue as mentioned in above sections. 90.6 ⁇ 5.4% and 99.4 ⁇ 0.1% of DCOne mDC cells were observed to have had efficiently internalized CRM-197 after 4 and 24 hours, respectively. Trypan blue quenching did not affect these results (87.6 ⁇ 8.0% and 99.5 ⁇ 0.2% respectively; FIG. 7A ).
- the percentage of CRM197-Alexa488 uptake after 4 hours by OV90 tumor cells was 82.0 ⁇ 2.5%, and after 24 hours labelling increased up to 98.2 ⁇ 0.1%.
- the trypan blue quenching did not affect the signal indicating that CRM197 is predominantly present inside the cell (72.7 ⁇ 11.9% and 97.6 ⁇ 1.4% with trypan blue after 4 and 24 hours respectively; FIG. 7C ).
- Tumor growth was monitored by weekly calliper measurements and optical imaging from the beginning of treatment.
- the OV90luc mice received two i.p. vaccinations of either PBS or CRM197 and one i.t. injection to mark the tumor either with PBS or CRM197.
- Tumor growth was monitored per week using a digital caliper.
- Tumor volumes (in mm 3 ) were calculated by the ellipsoid formula (L ⁇ W ⁇ H) ⁇ /6.
- CRM197 is used to study a tumor antigen-independent prime-boost strategy using CRM197 as a tumor-independent antigen in a humanized tumor mouse model. Goals of this study are: optimization of a vaccination protocol; repetition of an earlier experiment using an optimal mouse model for robust tumor regression; and assessment of tumors using immunohistochemistry for immune activation at the tumor site.
- mice I. Vaccination with saline (6 mice).
- the studies are performed in mice with an HB-EGF-expressing tumor using the U87MG glioblastoma cell line.
- the clinical readout is tumor regression/clearance and survival. Immunohistochemistry of the tumors is assessed to determine tumor infiltration of immune cells. A serum analysis is performed to detect anti-CRM antibodies.
- the vaccination dose is 50 ⁇ g CRM197/mouse.
- the intratumoral dose is 25 ⁇ g CRM197/mouse.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
A method for treating a tumor or generating an immune response against a tumor in a subject in need including a vaccination step comprising administration of a first composition, and a tumor-marking step comprising administration of a second composition, is provided. The first and second composition each comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. Also provided are antigenic polypeptides and compositions for use in methods described herein.
Description
- This is a continuation of U.S. patent application Ser. No. 16/857,851, filed Apr. 24, 2020, which claims priority to European Patent Application No. 19170999.7, filed Apr. 25, 2019, entitled “Pharmaceutical Combination”, International PCT Application No. PCT/NL19/50451, filed Jul. 16, 2019, entitled “Pharmaceutical Combination”, and U.S. Provisional Patent Application Ser. No. 62/961,554, filed Jan. 15, 2020, entitled “Methods of Tumor Vaccination”. The entire disclosure of each of these applications is hereby incorporated herein by reference.
- The content of the electronically submitted sequence listing in ASCII text file (Name: 719435_DCP9-004BCON_ST25; Size: 7,890 bytes; and Date of Creation: Jun. 9, 2021) is incorporated herein by reference in its entirety.
- Traditionally, and currently still, the focus in therapeutic tumor vaccines is on vaccination with tumor antigens, which are processed by antigen-presenting cells (APC's) such as dendritic cells (DCs) to thereby provide for T cell activation and the mounting of an immune response against the tumor.
- The goal of such a vaccination strategy is to enlarge the pool of tumor-specific T-cells from the naïve repertoire, but also to reverse tumor-associated dormancy or anergy through the presentation of tumor antigens, in an effort to break central tolerance to those antigens and to overcome blunting of the CD4+ and/or CD8+ T cell repertoire.
- The difficulty in designing therapeutic tumor vaccines, where preferentially T-cells against tumor-specific epitopes are stimulated, lies in the propensity of the tumor to evade immune control by altering itself to reduce expression of the tumor antigens or by creating an environment (the tumor micro-environment or TME) that is inhibitory for T cells and other cells of the immune system. In this way, T cell repertoires that recognize tumor antigens are inactivated, leading to inert or exhausted T cell populations.
- Current vaccination approaches are dependent upon the tumor antigens expressed at a specific moment by the tumor. This means that these vaccination approaches are circumvented by the immune-evasive properties of tumor cells because the natural selection pressure on the tumor is generally not strong enough to force the tumor into cell death. Further, it remains difficult to employ tumor-specific antigens that are not also self-antigens, the latter being generally tolerized by the immune system or provide for weak T-cell-mediated immune responses. A current research focus in the field of therapeutic tumor vaccines lies in the identification of inter alia tumor neoantigens. Although these neoantigens might sufficiently stimulate T-cells following vaccination, they have an intrinsic disadvantage in that they are generally patient-specific and thus are not suitable as a tumor vaccine that finds broad application over the patient population. Also, they are not stably expressed and may alter over time, making it even more challenging to compose the correct vaccines formulations. It is clear from the above that current tumor vaccination approaches are based on vaccination with tumor antigens and are directed to the antigenic state of a tumor at a given time point, and thus do not actively manipulate the antigenic state of the tumor.
- Accordingly, there is a need for improved therapeutic tumor vaccines and/or vaccination strategies, which are not dependent on tumor-antigen expressed by a tumor, and which incorporate antigens that provide for an optimal T-cell response upon vaccination. Such improved therapeutic tumor vaccines and/or vaccination strategies would be applicable in both human and veterinary use.
- A novel vaccination strategy, also referred to as ‘tumor-antigen independent vaccination,’ is provided herein. By designing a vaccination approach that is independent from tumor antigens, an immune response is raised against an antigen that is immunogenic in a subject (e.g., a human subject), wherein the antigen is of foreign (e.g., non-human) origin. Such an immunogen provides for a strong immune response, for instance by activating T-cells from the naïve repertoire or by tapping into pre-existing immunity by re-activating memory T-cells and/or memory B-cells that were generated during a prior immune response that was not an immune response against the tumor, and in some cases, was an immune response that occurred prior to establishment of a tumor as the result of common vaccination against infectious diseases. This principle overcomes the restrictions of tumor antigen-based vaccination methods described above and is applicable over the entire patient population. In addition, tumor-antigen independent vaccinations find value in animal healthcare, where readily targetable tumor antigens are poorly available, and where there is a high need for cost efficient immune therapies that are applicable across various species of animals.
- In a first aspect, a vaccination strategy comprises administration (e.g., a vaccination step) of an immunogenic composition (e.g., a vaccine composition) comprising an antigen that is foreign or exogenous to a subject (e.g., a human subject) as an immunogen. In certain embodiments, the antigen is highly immunogenic, and can be an antigen that is not, or is only rarely, encountered by the immune system of the subject (e.g., a human subject) except via common vaccination against infectious diseases. In certain exemplary embodiments, a vaccination step is performed using a non-human antigen. In certain exemplary embodiments, a vaccination step is performed by using a non-tumor antigen.
- In a second aspect, a vaccination strategy comprises actively marking a tumor cell (e.g., a tumor-marking step), or its direct or immediate environment (e.g., the tumor site or the tumor micro-environment (TME)) with the same antigen that was employed in the first aspect relating to vaccination. In certain exemplary embodiments, the tumor, or its direct environment (e.g., the tumor site or the tumor micro-environment (TME)) is manipulated by presentation of a non-tumor antigen (e.g., a non-human, non-tumor antigen). In certain exemplary embodiments, prior to tumor marking, such an immune response has already been elicited or mounted.
- In certain exemplary embodiments, any antigen that is immunogenic in a subject (e.g., a human subject), that is of foreign (e.g., non-human) origin, and that is expected to provide a strong immune response, e.g., by activating T-cells from the naïve repertoire or by tapping into pre-existing immunity against antigens that are not antigens specific to the tumor of interest is used: (i) to vaccinate against said antigen so as to mount the desired immune response against said antigen; and (ii) to mark the tumor as a target for such an immune response by allowing presentation of a corresponding antigen at the tumor site or in the tumor micro-environment. The step of administering the immunogenic composition can be performed prior to or subsequent to tumor marking. In certain exemplary embodiments, one or more vaccination steps are performed prior to a tumor-marking step.
- Accordingly, in certain aspects, a method for generating an immune response against a tumor in a subject comprising: a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen, wherein the time between the vaccination step and the tumor-marking step is between about one day and about 6 months, is provided.
- In certain exemplary embodiments, the method further comprises one or more booster steps each comprising administering a booster composition to the subject, wherein the booster composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. In certain exemplary embodiments, the one or more booster steps occur prior to the tumor-marking step.
- In certain exemplary embodiments, the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor.
- In certain exemplary embodiments, the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue. In certain exemplary embodiments, the vaccination step comprises intradermally administering the first composition. In certain exemplary embodiments, the first composition is prepared for intradermal injection. In certain exemplary embodiments, the first composition comprises a diluent or solvent acceptable for intradermal injection. In certain exemplary embodiments, the vaccination step comprises intramuscularly administering the first composition. In certain exemplary embodiments, the first composition is prepared for intramuscular injection. In certain exemplary embodiments, the first composition comprises a diluent or solvent acceptable for intramuscular injection.
- In certain exemplary embodiments, the vaccination step comprises administering the first composition into an organ system that is different than the organ system in which the tumor resides. In certain exemplary embodiments, the vaccination step comprises administering the first composition at a site contralateral to the tumor.
- In certain exemplary embodiments, the vaccination step is performed subsequent to the tumor-marking step. In certain exemplary embodiments, the tumor-marking step is performed subsequent to the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
- In certain exemplary embodiments, the tumor is a solid tumor. In certain exemplary embodiments, the solid tumor is glioblastoma or ovarian cancer.
- In certain exemplary embodiments, the first composition comprises a dendritic cell comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. In certain exemplary embodiments, the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell. In certain exemplary embodiments, the mature dendritic cell is derived from DCOne.
- In certain exemplary embodiments, the second composition is prepared for intratumoral administration. In certain exemplary embodiments, the second composition comprises a tumor targeting component. In certain exemplary embodiments, the tumor targeting component is a tumor-specific virus. In certain exemplary embodiments, the tumor-specific virus is an oncolytic virus. In certain exemplary embodiments, the tumor-specific virus comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. In certain exemplary embodiments, the tumor targeting component is a tumor-specific nanoparticle. In certain exemplary embodiments, the tumor-specific nanoparticle comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- In certain exemplary embodiments, the second composition comprises a dendritic cell comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. In certain exemplary embodiments, the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell. In certain exemplary embodiments, the mature dendritic cell is derived from DCOne.
- In certain exemplary embodiments, the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- In certain exemplary embodiments, the subject is a non-tumor antigen-naïve subject. In certain exemplary embodiments, the subject has previously been exposed to the non-tumor antigen. In certain exemplary embodiments, the subject has previously mounted an immune response against the non-tumor antigen.
- In certain exemplary embodiments, the subject is a human. In certain exemplary embodiments, the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
- In other aspects, a method for generating an immune response against a tumor in a subject comprising: a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor recall antigen or a nucleic acid encoding the non-tumor recall antigen; and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the recall antigen or a nucleic acid encoding the recall antigen, is provided.
- In certain exemplary embodiments, the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor.
- In certain exemplary embodiments, the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue. In certain exemplary embodiments, the vaccination step comprises intradermally administering the first composition. In certain exemplary embodiments, the first composition is prepared for intradermal injection. In certain exemplary embodiments, the first composition comprises a diluent or solvent acceptable for intradermal injection. In certain exemplary embodiments, the vaccination step comprises intramuscularly administering the first composition. In certain exemplary embodiments, the first composition is prepared for intramuscular injection. In certain exemplary embodiments, the first composition comprises a diluent or solvent acceptable for intramuscular injection.
- In certain exemplary embodiments, the vaccination step comprises administering the first composition into an organ system that is different than the organ system in which the tumor resides. In certain exemplary embodiments, the vaccination step comprises administering the first composition at a site contralateral to the tumor.
- In certain exemplary embodiments, the vaccination step and the tumor-marking step are temporally separated. In certain exemplary embodiments, the vaccination step is performed subsequent to the tumor-marking step. In certain exemplary embodiments, the tumor-marking step is performed subsequent to the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
- In certain exemplary embodiments, the tumor is a solid tumor. In certain exemplary embodiments, the solid tumor is glioblastoma or ovarian cancer.
- In certain exemplary embodiments, the first composition comprises a dendritic cell comprising the recall antigen or a nucleic acid encoding the recall antigen. In certain exemplary embodiments, the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell. In certain exemplary embodiments, the mature dendritic cell is derived from DCOne.
- In certain exemplary embodiments, the second composition is prepared for intratumoral administration. In certain exemplary embodiments, the second composition comprises a tumor targeting component. In certain exemplary embodiments, the tumor targeting component is a tumor-specific virus. In certain exemplary embodiments, the tumor-specific virus is an oncolytic virus. In certain exemplary embodiments, the tumor-specific virus comprises the recall antigen or a nucleic acid encoding the recall antigen. In certain exemplary embodiments, the tumor targeting component is a tumor-specific nanoparticle. In certain exemplary embodiments, the tumor-specific nanoparticle comprises the recall antigen or a nucleic acid encoding the recall antigen.
- In certain exemplary embodiments, the second composition comprises a dendritic cell comprising the recall antigen or a nucleic acid encoding the recall antigen. In certain exemplary embodiments, the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell. In certain exemplary embodiments, the mature dendritic cell is derived from DCOne.
- In certain exemplary embodiments, the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- In certain exemplary embodiments, the subject has previously been exposed to the recall antigen. In certain exemplary embodiments, the subject has previously mounted an immune response against the recall antigen.
- In certain exemplary embodiments, the subject is a human. In certain exemplary embodiments, the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
- In other aspects, a method for generating an immune response against a tumor in a subject comprising: a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof; and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof, is provided.
- In certain exemplary embodiments, the method further comprises one or more booster steps each comprising administering a booster composition to the subject, wherein the booster composition comprises the diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof. In certain exemplary embodiments, the one or more booster steps occur prior to the tumor-marking step.
- In certain exemplary embodiments, the diphtheria toxin or detoxified variant thereof is CRM197.
- In certain exemplary embodiments, the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor.
- In certain exemplary embodiments, the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue. In certain exemplary embodiments, the vaccination step comprises intradermally administering the first composition. In certain exemplary embodiments, he first composition is prepared for intradermal injection. In certain exemplary embodiments, the first composition comprises a diluent or solvent acceptable for intradermal injection. In certain exemplary embodiments, the vaccination step comprises intramuscularly administering the first composition. In certain exemplary embodiments, the first composition is prepared for intramuscular injection. In certain exemplary embodiments, the first composition comprises a diluent or solvent acceptable for intramuscular injection.
- In certain exemplary embodiments, the vaccination step comprises administering the first composition into an organ system that is different to the organ system in which the tumor resides. In certain exemplary embodiments, the vaccination step comprises administering the first composition at a site contralateral to the tumor.
- In certain exemplary embodiments, the vaccination step and the tumor-marking step are temporally separated. In certain exemplary embodiments, the vaccination step is performed subsequent to the tumor-marking step. In certain exemplary embodiments, the tumor-marking step is performed subsequent to the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step. In certain exemplary embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
- In certain exemplary embodiments, the tumor is a solid tumor. In certain exemplary embodiments, the solid tumor is glioblastoma or ovarian cancer.
- In certain exemplary embodiments, the first composition comprises a dendritic cell comprising CRM197 or a nucleic acid encoding CRM197. In certain exemplary embodiments, the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell. In certain exemplary embodiments, the mature dendritic cell is derived from DCOne.
- In certain exemplary embodiments, the second composition is prepared for intratumoral administration. In certain exemplary embodiments, the second composition comprises a tumor targeting component. In certain exemplary embodiments, the tumor targeting component is a tumor-specific virus. In certain exemplary embodiments, the tumor-specific virus is an oncolytic virus. In certain exemplary embodiments, the tumor-specific virus comprises CRM197 or a nucleic acid encoding CRM197. In certain exemplary embodiments, the tumor targeting component is a tumor-specific nanoparticle. In certain exemplary embodiments, the tumor-specific nanoparticle comprises CRM197 or a nucleic acid encoding CRM197.
- In certain exemplary embodiments, the second composition comprises a dendritic cell comprising CRM197 or a nucleic acid encoding CRM197. In certain exemplary embodiments, the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell. In certain exemplary embodiments, the mature dendritic cell is derived from DCOne.
- In certain exemplary embodiments, the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- In certain exemplary embodiments, the subject is a human. In certain exemplary embodiments, the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
- In other aspects, a method for generating an immune response against a tumor in a subject, comprising administering to the subject a non-tumor antigen or a nucleic acid encoding the non-tumor antigen at a tumor site, wherein the subject is previously vaccinated with the non-tumor antigen or a nucleic acid encoding the non-tumor antigen, is provided.
- In other aspects, a method for generating an immune response against a tumor in a subject, comprising administering to the subject a recall antigen or a nucleic acid encoding the recall antigen at a tumor site, wherein the subject is previously vaccinated with the antigen or a nucleic acid encoding the antigen, and wherein the antigen is a non-tumor antigen, is provided.
- In other aspects, a method for generating an immune response against a tumor in a subject, comprising administering to the subject a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof at a tumor site, wherein the subject is previously vaccinated with the diphtheria toxin or detoxified variant thereof or the nucleic acid encoding the diphtheria toxin or detoxified variant thereof, is provided.
- In certain exemplary embodiments, the diphtheria toxin or detoxified variant thereof is CRM197.
-
FIG. 1A -FIG. 1B depict the uptake of subunit KLH protein by DCOne mDC cells (n=3) (FIG. 1A ) and the labelling of OV90 ovarian cancer cells (n=2) (FIG. 1B ) after 4 hours and 24 hours. 0.08% trypan blue (TB) was added to quench extracellular bound subunit KLH-FITC to visualize the percentage intracellular subunit KLH-FITC. -
FIG. 2A -FIG. 2B depict the uptake of β-galactosidase protein by DCOne mDC cells (n=3) (FIG. 2A ) and the labelling of OV90 ovarian cancer cells (n=2) (FIG. 2B ) after 4 hours and 24 hours. 0.08% trypan blue was added to quench extracellular bound β-galactosidase-FITC to visualize the percentage intracellular β-galactosidase-FITC. -
FIG. 3 depicts the uptake of CRM197 protein by OV90 ovarian cancer cells (n=2) after 4 hours and 24 hours. 0.08% trypan blue was added to quench extracellular bound CRM197-Alexa488 to visualize the percentage intracellular CRM197-Alexa488. -
FIG. 4A -FIG. 4B depict tumor growth inhibition in a humanized U87-MG glioblastoma model. Tumor size was monitored three times per week using a digital caliper (FIG. 4A ). Tumor size at day 18 in vaccinated mice injected as indicated is shown inFIG. 4B . -
FIG. 5A -FIG. 5B depict tumor growth inhibition in a humanized A375 melanoma model. Tumor size was monitored three times per week using a digital caliper (FIG. 5A ). Tumor size afterday 30 in vaccinated mice injected as indicated is shown inFIG. 5B . -
FIG. 6A -FIG. 6D depict anti-KLH IgG (FIG. 6C-6D ) and IgM (FIG. 6A-6B ) levels in the serum of mice over time. Anti-KLH IgM and anti-KLH IgM concentrations (UI/mL) were measured by ELISA using the sera of mice taken at DO, D14 and at sacrifice. N=5 mice per group. Graphs represent the individual data of anti-KLH IgG and IgM per group ((FIG. 6A andFIG. 6C ) is the glioblastoma group, (FIG. 6B andFIG. 6D ) is the melanoma group). Two-way ANOVA with Dunnet's multiple comparison test was used. * vs vehicle group, *<0.05, **<0.01, ***<0.001, ****<0.0001). -
FIG. 7A -FIG. 7D depict the uptake of CRM197 protein by DCOne mDC cells (n=2) (FIG. 7A ) and labelling of DCOne progenitor AML cells (n=4) (FIG. 7B ), OV90 ovarian cancer cells (n=2) (FIG. 7C ), and U87 MG glioblastoma cancer cells (n=3) (FIG. 7D ) after 4 hours and 24 hours. 0.08% trypan blue was added to quench extracellular bound CRM197-Alexa488 to visualize the percentage intracellular CRM197-Alexa488. -
FIG. 8A -FIG. 8B depict tumor growth in a humanized OV90luc ovarian cancer mouse model. Tumor volumes (in mm3) were calculated by the ellipsoid formula (L×W×H)π/6 (FIG. 8A ). Bioluminescence intensity (photons/sec) is depicted (FIG. 8B ). -
FIG. 9 depicts imaging data showing bioluminescence intensity (total photon flux (Optical) per animal) over time. - Provided herein are methods for generating an immune response against a tumor in a subject. The methods generally comprise a vaccination step comprising administering a first composition to a subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen, and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the same non-tumor antigen (or nucleic acid encoding the same non-tumor antigen).
- The term “immune response,” as used herein, includes T-cell mediated and/or B-cell mediated immune responses. Exemplary immune functions of T cells include, e.g., cytokine production and induction of cytotoxicity in other cells. B-cell functions include antibody production. In addition, the term includes immune responses that are indirectly affected by T-cell activation, e.g., antibody production and activation of cytokine responsive cells, e.g., macrophages. Immune cells involved in the immune response include lymphocytes, such as B cells and T cells (CD4+ and CD8+ cells); antigen presenting cells (e.g., professional antigen presenting cells such as dendritic cells, macrophages, B lymphocytes, Langerhans cells, and non-professional antigen presenting cells such as keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes); natural killer cells; myeloid cells, such as macrophages, eosinophils, mast cells, basophils, and granulocytes. In certain embodiments, the term refers to a T-cell mediated immune response. The immune response may in some embodiments be a T cell-dependent immune response. The skilled person understands that the phrase “immune response against a tumor” also includes immune responses against a non-human antigenic polypeptide that is introduced into the tumor micro-environment by intratumoral administration, such as intratumoral administration of (i) dendritic cells, including autologous or allogeneic dendritic cells, loaded with said polypeptide or (ii) viruses comprising a nucleic acid encoding said polypeptide.
- The term “T-cell dependent immune response,” as used herein, refers to an immune response wherein either T-cells, B-cells or both T- and B-cell populations are activated, and wherein T-cells further assist T and B cells and other immune cells in executing their function.
- The term “tumor,” as used herein, includes reference to cellular material, e.g., a tissue, proliferating at an abnormally high rate. A growth comprising neoplastic cells is a neoplasm, also known as a “tumor,” and generally forms a distinct tissue mass in a body of a subject. A tumor may show partial or total lack of structural organization and functional coordination with the normal tissue. As used herein, a tumor is intended to encompass hematopoietic tumors as well as solid tumors. In certain embodiments, the tumor is a solid tumor. The term “tumor,” as used herein, includes reference to the tumor micro-environment or tumor site, i.e., the area within the tumor and the area directly outside the tumorous tissue. In certain embodiments, the tumor micro-environment or tumor site includes an area within the boundaries of the tumor tissue. In certain embodiments, the tumor micro-environment or tumor site includes the tumor interstitial compartment of a tumor, which is defined herein as all that is interposed between the plasma membrane of neoplastic cells and the vascular wall of the newly formed neovessels. As used herein, the terms “tumor micro-environment” or “tumor site” refers to a location within a subject in which a tumor resides, including the area immediately surrounding the tumor.
- A tumor may be benign (e.g., a benign tumor) or malignant (e.g., a malignant tumor or cancer). Malignant tumors can be broadly classified into three major types: those arising from epithelial structures are called carcinomas, those that originate from connective tissues such as muscle, cartilage, fat or bone are called sarcomas, and those affecting hematopoietic structures (structures pertaining to the formation of blood cells) including components of the immune system, are called leukemias and lymphomas. Other tumors include, but are not limited to, neurofibromatosis. In certain exemplary embodiments, the tumor is a glioblastoma. In certain exemplary embodiments, the tumor is an ovarian cancer (e.g., an epithelial ovarian cancer, which can be further subtyped into a serous, a clear cell, an endometrioid, a mucinous, or a mixed epithelial ovarian cancer).
- Solid tumors are abnormal masses of tissue that can be benign or malignant. In certain embodiments, solid tumors are named for the type of cells that form them (such as sarcomas, carcinomas, and lymphomas). Examples of solid tumors, such as sarcomas and carcinomas, include, but are not limited to, liposarcoma, fibrosarcoma, chondrosarcoma, osteosarcoma, myxosarcoma, and other sarcomas, mesothelioma, synovioma, leiomyosarcoma, Ewing's tumor, colon carcinoma, rhabdomyosarcoma, pancreatic cancer, lymphoid malignancy, lung cancers, breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, adenocarcinoma, basal cell carcinoma, sweat gland carcinoma, squamous cell carcinoma, medullary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary thyroid carcinoma, papillary adenocarcinomas, papillary carcinoma, medullary carcinoma, bronchogenic carcinoma, hepatoma, renal cell carcinoma, bile duct carcinoma, Wilms' tumor, choriocarcinoma, cervical cancer, seminoma, testicular tumor, bladder carcinoma, melanoma, CNS tumors (e.g., a glioma, e.g., brainstem glioma and mixed gliomas, glioblastoma (e.g., glioblastoma multiforme), germinoma, astrocytoma, craniopharyngioma, medulloblastoma, ependymoma, Schwannoma, CNS lymphoma, acoustic neuroma, pinealoma, hemangioblastoma, meningioma, oligodendroglioma, retinoblastoma, neuroblastoma, and brain metastases), and the like.
- Carcinomas that can be amenable to therapy by a method disclosed herein include, but are not limited to, squamous cell carcinoma (various tissues), basal cell carcinoma (a form of skin cancer), esophageal carcinoma, bladder carcinoma, including transitional cell carcinoma (a malignant neoplasm of the bladder), hepatocellular carcinoma, colorectal carcinoma, bronchogenic carcinoma, lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung, colon carcinoma, thyroid carcinoma, gastric carcinoma, breast carcinoma, ovarian carcinoma, adrenocortical carcinoma, pancreatic carcinoma, sweat gland carcinoma, prostate carcinoma, papillary carcinoma, adenocarcinoma, sebaceous gland carcinoma, medullary carcinoma, papillary adenocarcinoma, ductal carcinoma in situ or bile duct carcinoma, cystadenocarcinoma, renal cell carcinoma, choriocarcinoma, Wilm's tumor, seminoma, embryonal carcinoma, cervical carcinoma, testicular carcinoma, nasopharyngeal carcinoma, osteogenic carcinoma, epithelial carcinoma, uterine carcinoma, and the like.
- Sarcomas that can be amenable to therapy by a method disclosed herein include, but are not limited to, myxosarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, liposarcoma, fibrosarcoma, angiosarcoma, lymphangiosarcoma, endotheliosarcoma, osteosarcoma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, lymphangioendotheliosarcoma, synovioma, and other soft tissue sarcomas.
- The term “subject,” as used herein, refers to the recipient of a method as described herein, i.e., a recipient that can mount a cellular immune response, and is a mammal. In certain embodiments, the subject is a human. In certain embodiments, the subject is a domesticated animal, e.g., a horse, a cow, a pig, a sheep, a dog, a cat, etc. In certain embodiments, the subject is an animal suitable for veterinary healthcare, e.g., a zoo animal. The terms “patient” and “subject” may be used interchangeably. In certain embodiments, the subject is a human suffering from a tumor (e.g., a solid tumor). In certain embodiments, the subject is a domesticated animal suffering from a tumor (e.g., a solid tumor). In certain embodiments, the subject is an animal suitable for veterinary healthcare suffering from a tumor (e.g., a solid tumor). As used herein, an “animal suitable for veterinary healthcare” is any animal that is suitable for treatment by a veterinarian, and includes, without limitation, wild animals, domesticated animals, and zoo animals that are capable of mounting a cellular immune response.
- The term “polypeptide,” as used herein, refers to a molecule composed of amino acid monomers linearly linked by amide bonds (peptide bonds). As used herein, the term is mutually inclusive of the terms “peptide” and “protein” and includes reference to parts of said polypeptides.
- The term “nucleic acid,” as used herein, refers to DNA and RNA including mRNA or cDNA, as well as synthetic congeners thereof. The nucleic acid can be a recombinant or synthetic nucleic acid.
- The term “antigen” or “antigenic,” as used in relation to a polypeptide as described herein, refers generally to a biological molecule which contains at least one epitope specifically recognized by a T-cell receptor, an antibody, or other elements of specific humoral and/or cellular immunity. The whole molecule may be recognized, or one or more portions of the molecule, for instance following intracellular processing of a polypeptide into an MHC peptide antigen complex and subsequent antigen presentation. The term “antigenic polypeptide” is interchangeable with “polypeptide antigen.” This terminology includes antigenic parts of said polypeptides, for instance produced after intracellular processing of a polypeptide and in the context of a MHC peptide antigen complex. The term “antigen” or “antigenic” includes reference to at least one, or more, antigenic epitopes of a polypeptide as described herein. In certain embodiments, a “non-tumor antigen” refers to herein as an antigen that is not derived from a tumor. For example, in certain embodiments, a non-tumor antigen may be a foreign antigen. In certain exemplary embodiments, a non-tumor antigen may be a bacterial toxin, e.g., a non-toxic variant of diphtheria toxin.
- The term “antigen” or “antigenic” may also be used to refer to a polypeptide that includes modifications, such as deletions, additions and substitutions to the native sequence, as long as the polypeptide maintains the ability to be specifically recognized by T-cell receptors and/or antibodies following vaccination with said polypeptide as an immunogen. These modifications may be deliberate, as through site-directed mutagenesis, or through particular synthetic procedures, or through a genetic engineering approach, or may be accidental, such as through mutations of hosts, which produce the antigens. Synthetic antigens are also included, for example, polyepitopes, flanking epitopes, and other recombinant or synthetically derived antigens (Bergmann et al. (1993) Eur. J. Immunol. 23:2777 2781; Bergmann et al. (1996) J. Immunol. 157:3242 3249; Suhrbier, A. (1997) Immunol. and Cell Biol. 75:402 408; Gardner et al. (1998) 12th World AIDS Conference, Geneva, Switzerland, Jun. 28-Jul. 3, 1998, the disclosures of which are incorporated by reference herein in their entireties). In certain embodiments, the antigenic polypeptide contains at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 CD4+ T-helper cell epitope(s) and/or at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 CD8+ cytotoxic T-cell epitope(s).
- The term “immunogenic composition,” as used herein, refers to a substance which induces a specific immune response against an immunogen in a subject who is in need of an immune response against said immunogen. The composition may include an adjuvant and optionally one or more pharmaceutically-acceptable carriers, excipients and/or diluents. The immunogenic composition can be employed in prime-boost vaccination, such as at least 2, 3, 4 or at least 5 immunizations separated in time. The immunogenic composition can be an (allogeneic) dendritic cell comprising said immunogen.
- The term “immunogen,” as used herein, refers to a compound such as a polypeptide capable of eliciting an immune response that is specifically directed against an antigenic polypeptide as described herein. An immunogen is also an antigen, i.e., an antigenic polypeptide. In contrast, an antigen is not necessarily an immunogen. In certain embodiments, the immunogen is used for vaccination (in an immunogenic composition such as a vaccine composition), and the antigenic polypeptide prepared for intratumoral delivery is instead used for marking a tumor as a target for an immune response to be elicited, or as a target for an immune response that is already elicited, in a subject. The term “immunogen” is also used to refer to a nucleic acid which encodes the non-human antigenic polypeptide as described herein. In addition, embodiments that describe the antigenic polypeptide, also apply to an immunogen as described herein.
- The term “non-human,” as used herein in the context of an antigenic polypeptide, includes polypeptides that are not of human origin, including a bacterial polypeptide, a polypeptide of an organism of the Archaea domain, a fungal polypeptide and a viral polypeptide. Also included are plant polypeptides and non-human mammalian polypeptides such as polypeptides of non-human primates, rodents (e.g., mice and rats), rabbits, pigs, sheep, goats, cows, pigs, horses and donkeys, and birds (e.g., chickens, turkeys, ducks, geese and the like). Also included are polypeptides of snails or other mollusks, including Megathura crenulata. The term “non-human” also encompasses synthetic polypeptides, i.e., polypeptides that have an artificial sequence designed by man and that do not occur in nature or are not yet identified in nature. In addition, the term comprises human polypeptides comprising an amino acid alteration from the native sequence, the alteration providing for immunogenicity in a human subject.
- The term “intratumoral,” as used herein, refers to delivery or transport of the antigenic polypeptide, or the nucleic acid encoding said polypeptide, into a tumor. One example of intratumoral delivery, or transport, of an antigenic polypeptide as described herein is by intratumoral administration, a route of administration generally known in the art. As an alternative route for intratumoral administration, the antigen may be delivered to the tumor via a tumor-specific carrier, such as an oncolytic virus or a gene therapy vector, which have been broadly developed to deliver gene sequences to tumors. The use of such vehicles allows for multiple routes of administration, in addition to intratumoral administration, such by as intravenous or intraperitoneal administration, subsequently resulting in the delivery of the nucleic acid encoding said polypeptide, into the tumor (Lundstrom, Diseases, 6(2):42 (2018); Alemany, Biomedicines, 2, p. 36-49 (2014); Twumasi-Boateng et al., Nature Reviews Cancer 18, p. 419-432 (2018), the disclosures of which are incorporated by reference herein in their entireties).
- The phrase “prepared for intratumoral delivery,” as used herein, refers to an antigenic polypeptide as described herein, or a nucleic acid encoding said polypeptide as described herein, that is adapted for intratumoral delivery and/or is in a formulation that allows for intratumoral delivery. The preparation used for intratumoral delivery may be composed such that it has a beneficial effect on the interaction between the immune system and the tumor. For instance, dendritic cells, such as autologous or allogeneic dendritic cells, can be loaded with said polypeptide and upon intratumoral administration may provide for additional immune stimulation via direct interaction with T cells entering the tumor and/or indirectly by recruiting bystander antigen-presenting cells (Laurell et al., Journal for Immunotherapy of Cancer, 5:52 (2017); Wallgren et al., Scandinavian Journal of Immunology, 62, p. 234-242 (2005), the disclosures of which are incorporated by reference herein in their entireties). Another example of such preparation is that the polypeptide or nucleic acid as described herein can be comprised in a tumor-delivery vehicle such as a tumor-targeted vehicle including a tumor-specific virus such as an oncolytic virus (or any other virus that selectively replicates in tumor cells) that infects a tumor cell and which allows for (i) expression of said nucleic acid in a tumor cell, and (ii) (subsequently) intracellular processing and antigen presentation (MHC) of said (expressed) polypeptide by said tumor cell. The skilled person is well aware of other methods and means for preparing a polypeptide, or a nucleic acid encoding said polypeptide, for intratumoral delivery. For instance, the skilled person can apply other tumor-targeted delivery vehicles such as a tumor-specific nanoparticle or he can apply intratumoral administration through intratumoral injection in order to deliver said polypeptide or nucleic acid into a tumor. In certain embodiments, the polypeptide or nucleic acid prepared for intratumoral delivery as described herein, is comprised in a tumor-targeted vehicle.
- As used herein, the term “extratumoral” refers to a location, e.g., in the body of a subject, that is away (e.g., distal) from a tumor and immediately surrounding tissue (e.g., that may make up the tumor micro-environment).
- The compositions for use as described herein, elicit an immune response specifically directed against a tumor in a subject. The skilled person understands that “specifically directed” refers to an immune response that is specific for a tumor. The specificity is introduced by a step of marking a tumor with a non-human antigenic polypeptide as a target for an immune response, and by eliciting an immune response against an antigenic part of said non-human antigenic polypeptide (i.e., the target). Thus, In certain embodiments, the compositions for use as described herein, is for use in eliciting an immune response against a tumor marked as a target for said immune response. In certain embodiments, the compositions for use as described herein, is for use in eliciting an immune response against a tumor that is marked as a target for said immune response; wherein said target is a non-human antigenic polypeptide as described herein.
- In certain embodiments, the non-human antigenic polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery as described herein, serves the purpose of marking the tumor as a target for an immune response (polypeptide/nucleic acid for marking a tumor). Thus, In certain embodiments, said polypeptide or said nucleic acid prepared for intratumoral delivery marks the tumor as a target for an immune response following intratumoral delivery.
- As used herein, the term “vaccination step” refers to a step in a method (vaccination strategy) as described herein, wherein a composition comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide is administered to a subject at a site distal to a tumor site. In certain embodiments, in a vaccination step of a method as described herein, the composition is administered at a site that is not the site in which the tumor resides (e.g., not the tumor site). In certain embodiments, in a vaccination step of a method as described herein, the composition is administered at an extratumoral site.
- As used herein, the term “booster step” refers to a step in a method (vaccination strategy) as described herein, wherein a booster composition comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding the antigenic polypeptide is administered to a subject at a site distal to a tumor site. In certain embodiments, a booster step is performed after a vaccination step, wherein the vaccination step results in an immune response against the antigen, and the booster step enhances the immune response against the antigen. In certain embodiments, a booster step results in an enhanced immune response in a subject having pre-existing immunity against, e.g., an antigenic polypeptide (e.g., a non-tumor antigen). In certain embodiments, the vaccination step in a method as described herein is a booster stem, e.g., when the subject has pre-existing immunity against, e.g., a non-tumor recall antigen.
- The term “marking,” “mark” or “marked,” as used herein, refers to active manipulation of the antigenic state of a tumor by intratumoral delivery of an antigenic polypeptide, or a nucleic acid encoding said polypeptide, as described herein. This provides for direct labelling of a tumor cell through intracellular delivery and subsequent processing and presentation of said polypeptide by said tumor cell, or provides for indirect labelling of a tumor via: (i) intracellular delivery and subsequent processing and presentation of said polypeptide by a non-tumor cell in said tumor; or (ii) extracellular delivery of said antigenic polypeptide to said tumor (i.e., extracellular to the cells present in said tumor before marking), for instance by using a dendritic cell that comprises a nucleic acid encoding said polypeptide or that is loaded with said antigenic polypeptide. As used herein, the term “tumor-marking step” refers to a step in a method (e.g., a vaccination strategy) as described herein, wherein a composition comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide is administered to a subject at a tumor site. In certain exemplary embodiments, the tumor-marking step comprises the use of compositions, methods or technologies which facilitate the delivery of antigens into the cytosol of tumor cells.
- The immunogenic composition as described herein, which also comprises said non-human antigenic polypeptide or a nucleic acid encoding said polypeptide, but as an immunogen (polypeptide/nucleic acid for eliciting an immune response), serves the purpose of eliciting an immune response against a tumor that is marked, or to be marked, with said non-human antigenic polypeptide. Thus, in certain embodiments, said immunogen is used to elicit an immune response against a tumor that is marked, or is to be marked, with said non-human antigenic polypeptide, or a nucleic acid encoding said antigenic polypeptide, prepared for intratumoral delivery. In principle, any antigenic polypeptide can be introduced into a tumor to generate a new antigenic target. In certain embodiments, any antigenic polypeptide can be introduced into a tumor to generate new antigenic target that is a B-cell epitope and/or T-cell epitope recognizable by an antibody and/or T-cell receptor, respectively, when an immune response against said target is elicited following administration of an immunological composition as described herein to a subject.
- The skilled person directly understands that: (i) the non-human antigenic polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery as described herein (polypeptide/nucleic acid for marking a tumor); and (ii) the non-human antigenic polypeptide, or a nucleic acid encoding said polypeptide, comprised as an immunogen in an immunogenic composition as described herein (polypeptide/nucleic acid for eliciting an immune response), are matched in that the immunogen, when administered, elicits an immune response that is directed against one or more (target) epitopes established by the polypeptide or nucleic acid for marking the tumor.
- Thus, for instance, the polypeptides under (i) and (ii) are immunologically matched in that a T-cell epitope and/or a B-cell epitope of the marking polypeptide in a tumor are recognized by, or are reactive with, a T-cell and/or B-cell response elicited by the polypeptide employed as an immunogen. It is thus understood that the polypeptides under (i) and (ii) are based on the same non-human antigenic polypeptide and optionally share an identical antigenic part thereof, optionally at least one B-cell and/or T-cell epitope thereof (i.e., are immunologically matched). In this manner, the elicited immune response is specifically directed to the tumor marked as a target for said immune response. Thus, the formulations of the said polypeptide used for eliciting an immune response on the one hand and tumor marking on the other hand need not be the same. In fact, the skilled person appreciates that it might be beneficial to use different formulations of the said polypeptide for vaccination and tumor marking.
- The term “T-cell mediated immune response,” as used herein, refers to an immune response that is T-cell driven, and where elicitation of another or further immune response is dependent on activation of T-cells. In certain embodiments, the immune response is a T-cell mediated immune response/T-cell dependent immune response. The skilled person is well aware of methods and means for mounting a T-cell mediated immune response/T-cell dependent immune response, for instance through selection of an appropriate antigen of which many have been described in literature including but not limited to bacterial-, fungal-, mollusk-, snail-, insect- or plant-derived antigens to which measurable T cell responses have been documented, or by selecting an appropriate adjuvant or carrier such as a chemical adjuvant, biological adjuvant, protein, viral vaccine, dendritic cell vaccine or any other composition that can be administered as a vaccine composition (Bender et al., J. Exp. Med, 182:1663-1671 (1995); Bennett et al., Nature, 393:478-480 (1998); Kalinski and Moser, Nature, 5:251-260 (2005); Pashine et al., Nature Medicine Supplement, 11:S63-S68 (2005), the disclosures of which are incorporated by reference herein in their entireties).
- The term “tumor-specific virus,” as used herein, includes reference to any virus that has the capacity to selectively replicate in tumor cells.
- The term “oncolytic virus,” as used herein, refers to a virus that preferentially kills tumor cells as compared to normal cells. In addition, the term refers to viruses that can be engineered to carry a nucleic acid construct encoding a polypeptide, which is to be expressed in a tumor cell after infection of said tumor cell.
- The term “nanoparticle,” as used herein, refers to compositions that can carry a compound of interest, such as an antigenic polypeptide as described herein, and which can be functionalized on their surface with tumor-targeting or tumor-specific moieties. Examples of nanoparticles that can be engineered to actively target tumor cells are micelles and liposomes.
- The term “dendritic cell,” as used herein, refers to a professional antigen presenting cell (APC) that can take up an antigen such as an antigenic polypeptide into its cell, and presents the antigen, or an immunogenic part thereof together with an MHC class I complex or MHC class II complex. The term includes both immature dendritic cells (“imDC”) and mature dendritic cells (“mDC”), depending on maturity. In certain embodiments, the dendritic cell is a mature dendritic cell. In certain embodiments, the dendritic cell is a mature dendritic cell obtained from a cell of cell line DCOne as deposited under the conditions of the Budapest treaty with the DSMZ under accession number DSMZ ACC3189 on 15 Nov. 2012. The process of obtaining mature dendritic cells from the deposited DCOne cell line is for instance described in EP2931878B1.
- As used herein, the term “about” or “approximately” when referring to a measurable value, such as a distance from a tumor site, encompasses variations of ±20% or ±10%, ±5%, ±1%, or ±0.1% of a given value or range, as are appropriate to perform the methods disclosed herein.
- As provided herein, a first aspect relates to a vaccination step comprising the administration of (vaccination with) a first composition (e.g., an immunogenic composition) comprising a non-tumor antigen (e.g., a non-human antigenic polypeptide as an immunogen), or comprising a nucleic acid encoding a non-tumor antigen (e.g., a nucleic acid encoding a non-human antigenic polypeptide). In certain embodiments, the first composition comprises a non-tumor antigen or a nucleic acid encoding a non-tumor antigen. In certain embodiments, the first composition optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- As provided herein, a second aspect relates to a tumor-marking step comprising the administration of (vaccination with) a second composition (e.g., an immunogenic composition) comprising a non-tumor antigen (e.g., a non-human antigenic polypeptide as an immunogen), or comprising a nucleic acid encoding a non-tumor antigen (e.g., a nucleic acid encoding a non-human antigenic polypeptide). In certain embodiments, the second composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen. In certain embodiments, the second composition optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
- In certain embodiments, the non-tumor antigen (e.g., non-human antigenic polypeptide) as disclosed herein serves two purposes. The first purpose is in generating an immune response. In certain embodiments, the immune response is a T-cell mediated immune response, against the antigen (e.g., non-human antigen, non-tumor antigen), by being incorporated in an immunogenic composition as an immunogen. The second purpose is in marking a tumor as a target for said immune response. The skilled person will directly understand that it is necessary that the tumor marking and mounting/generation of an immune response are matched in that the mounted immune response is directed against the tumor thus marked. “Matched” means that the immune response (to be) elicited is specifically directed against the antigenic polypeptide actively introduced into the tumor. In certain embodiments, the same or a corresponding antigenic epitope is used in marking the tumor and in elicitation of an immune response. Therefore, In certain embodiments, following the administration of a first composition (e.g., an immunogenic composition) as described herein to a subject, an immune response is elicited that is specifically directed against a tumor that is to be marked (or a tumor that is already marked) as a target for an immune response based on the same antigen.
- In other words, the antigenic polypeptide in the second composition for marking, and the antigenic polypeptide in the first composition are matched, in that the immune response that is elicited following administration of the first composition to a subject is directed against a tumor marked with said antigenic polypeptide following intratumoral delivery of the same, or at least immunogenically the same, antigenic polypeptide. This may mean that the immune response elicited following administration of an immunogenic composition as described herein, is specifically directed to at least one T-cell epitope and/or B-cell epitope with which the tumor is to be marked (or is marked). In certain embodiments, the non-human antigenic polypeptide in said immunogenic composition is a polypeptide corresponding to the polypeptide used for tumor marking as described herein.
- In certain embodiments, the immune response elicited following administration of a first composition (e.g., an immunogenic composition) as described herein, is a T-cell mediated immune response or a T-cell-dependent immune response. It is within the skilled person's capabilities to identify appropriate immunogens and/or adjuvants that activate the cellular arm of immunity. References that aid the skilled person in selecting appropriate antigens are for instance Bender et al., J. Exp. Med, 182:1663-1671 (1995); Bennett et al., Nature, 393:478-480 (1998); Kalinski and Moser, Nature, 5:251-260 (2005); Van Tenderloo et al., PNAS, 107:31, p. 13824-13829 (2010); Anguille et al., Blood, 12; 130(15):1713-1721 (2017); Tacken et al., Blood, 106:4, p. 1278-1285 (2005); Vigneron et al, Cancer Immunity, 13:15 (2013); and Cheever et al, Clin Cancer Res; 15:5323-5337 (2009), all of which are incorporated by reference herein in their entirety. The skilled person directly understands that antigenic polypeptides described in relation to immunogenic compositions stand also in relation to intratumoral delivery aspects, and vice versa. Examples of suitable antigens include proteins of viral, bacterial, fungal origin; allergens, toxins and venoms, or model antigens of various sources such as chicken egg ovalbumin and keyhole limpet hemocyanin from the giant keyhole limpet, Megathura crenulata. In certain embodiments, a suitable antigen is of bacterial origin. In certain embodiments, a suitable antigen is a diphtheria toxin. In certain embodiments, a suitable antigen is a non-toxic variant of diphtheria toxin. In certain embodiments, a suitable antigen is CRM197. Other suitable antigenic polypeptides are polypeptides employed in a prior vaccination of a subject, such as recall antigens, which are described in more detail herein below. Common vaccines, used in such vaccinations, may include different antigenic polypeptides, which can be multivalent in that they comprise different microbial (recall) antigens with or without adjuvants.
- The term “recall antigen,” as used herein, refers to an antigen (e.g., antigenic polypeptide) which has previously (e.g., prior to the occurrence of a tumor in the subject or prior to a tumor-marking step) been encountered by a subject. Recall antigens are those which have previously been encountered by the subject and for which there exists pre-existing memory lymphocytes in the subject. In certain embodiments, a recall antigen refers to an antigen (e.g., antigenic polypeptide) for which pre-existing memory lymphocytes exist in the subject, e.g., as a result of prior infections or vaccinations. In certain embodiments, a recall antigen refers to an antigenic polypeptide which has previously been encountered by a subject via vaccination. In certain embodiments, the recall antigen is an antigenic polypeptide for which there is pre-existing immunity in said subject.
- The skilled person has multiple methods and means at his disposal that he can routinely apply in order to provide mounting of an immune response against a non-human antigenic polypeptide as an immunogen comprised in an immunogenic composition as described herein.
- References that aid the skilled person in selecting adjuvants that direct the immune response towards cellular immunity are for instance Pashine et al., Nature Medicine Supplement, 11: S63-S68 (2005) and Awate et al., Frontiers in Immunology, 4:114, p. 1-10 (2013), the disclosures of which are incorporated by reference herein in their entirety. Examples of such adjuvants are aluminum mineral salts, oil-in-water emulsions, liposomes, toll-like receptor agonists or combinations thereof. Other adjuvants include liposomes, virosomes, MF59, Montanide, ISCOMs, QS-21, aluminum, ASO4, Poly I:C, MPL, GLA, imiquimod, CpG ODN, chitin, chitosan, β-glucan, or combinations thereof. (Temizoz et al. Int Immunol. 2016 July; 28(7): 329-338, the disclosure of which is incorporated by reference herein in its entirety).
- In certain embodiments, compositions (e.g., a first composition comprising a non-tumor antigen and a second composition comprising the same non-tumor antigen) for use according to methods as described herein optionally comprise: a dendritic cell comprising the non-tumor antigen; a T-cell immune response-eliciting adjuvant; a T-cell immune response-eliciting virus or a virus-like particle comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen; or a combination thereof.
- In general, it is explicitly envisaged herein that embodiments that relate to the compositions for use in a method as described herein, also apply to aspects for instance the (i) non-tumor antigen (e.g., non-human antigenic polypeptide), or nucleic acid encoding the same for use in a method as described herein, (ii) immunogenic composition for use in a method as described herein, (iii) a method for eliciting an immune response, (iv) a method of treatment, and other aspects for use in a method as described herein where appropriate.
- In certain embodiments, a method of the present disclosure employs the use of a first composition and a second composition. In certain embodiments, the first composition comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. In certain embodiments, the first composition comprises an antigenic polypeptide. In certain embodiments, the first composition comprises a nucleic acid encoding an antigenic polypeptide. In certain embodiments, the first composition comprises a non-tumor antigen. In certain embodiments, the first composition comprises a nucleic acid encoding a non-tumor antigen.
- In certain embodiments, the second composition comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide (i.e., the second composition comprises an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide which is the same as the antigenic polypeptide as in the first composition, or at least, immunologically the same antigenic polypeptide as in the first composition). In certain embodiments, the second composition comprises an antigenic polypeptide. In certain embodiments, the second composition comprises a nucleic acid encoding the antigenic polypeptide. In certain embodiments, the second composition comprises a non-tumor antigen. In certain embodiments, the second composition comprises a nucleic acid encoding a non-tumor antigen.
- In certain embodiments, the first composition and/or the second composition may comprise a dendritic cell comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. In certain embodiments, the first composition comprises a dendritic cell comprising an antigenic polypeptide or a nucleic acid encoding an antigenic polypeptide. In certain embodiments, the second composition comprises a dendritic cell comprising an antigenic polypeptide or a nucleic acid encoding an antigenic polypeptide. In certain embodiments, the first composition comprises a dendritic cell comprising a non-tumor antigen or a nucleic acid encoding a non-tumor antigen. In certain embodiments, the second composition comprises a dendritic cell comprising a non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- In certain embodiments, the dendritic cell is employed as a dendritic cell vaccine, provided that such cells are loaded with the antigenic polypeptide as described herein. In certain embodiments, a composition (e.g., a first composition or a second composition) comprises a mature dendritic cell differentiated from a precursor cell line. In certain embodiments, a composition (e.g., a first composition or a second composition) comprises a mature dendritic cell that is CD34-positive, CD1a-positive, and CD83-positive. In certain embodiments, the dendritic cell is a cell of cell line DCOne as deposited at the DSMZ under accession number DSMZ ACC3189 on 15 Nov. 2012. See, e.g., WO 2014/006058, the disclosure of which is incorporated by reference herein in its entirety For example, in certain embodiments, the first composition and/or the second composition each comprise a dendritic cell of cell line DCOne comprising an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding the antigenic polypeptide. Loading strategies for dendritic cells are discussed herein. The skilled person has ample guidance on how dendritic cells can be effectively used in the form of immunogenic compositions, which is for instance described in multiple references including EP2931878 B1, WO 2014/006058 A1, WO 2009/019320 and Saxena and Bhardwaj, Trends in Cancer, 4:2, p. 119-137 (2018), the disclosures of which are incorporated by reference herein in their entirety.
- In certain embodiments, a pharmaceutically effective amount of a composition is administered. As used herein, an “effective amount” or a “pharmaceutically effective amount” of, e.g., a first composition or a second composition, refers to an amount effective, at dosages and for periods of time necessary to achieve an immune response. For example, an effective amount is sufficient to induce an immune response against an antigenic polypeptide (e.g., non-tumor antigen), optionally comprised in a dendritic cell. An effective amount is sufficient to induce an immune response against a tumor that has been marked using an antigenic polypeptide (e.g., non-tumor antigen) as described herein.
- A first composition and/or a second composition as described herein may comprise any adjuvant known to those in the art. Adjuvants known in the art, regardless of the route of administration, may be employed to improve/enhance the immunogenicity of an antigenic polypeptide (e.g., a non-tumor antigen) comprised within a composition of the present disclosure. Adjuvants enhance the immunogenicity of an antigen (e.g., a composition comprising a non-tumor antigen) but are not necessarily immunogenic themselves.
- Adjuvants have been used by those of skill in the art to improve immune responses to, e.g., vaccines. Adjuvants may be intrinsic or extrinsic. Intrinsic adjuvants may be derived from killed or attenuated bacteria used as vaccines. Extrinsic adjuvants maybe an immune modulating substance non-covalently linked to antigens and are formulated to enhance immune responses.
- In certain embodiments, the first composition and/or the second composition may comprise a T-cell immune response-eliciting adjuvant. The term “T-cell immune response-eliciting,” as used in relation to adjuvants or virus or virus-like particles herein, refers to enhancing CD4+ and/or CD8+ T-cell immune responses or driving the immune response towards CD4+ and/or CD8+ T-cell activation. The skilled person is well aware of adjuvants that can be employed for this purpose, such as liposomes, virosomes, MF59, Montanide, ISCOMs, QS-21, aluminum, ASO4, Poly I:C, MPL, GLA, imiquimod, CpG ODN, chitin, chitosan, β-glucan, or combinations thereof. (Temizoz et al. Int Immunol. 2016 July; 28(7): 329-338, the disclosure of which is incorporated by reference herein in its entirety).
- In certain embodiments, adjuvants may be used specifically for parenteral modes of administration. Such adjuvants include, e.g., aluminum compounds (such as aluminum phosphate and aluminum hydroxide). The antigen can be precipitated with, or adsorbed onto, an aluminum compound according to standard protocols. Other adjuvants for parenteral modes of administration, as well as intratumoral or peri-tumoral modes of administration, are known to those of skill in the art.
- A first composition and/or a second composition as described herein may comprise a virus, for example, a T-cell immune response-eliciting virus, or a virus-like particle (VLP), comprising an antigenic polypeptide (e.g., non-tumor antigen) or a nucleic acid encoding the antigenic polypeptide. It is within routine experimentation to design and produce a virus or VLP that can be employed in, or as a composition as described herein. Such viruses, especially T-cell immune response-eliciting viruses or VLPs, have been described extensively for vaccination purposes. This follows for instance from Frietze et al., Curr Opin Virol., 18: 44-49 (2016); Koup and Douek, Cold Spring Harb Perspect Med, 2011; 1: a007252, the disclosures of which are incorporated by reference herein in their entireties. Examples of T-cell immune response-eliciting viruses or VLPs are for instance cowpox (vaccinia) viruses or derivatives thereof such as modified vaccinia virus Ankara (MVA), adenovirus or adeno-associated viruses and VLP's based on human papillomavirus, hepatitis B virus or VLP's engineered to present different tumor antigens. In certain embodiments, a composition as described herein (e.g., the second composition used in a tumor marking step) may comprise an oncolytic virus. Viruses that have been clinically tested to be oncolytic include, without limitation, adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus, and vaccinia.
- As used herein, the term “pharmaceutical composition” or “pharmaceutical formulation” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective (e.g., permit an antigenic polypeptide contained therein to be immunogenic), and which contains no additional unacceptably toxic components, with respect to toxicity when administered to a subject. A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation and/or composition, other than an active ingredient, which is nontoxic to a subject. Pharmaceutically acceptable carriers include, without limitation, a stabilizer, excipient, buffer, or preservative. In certain embodiments, the choice of carrier is determined in part by the particular method of administration. Accordingly, there are a variety of suitable formulations and compositions. Various formulations and compositions are known in the art that are suitable for, e.g., intratumoral administration, intramuscular administration, and other routes of administration.
- In certain embodiments, the pharmaceutical composition can contain preservatives. Suitable preservatives may include, e.g., propylparaben, methylparaben, benzalkonium chloride, and sodium benzoate. In certain embodiments, a mixture of two or more preservatives is used. The preservative or mixtures thereof are typically present in an amount of about 0.0001% to about 2% by weight of the total composition.
- Carriers are further described, e.g., by Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriers are generally nontoxic to subjects administered compositions according to methods described herein at the dosages and concentrations employed, and include, but are not limited to: buffers such as citrate, phosphate, and other organic acids; antioxidants including methionine and ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; hydrophilic polymers such as polyvinylpyrrolidone; proteins, such as gelatin, immunoglobulins, or serum albumin; preservatives (such as benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; octadecyldimethylbenzyl ammonium chloride; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; hexamethonium chloride; 3-pentanol; cyclohexanol; and m-cresol); amino acids such as glutamine, asparagine, histidine, glycine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including dextrins, glucose, or mannose; sugars such as sucrose, trehalose, sorbitol, or mannitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); non-ionic surfactants such as polyethylene glycol (PEG); and/or chelating agents such as EDTA.
- In certain embodiments, buffering agents are included in the compositions. Suitable buffering agents include, for example, sodium citrate, citric acid, potassium phosphate, phosphoric acid, and various other acids and salts. In certain embodiments, a mixture of two or more buffering agents is used. The buffering agent or mixtures thereof are typically present in an amount of about 0.001% to about 4% by weight of the total composition. Methods for preparing administrable pharmaceutical compositions are known to those in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).
- In certain embodiments, the compositions and formulations described herein can include aqueous solutions. The formulation or composition may also contain more than one active ingredient useful for the particular indication, disease, or condition (e.g., tumor type) being treated using a method as described herein. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
- Formulations and compositions include those for oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. Formulations and compositions include those for any one of various routes of administration known in the art to those of skill in the art. In certain embodiments, the compositions are administered parenterally. The term “parenteral,” as used herein, includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration.
- In certain embodiments, compositions and formulations are provided as sterile liquid preparations, e.g., suspensions, emulsions, dispersions, viscous compositions, or isotonic aqueous solutions, which may in some embodiments be buffered to a selected pH. In certain embodiments, compositions and formulations are provided as gels, other viscous compositions, and solid compositions. Viscous compositions, can be formulated within the appropriate viscosity range to provide longer contact periods with specific tissues. Liquid or viscous compositions can comprise carriers, which can be a solvent or dispersing medium containing, e.g., saline, phosphate buffered saline, water, polyol (e.g., propylene glycol, liquid polyethylene glycol, glycerol) and suitable mixtures thereof.
- Sterile injectable solutions can be prepared by incorporating into the compositions a solvent, such as in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, dextrose, or the like. The compositions can contain gelling or viscosity enhancing additives, pH buffering agents, auxiliary substances such as wetting, dispersing, or emulsifying agents (e.g., methylcellulose), flavoring agents, colors, and/or preservatives, depending upon the route of administration and the preparation desired. Standard texts available to those having knowledge in the art may in some aspects be consulted to prepare suitable preparations.
- Various additives which enhance the sterility and stability of the compositions, can be added, including without limitation chelating agents, antimicrobial preservatives, buffers, and antioxidants. Compositions can be kept sterile from or of the action of microorganisms by various antibacterial and antifungal agents, e.g., chlorobutanol, parabens, phenol, and sorbic acid. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- The skilled person is aware of other suitable immunogenic compositions that mount an immune response against an antigen as described herein. For instance, other options involve the use of a subunit vaccine comprising an immunogen as described herein, and carrier proteins coupled to an immunogen.
- In certain embodiments, a composition for use in a method as described herein comprises an antigenic polypeptide (e.g., a non-tumor antigen), or a nucleic acid encoding the antigenic polypeptide. In certain embodiments, where the antigenic polypeptide is in a composition for intratumoral administration, the antigenic polypeptide is tumor-targeted or prepared for intratumoral delivery, or the nucleic acid encoding the antigenic polypeptide, is either tumor-targeted or is prepared for intratumoral administration. The skilled person will understand that the new concept of tumor antigen-independent vaccination can be realized with multiple methods and means known in the art, both with regard to the marking of a tumor, as well as with the vaccination that mounts an immune response against a marked tumor as already described.
- In the medical methods described herein, marking or labelling of a tumor as a target for an immune response by employing a non-human antigenic polypeptide as described herein, occurs in vivo, not in vitro or ex vivo.
- More specifically, the antigenic polypeptide or nucleic acid as described herein can be prepared for intratumoral delivery in a variety of ways, generally well known in the art. For instance, preparing may involve tumor-targeting of said polypeptide or nucleic acid, e.g., by preparing a tumor-targeting composition comprising said polypeptide or nucleic acid. A tumor-targeting composition comprises the polypeptide or nucleic acid in such a way that it is rendered tumor-specific. In certain embodiments, upon administration of a tumor-targeted polypeptide or nucleic acid to a subject, intratumoral delivery is effectuated on the basis of specificity for tumor tissue as compared to non-tumor tissue. Tumor specificity also indicates that it may allow for homing to a tumor so as to provide for intratumoral delivery.
- In certain embodiments, the polypeptide prepared for intratumoral delivery, or the nucleic acid encoding said polypeptide, is tumor-targeted by using one or more of, e.g., a tumor-specific virus, including an oncolytic virus, comprising a nucleic acid encoding said polypeptide; a tumor-specific nanoparticle comprising said polypeptide or a nucleic acid encoding said polypeptide. In certain embodiments, said polypeptide or nucleic acid is tumor-targeted by using a tumor-targeting antibody, peptide, small molecule, or nucleic acid aptamer fused to said polypeptide or nucleic acid.
- Another way of tumor-targeting a polypeptide or nucleic acid as described herein (so as to effectuate intratumoral delivery upon administration to a subject) involves the preparation of an oncolytic virus that comprises a nucleic acid encoding an antigenic polypeptide as described herein, which is engineered to express said nucleic acid into a tumor cell. That oncolytic viruses can be used to specifically target tumor cells is extensively described in the art, for instance in Lawler et al., JAMA Oncol. 1; 3(6):841-849 (2017); Howells et al., Front Oncol. 7:195 (2017), the disclosures of which are incorporated by reference herein in their entireties. In addition, as exemplified in for instance WO2014138314 A1 (the disclosure of which is incorporated by reference herein in its entirety), oncolytic viruses can be modified to engage tumor cells. It is also well-known in the art that oncolytic viruses can be used to deliver a nucleic acid construct encoding a polypeptide into a tumor cell, said virus being engineered to express said polypeptide into a tumor cell (Hutzler et al., Scientific Reports, 7: 16892 (2017); Grossardt et al., Human Gene Therapy, 24:644-654 (2013); Andtbacka et al., Journal of Clinical Oncology, 22:25, p. 2780-2788 (2015), the disclosures of which are incorporated by reference herein in their entireties). Subsequent intracellular processing of said polypeptide and antigen-presentation by said tumor cell provide for a tumor marked with an antigenic polypeptide as described herein. In other words, and in certain embodiments, following intratumoral delivery an antigenic polypeptide as described herein is presented by the MHC system of a tumor cell upon expression of said nucleic acid as described herein in a cell of said tumor to thereby mark said tumor as a target for an immune response.
- Examples of oncolytic viruses that can be used for tumor-targeting are Adenovirus, Herpes simplex virus, Pox virus, Coxsackie virus, Maraba virus, Poliovirus, Measles virus, Newcastle Disease virus (Lal and Rajala, Cancer Gene Therapy, DOI 10.1038/s41417-018-0018-1 (2018); Haddad, Frontiers in Immunology, 7:96 (2017); Bommareddy et al., Nature Reviews Immunology (2018), the disclosures of which are incorporated by reference herein in their entireties).
- A tumor-specific virus such as an oncolytic virus may be prepared in a pharmaceutical formulation adapted for parenteral administration. Such a formulation generally comprises a carrier such as for instance an aqueous or oily solution, dispersion, emulsion and/or suspension. Parenteral administration involves the injection or infusion into a body tissue or body fluid, whereby in certain embodiments, a syringe, needle, or catheter is used. In certain embodiments, the carrier is an aqueous solution, and in certain embodiments, distilled sterile water, saline, buffered saline, or another pharmaceutically acceptable excipient for injection. Examples of parenteral modes of administration are intravenous, intra-arterial, intra-peritoneal, subcutaneous, intramuscular and intratumoral administration, which are well known to the person skilled in the art. In certain embodiments, a mode of administration of a tumor-specific virus such as an oncolytic virus is intravenous or intratumoral administration (Marelli et al., Frontiers in Immunology, 9:866 (2018), the disclosure of which is incorporated by reference herein in its entirety).
- The dose to be administered of a tumor-specific virus such as an oncolytic virus is a pharmaceutically effective dose, i.e., a dose sufficient to deliver an antigenic polypeptide or nucleic acid as described herein into a tumor. It is routine practice to determine a dosing regimen for a tumor-specific virus.
- An alternative way of tumor-targeting a polypeptide or nucleic acid as described herein (so as to effectuate intratumoral delivery upon administration to a subject), involves the preparation of a tumor-specific nanoparticle comprising an antigenic polypeptide or nucleic acid as described herein, the latter being engineered to express said nucleic acid in a tumor cell after delivery. In the field of cancer therapy, it is well known that a nanoparticle, which comprises a nanocarrier loaded or combined with for instance a polypeptide of interest, are extensively described in relation to specifically/selectively targeting (homing to) tumor cells and to subsequently deliver for instance a medicament such as a polypeptide to said tumor cell. Methods and means for tumor-targeting of nanoparticles or nanocarriers is generally known and is inter alia described in Olusanya et al., Molecules 23:907 (2018); Din et al., Int J Nanomedicine, 12:7291-7309 (2017); Alibakhshi et al., J Control Release, 268:323-334 (2017); and US 2013/0330399 A1, the disclosures of which are incorporated by reference herein in their entireties. In certain embodiments, tumor-specific delivery methods including, without limitation, use of nanoparticles, use of liposomes, and use of photochemical processes (e.g., photochemical internalization) may be used to enhance the delivery of an antigen (e.g., an antigenic polypeptide (e.g., a non-tumor antigen), or a nucleic acid encoding the antigenic polypeptide) into the cytosol of a tumor cell.
- Photochemical internalization refers to a delivery method which involves the use of light and a photosensitizing agent for introducing otherwise membrane-impermeable molecules into the cytosol of a target cell, but which does not necessarily result in destruction or death of the target cell. In this method, the molecule to be internalized or transferred is applied to the cells in combination with a photosensitizing agent. Exposure of the cells to light of a suitable wavelength activates the photosensitizing agent which in turn leads to disruption of the intracellular compartment membranes and the subsequent release of the molecule into the cytosol. In photochemical internalization, the interaction between the photosensitizing agent and light is used to affect the cell such that intracellular uptake of the molecule is improved. Photochemical internalization as well as various photosensitizing agents are described in PCT Publication Nos. WO 96/07432, WO 00/54708, WO 01/18636, WO 02/44396, WO 02/44395, and WO 03/020309, U.S. Pat. Nos. 6,680,301, 5,876,989, the disclosures of which are incorporated by reference herein in their entireties. In certain embodiments, photochemical internalization is used to deliver an antigen into the cytosol of a tumor cell. In certain embodiments, photochemical internalization is used to enhance the delivery of an antigen into the cytosol of a tumor cell.
- The nanoparticle, or nanocarrier as main part of the nanoparticle, can be a polymeric nanoparticle, a micelle, a liposome, a nanogel or a carbon nanotube. Such a particle or carrier can be loaded with a compound of interest (such as a polypeptide) and actively targeted to a tumor by decorating such a particle or carrier with for instance antibodies or antibody fragments specific for a tumor antigen expressed on the surface of a tumor cell (see also the aforementioned references). Tumor-targeting moieties for a nanoparticle can in principle be any biological or chemical structure that displays affinity for a molecule expressed on a tumor cell, such as a peptide, oligopeptide or polypeptide, a protein, a hormone, a vitamin, an enzyme, a ligand of a tumor antigen or an antibody or antibody fragment that specifically binds to a tumor antigen. In certain embodiments, after administration of a tumor-targeted nanoparticle and subsequent homing and binding to a tumor cell, receptor-mediated endocytosis (internalization) allows for uptake of a nanocarrier by a tumor cell, thereby providing intracellular delivery of for instance a polypeptide of interest, which can be intracellularly processed and subsequently presented as an antigen in an MHC complex by a tumor cell.
- Alternatively, after administration of a tumor-targeted nanoparticle and subsequent homing to a tumor and binding to a non-tumorous cell in the tumor, including an immune cell, such as a phagocytic cell or fibroblast, receptor-mediated endocytosis (internalization) allows for uptake of a nanocarrier by said cell, thereby providing intracellular delivery of for instance a polypeptide of interest in a tumor, which can be intracellularly processed and subsequently presented as an antigen in an MHC complex by said cell in said tumor. Specific examples of tumor-specific (or tumor-targeted) nanoparticles that can be employed for intratumoral delivery of an antigenic polypeptide or nucleic acid as described herein, are for instance poly(propylene) sulfide (PPS) nanoparticles, gold nanoparticles, PLGA nanoparticles, artificial exosomes, micelles or dendrimers.
- In certain embodiments, a tumor-specific nanoparticle as described herein is prepared in a pharmaceutical formulation adapted for parenteral administration. Such a formulation generally comprises a carrier such as for instance an aqueous or oily solution, dispersion, emulsion and/or suspension. Parenteral administration involves the injection or infusion into a body tissue or body fluid, whereby in some cases, a syringe, needle, or catheter is used. In certain embodiments, the carrier is an aqueous solution, and in certain embodiments, the carrier is distilled sterile water, saline, buffered saline, or another pharmaceutically acceptable excipient for injection. Examples of parenteral modes of administration are intravenous, intra-arterial, intra-peritoneal, subcutaneous, intramuscular and intratumoral administration, which are well known to the person skilled in the art. In certain embodiments, a mode of administration of a tumor-specific nanoparticle is intravenous or intratumoral administration.
- The dose of tumor-specific nanoparticle to be administered is a pharmaceutically effective dose, i.e., a dose sufficient to deliver an antigenic polypeptide or nucleic acid as described herein into a tumor. For a skilled person, it is routine practice to determine a dosing regimen for a tumor-specific nanoparticle.
- In embodiments where the antigenic polypeptide or the nucleic acid as described herein is not tumor-targeted, they are prepared for intratumoral delivery by being in a form that allows for intratumoral injection. The skilled person directly understands that tumor-targeted compositions as described herein can also be administered intratumorally. The skilled person is aware of pharmaceutical formulations that are adapted for intratumoral injection, which may comprise a carrier such as for instance an aqueous or oily solution, dispersion, emulsion and/or suspensions. In embodiments where the antigenic polypeptide or nucleic acid as described herein are not tumor-targeted, the antigenic polypeptide and/or nucleic acid are, In certain embodiments, comprised in a dendritic cell, or the antigenic polypeptide is in an aqueous suspension or solution. In the same manner, in embodiments where the antigenic polypeptide or nucleic acid as described herein are not tumor-targeted, the antigenic polypeptide and/or nucleic acid can be comprised in a virus. It is thus explicitly envisaged herein that marking of a tumor with an antigenic polypeptide can occur at a tumor cell, but does not necessarily require intracellular processing and antigen presentation by a tumor cell itself. For instance, such intracellular processing can also be effectuated by other cell types in the tumor, including immune cells such as phagocytic cells—of which macrophages are an example—or fibroblasts. When dendritic cells are employed for tumor marking, marking of a tumor can be performed by antigen processing through the MHC system of the dendritic cell itself which dendritic cell is intratumorally injected. It is also known that dendritic cells, in particular allogeneic dendritic cells, may attract endogenous immune cells including NK cells and cross-prime dendritic cells which enforces the immune response in the tumor (Laurell et al. 2017, J for Immunother. Of Cancer 5: 52, the disclosures of which is incorporated by reference herein in its entirety).
- Without being bound by theory, recruitment of previously ‘untouched’ immune cells into the tumor, or using pre-existing immunity that was, before tumor marking, not directed against a tumor, breaks immune tolerance resulting in further recruitment of immune cells directed against, i.e., tumor antigens of the tumor.
- With regard to tumor marking, the skilled person is well aware of methods and means relating to loading of dendritic cells with an antigenic polypeptide or with a nucleic acid, such as mRNA, encoding such a polypeptide. See for instance Van Nuffel et al., ISBT Science Series, 8, 161-164 (2013); WO 2014/006058 A1; WO 2009/034172 A1, the disclosures of which are incorporated by reference herein in their entireties. In addition, the skilled person is well aware of methods and means for intratumoral injection of dendritic cells. See for instance US 2004/0057935 A1; Cripe et al., Molecular Therapy, 23: 3, p. 602-608 (2015); Hirooka et al., Oncotarget, 9:2, p. 2838-2847 (2018); Triozzi et al., Cancer, 89:12, p. 2646-2654 (2000); Laurell et al., Journal for ImmunoTherapy of Cancer, 5:52 (2017), the disclosures of which are incorporated by reference herein in their entireties. In certain embodiments, said polypeptide prepared for intratumoral delivery, or said nucleic acid encoding said polypeptide, is for intratumoral administration and is in the form of a dendritic cell. In certain embodiments, the dendritic cell is a (mature) dendritic cell obtained from a cell of cell line DCOne as described herein, comprising said polypeptide or said nucleic acid encoding said polypeptide as described herein. A person skilled in the art can routinely define a dosing regimen that suits intratumoral administration of a dendritic cell comprising an antigenic polypeptide or a nucleic acid encoding said polypeptide (such as an mRNA) as described herein. The same applies to an aqueous suspension or solution comprising an antigenic polypeptide as described herein.
- It is clear that tumor marking can be effectuated via multiple different methods and means, as long as the tumor is marked with an antigenic polypeptide as described herein. For instance, tumor marking does not have to be effectuated exclusively by intracellular processing of antigenic polypeptides by tumor cells or other cell types in the tumor. It is also possible that the antigenic polypeptides prepared for intratumoral delivery are extracellular in the tumor and are thus not internalized by cells in said tumor. The presence of an extracellular antigenic polypeptide in the tumor will attract immune cells activated prior to marking by a vaccination step as described herein. In certain embodiments, such a vaccination step, and subsequent generation of immunity, is performed prior to tumor marking.
- Further, the polypeptide, or nucleic acid encoding said polypeptide, prepared for intratumoral delivery are, in certain embodiments, accompanied by immuno-modulatory compounds, such as a chemokine and/or cytokine, that modulates the tumor, in certain embodiments, the tumor site or TME, to increase susceptibility to an immune response, in some cases to convert at least partially an immuno-tolerant tumor environment into an immuno-sensitive tumor environment or to facilitate (optimal) T-cell functionality in the tumor site or TME. Such an immunomodulatory compound is in some cases included in an tumor-specific virus, tumor-specific nano-particle, dendritic cell, or aqueous suspension or solution as described herein, either in the form of a polypeptide, or as a nucleic acid encoding such an polypeptide. In certain embodiments, examples of such immunomodulatory compounds are e.g., GM-CSF, CCRS, XCL1, CCL20 and CCL21 (Mohan et al., Immunobiology, 223:477-485 (2018); He et al., Journal of Experimental & Clinical Cancer Research, 29:37 (2010); Nguyen-Hoai et al., Cancer Gene Therapy, 19: 69-76 (2012), the disclosures of which are incorporated by reference herein in their entireties). Thus, for use in a method as described herein, said antigenic polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery is in a composition that also comprises an immuno-modulatory compound (such as an immuno-modulatory polypeptide or a nucleic acid encoding said immuno-modulatory polypeptide), that converts at least partially an immuno-tolerant tumor site or TME into an immuno-sensitive tumor site or TME, and/or facilitates T-cell functionality in the tumor site or TME. In certain embodiments, said immuno-modulatory compound is an immunomodulatory polypeptide, or a nucleic acid encoding said immuno-modulatory polypeptide. In certain embodiments, the immuno-modulatory polypeptide is, or encodes for, GM-CSF, CCRS, XCL1 or CCL20, human GM-CSF, CCRS, XCL1 or CCL20. In certain embodiments, such an immuno-modulatory compound facilitates T-cell functionality in the tumor site or TME.
- The term “immuno-tolerant TME,” or “immuno-tolerant tumor site” as used herein, refers to a well-established phenomenon wherein the environment within a tumor provides for tolerance of, or insensitivity to, an antitumor immune response. In certain embodiments, a tumor site or TME is immuno-tolerant if it is more tolerant of, or more insensitive to, an immune response directed against a tumor in said TME, as compared to an immune response directed against a target in an environment outside said tumor, such as for instance an environment in or near healthy cells or healthy tissue.
- The term “immuno-sensitive TME” or “immuno-sensitive tumor site,” as used herein, refers to a situation wherein a tumor is sensitive or susceptible to an antitumor immune response.
- With regard to the antigenic polypeptide for use in a method as described herein, it is an embodiment of the present disclosure that the polypeptide is not a tumor antigen. The term “tumor antigen,” as used herein, includes both tumor associated antigens (TAAs) and tumor specific antigens (TSAs), including tumor neo-antigens. A tumor associated antigen is an antigen that is expressed on the surface of a tumor cell in higher amounts than is observed on normal cells or an antigen that is expressed on normal cells during fetal development. A tumor specific antigen is an antigen that is unique to tumor cells and is not expressed on normal cells. The term tumor antigen includes TAAs or TSAs that have been already identified and those that have yet to be identified.
- Any antigenic polypeptide can be employed insofar it is immunogenic in a human subject. This includes both antigenic polypeptides of human and non-human origin. Therefore, an antigenic polypeptide can be a human or non-human antigenic polypeptide that is immunogenic in a human subject. In certain embodiments, the antigenic polypeptide is non-human. It is nonetheless explicitly envisaged herein that in aspects and/or embodiments that recite the term “non-human antigenic polypeptide,” that aspect or embodiment can be amended so as to refer to “human antigenic polypeptide,” or the term “human antigenic polypeptide” can be added in such aspects and/or embodiments. Human antigenic polypeptides that are immunogenic in a human subject are for instance embryonic, ovarian or testis polypeptides. This applies for instance to NY-ESO-1, WT-1 and the MAGE antigens (see for instance Cheever et al, Clin Cancer Res; 15:5323-5337 (2009); Vigneron et al, Cancer Immunity, 13:15 (2013) the disclosures of which are incorporated by reference herein in their entireties).
- In one aspect, it is provided that the non-human antigenic polypeptides that are to be employed as the immunogen and marker in aspects of a method as described herein are not previously encountered by a subject as part of an immune response against a tumor. As such, in certain embodiments, the antigenic polypeptides are non-tumor antigens. In certain embodiments, the antigenic polypeptides are antigens that have not previously been encountered by the immune system of the subject and to which a subject is thus immunologically naïve, or are antigenic polypeptides previously encountered by a subject, but not as part of an immune response against a tumor, and in some cases for which protective immunity (memory T-cells and/or B-cells) exists. The latter can be highly beneficial, since it is not necessary to mount a de novo immune response, which takes time to mount, but instead taps into, or re-activates, existing immunity and directs it to a tumor according to the principle mechanism of a method as described herein. Therefore, in one embodiment, an non-human antigenic polypeptide as described herein is rarely if ever encountered (by the immune system) by a large portion of the human population intended for potential vaccination or is an antigenic polypeptide against which immunity pre-exists (is present in a subject), wherein said immunity is not directed against a tumor. The latter form of immunity can for instance be provided by a prior vaccination against an infectious disease earlier in life, including vaccination against hepatitis, such as hepatitis A and/or B, diphtheria, tetanus, pertussis, influenza, Haemophilus influenzae type b, polio (poliomyelitis), measles, mumps, rubella, varicella, human papillomavirus, Streptococcus pneumoniae (pneumonia), Neisseria meningitides (meningitis) or rotaviruses (rotaviral infection). Explicitly envisaged herein as non-human antigenic polypeptides for use according to a method as described herein are immunogenic polypeptides of one or more of hepatitis, including hepatitis A and/or B, diphtheria, tetanus, pertussis, influenza, Haemophilus influenzae type b, polio, measles, mumps, rubella, varicella, human papillomavirus, Streptococcus pneumoniae, Neisseria meningitides or rotaviruses. In certain embodiments, a non-human antigen polypeptide as described herein is a microbial polypeptide employed in a prior vaccination of said subject. In certain embodiments, the prior vaccination was against an infectious disease. In certain embodiments, the prior vaccination was against hepatitis A and/or B; diphtheria; tetanus; pertussis; influenza; Haemophilus influenzae type b; polio; measles; mumps; rubella; varicella; human papillomavirus, Streptococcus pneumoniae, Neisseria meningitides or rotaviruses. The skilled person understands that the polypeptide employed in a prior vaccination could be administered in different forms, such as part of (i) subunit vaccine, (ii) inactivated or attenuated micro-organism, (iii) toxoid vaccine (i.e., vaccine comprising inactivated toxins), etc.
- In certain embodiments, a non-human antigenic polypeptide as described herein is a polypeptide selected from the group formed by VP3 from hepatitis A virus, including VP3 as identified in UniProtKB Acc. No. P08617, last modified: Aug. 1, 1988—v1; tetanus toxin from Clostridium tetani, including tetanus toxin as identified in UniProtKB Acc. No. P04958, last modified Jan. 23, 2007—v2; pertussis toxin from Bordetella pertussis, including pertussis toxin as identified in UniProtKB Acc. No. P04977, last modified: Aug. 13, 1987—v1; protein D from Haemophilus influenzae, including protein D as identified in UniprotKb Acc. No. R4R7Q5 (last modified: Jul. 24, 2013—v1); Vp1 capsid protein from poliovirus, including Vp1 capsid protein as identified in UniProtKB Acc. No. P03300, last modified: Jan. 23, 2007—v3; hemagglutinin from measles virus, including hemagglutinin as identified in UniProtKB Acc. No. P08362, last modified Aug. 1, 1988—v1; nucleoprotein from mumps virus, including nucleoprotein as identified in UniProtKB Acc. No. Q771S8, last modified: Jul. 5, 2004—v1; glycoprotein E1 or E2 from rubella virus, including glycoprotein E1 or E2 as identified in UniprotKb Acc. No. P08563, last modified: May 30, 2006—v2; immediate early 62 (1E62) protein from varicella zoster virus, including 1E62 protein as identified in UniprotKb Acc. No. P09310, last modified: Jul. 1, 1989—v1; E6 or E7 protein from HPV16 or HPV18, including E6 or E7 protein as identified in UniprotKb Acc. Nos. P03126 (last modified: Jul. 21, 1986-v1), P03129 (last modified: Jul. 21, 1986—v1), P06463 (last modified: Jan. 1, 1988—v1) or P06788 (last modified: Apr. 1, 1990—v2); Spr96/2021, PV7 (7-valent) and/or PV13 (13-valent), in some cases, derived from or based on Streptococcus pneumoniae; Neisseria heparin binding antigen (NHBA), factor H binding protein (fHbp) or Neisserial adhesin A (nadA) from Neisseria meningitides, including NHBA as identified in UniprotKb Acc. No. Q7WYZO (last modified: Oct. 1, 2003—v1), fHbp as identified in UniprotKb Acc. No. B2CQ00 (last modified May 20, 2008—v1) or nadA as identified in UniprotKb Acc. No. Q9K105 (last modified Oct. 1, 2000—v1); VP8 or VP6 from rotaviruses, including VP8 as identified in UniprotKb Acc. No. P12473 (last modified: Mar. 24, 2009—v2) or VP6 as identified in UniprotKb Acc. No. P04509 (last modified: May 30, 2000—v2); and diphtheria toxin from Corynebacterium diphtheria, including a detoxified variant thereof referred to as CRM-197. It is noted that when reference is made to polypeptides employed in a prior vaccination, also included in said terminology are detoxified and immunogenic variants or parts of said polypeptides. In certain embodiments, an antigenic polypeptide as described herein is a recall antigen. In certain embodiments, an antigenic polypeptide as described herein is a microbial recall antigen.
- In certain embodiments, the antigenic polypeptide chosen is matched with existing immunity (e.g., memory immunity in the form of memory T-cells and/or B-cells) in a subject, such that vaccination with such an antigenic polypeptide as immunogen, and tumor marking with such an antigenic polypeptide, taps into said pre-existing immunity (i.e., activates memory T-cells and/or B-cells to mount an immune response against said tumor). The skilled person can easily establish whether immunity against an antigenic polypeptide exists. In certain embodiments, the pre-existing immunity was generated prior to establishment of a tumor. In certain embodiments, the pre-existing immunity was generated early in life of the subject, e.g., at a time between the age of 0-20 years, at a time between the age of 1-12 or 1-6 years. In certain embodiments, the pre-existing immunity was generated at a time between the age of about 0-1 years, about 0-2 years, about 0-3 years, about 1-3 years, about 2-4 years, about 3-5 years, about 4-6 years, about 5-7 years, about 6-8 years, about 7-9 years, about 8-10 years, about 9-11 years, about 10-12 years, about 11-13 years, about 12-14 years, about 13-15 years, about 14-16 years, about 15-17 years, about 16-18 years, about 17-19 years, about 18-20 years, at a time before the age of 1, at a time before the age of 2, at a time before the age of 3, at a time before the age of 4, at a time before the age of 5, at a time before the age of 6, at a time before the age of 7, at a time before the age of 8, at a time before the age of 9, at a time before the age of 10, at a time before the age of 11, at a time before the age of 12, at a time before the age of 13, at a time before the age of 14, at a time before the age of 15, at a time before the age of 16, at a time before the age of 17, at a time before the age of 18, at a time before the age of 19, at a time before the age of 20, at a time before the age of 25, at a time before the age of 30, at a time before the age of 35, at a time before the age of 40, at a time before the age of 45, at a time before the age of 50, at a time before the age of 60, at a time before the age of 70, at a time before the age of 80, at a time before the age of 90, at a time before the age of 100, or at a time during the life of the subject.
- In order to capitalize on pre-existing immunity, in certain embodiments, dormant immune cells are reactivated by at least one immunization with an immunogenic composition as described herein.
- In certain embodiments, the antigenic polypeptide used in aspects of a method as described herein is not previously encountered by a subject as part of an immune response against a tumor, is (i) not (or rarely) encountered by a human subject as part of an immune response, or (ii) is encountered as part of an immune response, but not an immune response against a tumor, and wherein protective immunity is present in a subject.
- In certain embodiments, the antigenic polypeptide as described herein mounts an immune response in cancer patients, e.g., patients suffering from a tumor. In certain embodiments, the antigenic polypeptide mounts an immune response in at least 90% of the patients intended for potential vaccination using a method as described herein. For example, the antigenic polypeptide mounts an immune response in at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the patients intended for potential vaccination using a method as described herein. The immune response thus mounted in cancer patients can be a de novo response due to the fact that the patients' immune system has not previously encountered this immunogen.
- In certain exemplary embodiments, the antigenic polypeptide is a non-mammalian polypeptide, such as a microbial polypeptide, or a synthetic polypeptide. In certain exemplary embodiments, the antigenic polypeptide is selected from the group formed by keyhole limpet hemocyanin (KLH), green fluorescent protein (GFP) including enhanced green fluorescent protein (eGFP), luciferase, beta-galactosidase and a diphtheria toxin.
- The term “microbial polypeptide,” as used herein, refers to a polypeptide of a micro-organism, which includes bacteria, archaea, protists, fungi, unicellular plants and viruses.
- In certain embodiments, the antigenic polypeptide (e.g., non-human antigenic polypeptide) is a bacterial polypeptide, a polypeptide originating from an organism of the Archaea domain, a fungal polypeptide or a viral polypeptide. In certain embodiments, the antigenic polypeptide is a plant polypeptide. Also envisaged are a non-human mammalian polypeptide such as a polypeptide of a non-human primate, a rodent (e.g., mice and rats), a rabbit, a pig, a sheep, a goat, a cow, a horse and a donkey, a birds (e.g., a chicken, a turkey, a duck, a goose and the like). The antigenic polypeptide can also be a polypeptide of a snail or other mollusk, e.g., one of the genus of Megathura, or Megathura crenulata.
- In certain embodiments, antigenic polypeptides that are not mammalian polypeptides find certain use in a method as described herein, since non-mammalian antigenic polypeptides are more immunogenic than mammalian polypeptides when administered to a human subject. Examples of suitable non-mammalian antigenic polypeptides are for instance green fluorescent protein (GFP) including enhanced green fluorescent protein (eGFP), luciferase and beta-galactosidase.
- One example of an antigenic polypeptide is Keyhole Limpet Hemocyanin (KLH) of Megathura crenulata. KLH can be either KLH1 (amino acid sequence is provided in UniProtKB—Q53IP9, last modified: Feb. 19, 2014—v2) or KLH2 (amino acid sequence is provided in UniProtKB—Q1MVA1, last modified: May 30, 2006—v1). KLH is an example of a highly immunogenic antigen, which has been widely used as a universal immunogen and vaccine carrier.
- Another example of an antigenic polypeptide is a diphtheria toxin, which term includes detoxified variants thereof such as cross-reacting material (CRM)-197. In certain embodiments, the antigenic polypeptide (e.g., non-tumor antigen) is CRM197. In certain embodiments, diphtheria toxin has the amino acid sequence as indicated in SEQ ID NO:1. In certain embodiments, a detoxified variant of diphtheria toxin is CRM-197, which has the amino acid sequence as indicated in SEQ ID NO:1, except for glycine (G) at amino acid residue position 52 being substituted with glutamic acid (E). The term also includes variants of diphtheria toxin that have at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:1 or to a part of SEQ ID NO:1 having a continuous stretch of least 100, at least 200 or at least 300 amino acid residues. In certain embodiments, the continuous stretch is in—or is—the amino acid region indicated by positions 1-385 of SEQ ID NO:1. Alternatively, such variants include proteins having the amino acid sequence of SEQ ID NO:1, except that 1-50, 1-20, or 1-10, amino acid residues are deleted, inserted or substituted. Such variants may exhibit antigenicity and/or immunogenicity as described herein.
- The term “% sequence identity” is defined herein as the percentage of amino acids in an amino acid sequence that is identical with the amino acids in an amino acid sequence of interest, after aligning the sequences and optionally introducing gaps, if necessary, to achieve the maximum percent sequence identity. Methods and computer programs for alignments are well known in the art. Sequence identity is calculated over substantially the whole length, in some cases, the whole (full) length, of an amino acid sequence of interest. The skilled person understands that consecutive amino acid residues in one amino acid sequence are compared to consecutive amino acid residues in another amino acid sequence.
- In certain embodiments, in methods as described herein wherein diphtheria toxin is employed for intratumoral delivery of an antigenic polypeptide, the tumor is a tumor that expresses the HB-EGF receptor. In certain embodiments, a tumor that expresses the HB-EGF receptor is selected from the group consisting of an ovarian tumor; a lung tumor; a bladder tumor; a gastric tumor; a pancreatic tumor; a breast tumor; a liver tumor (e.g., hepatocellular carcinoma); a brain tumor (e.g., glioblastoma, astrocytoma, brain stem glioma, mixed glioma, oligodendroglioma, optic nerve glioma, and other tumors that originate in the brain, e.g., anaplastic astrocytoma, fibrillary astrocytoma, pilocytic astrocytoma); a neuroblastoma; a lymphoma including Hodgkin lymphoma or non-Hodgkin lymphoma, a histiocytic lymphoma or anaplastic large cell lymphoma; and a leukemia (e.g., AML, CML or ALL). In certain embodiments, the tumor that expresses the HB-EGF receptor is a malignant tumor selected from the group formed by ovarian cancer; lung cancer; bladder cancer; gastric cancer; pancreatic cancer; breast cancer; hepatocellular carcinoma; brain cancer (e.g., glioblastoma); neuroblastoma; lymphoma including Hodgkin lymphoma or non-Hodgkin lymphoma, histiocytic lymphoma or anaplastic large cell lymphoma; and leukemia, e.g., AML, CML or ALL.
- Also provided herein are nucleic acids encoding the antigenic polypeptide as described herein. In certain embodiments, a nucleic acid encoding CRM197 for use in a method as described herein, is provided.
- Amino acid sequences of proteins or polypeptides as described herein can be produced by methods and means generally available in the art. For instance, the person skilled in the art will understand how to generate a DNA sequence that encodes a fusion protein as described herein and how to manufacture and isolate a nucleic acid molecule with said DNA sequence using generally known recombinant DNA techniques. In certain embodiments, the sequence of the nucleic acid molecule is codon-optimized for expression in a host cell. In this way codons are used that are favored for high level expression in a specific host cell. In certain embodiments, nucleic acid molecules are inserted in an expression vector using recombinant DNA techniques known by the person skilled in the art. Expression vectors direct the expression of a fusion protein as described herein in a host cell. In certain embodiments, these expression vectors are replicable in a host cell, either as episomes or as part of the chromosomal DNA. Further, in certain embodiments, the expression vector comprises (i) a strong promoter/enhancer, such as the CMV or SV40 promoter, (ii) an optimal translation initiation sequence, such as a ribosomal binding site and start codon, and/or a KOZAK consensus sequence and (iii) a transcription termination sequence, including a poly(A) signal when the protein is expressed in eukaryotic cells. Suitable expression vectors include plasmids and viral vectors such as adenoviruses, adeno-associated viruses and retroviruses. The person skilled in the art will understand that the expression vector to be used is dependent on the host cell that is used for expression of a recombinant protein. In certain embodiments, an expression vector is suited for expression of a nucleic acid in a prokaryotic cell including a bacterial cell, or in a eukaryotic host cell, such as a yeast cell and a mammalian cell. A suitable example is mammalian expression vector pCMV4.
- As an alternative, a nucleic acid molecule may be inserted in the genome of a host cell. In certain embodiments, the insertion is at a locus or within a region that ensures expression of a nucleic acid molecule as described herein in the host cell.
- Suitable host cells include prokaryotic and eukaryotic cells, such as bacterial cells, yeast cells, insect cells, animal cells, mammalian cells, murine cells, rat cells, sheep cells, simian cells and human cells. Examples of suitable eukaryotic host cells include, but are not limited to HEK 293 cells, the hamster cell line CHO and BHK-21; the murine host cells NIH3T3, NSO and C127; the simian host cells COS and Vero; and the human host cells HeLa, PER.C6, U-937 and Hep G2. Suitable cells are available from public sources such as ATCC and Life Technologies. A number of transfection techniques are known in the art, see, e.g., Graham et al., 1973. Virology 52: 456; Green et al., 2012. “Molecular Cloning: A Laboratory Manual,” CSHL Press; Davis et al., “Basic Methods in Molecular Biology,” 1986, Elsevier; and Chu et al., 1981. Gene 13: 197, the disclosures of which are incorporated by reference herein in their entireties. The person skilled in the art may employ techniques as described in these references to introduce one or more exogenous nucleic acid molecules into suitable host cells. An example of a host cell for the production of a fusion protein as described herein is a HEK 293 cell.
- The antigenic polypeptide as described herein can also be a synthetic polypeptide, e.g., a synthetic polypeptide that is designed for eliciting a strong cellular immune response upon administration to a human subject.
- When the antigenic polypeptide is for administration as an immunogen, it may comprise a further polypeptide or conjugation partner so as to enhance elicitation of an immune response. Thus, said immunogen can be a fusion polypeptide comprising said antigenic polypeptide and for instance a carrier protein.
- Provided herein are methods for treating a tumor (e.g., a solid tumor) in a subject. Also provided are methods for generating an immune response against a tumor in a subject. Such methods comprise a vaccination step comprising distally administering a first composition, and a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition. Such methods comprise a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. The first composition and the second composition are described elsewhere herein.
- In certain embodiments, the vaccination step comprises administering the first composition to a site that is away from the tumor. In certain embodiments, the vaccination step comprises administering the first composition to a site distal to the tumor. In certain embodiments, distal administration of an immunogenic composition (e.g., a first composition) in a vaccination step as described herein is through the parenteral route, which includes intravenous, intra-arterial, subcutaneous, intradermal, intranodal, intralymphatic and intramuscular administration, which are all well known to the person skilled in the art. In certain embodiments, distal administration of an immunogenic composition (e.g., a first composition) described herein is delivered by a mode selected from the group consisting of intramuscular injection, subcutaneous injection, intravenous injection, intraarterial injection, intraperitoneal injection, intrasternal injection, intradermal injection, transcutaneous injection, transdermal injection, and delivery to the interstitial space of a tissue
- In certain embodiments, the vaccination step comprises administration of the first composition, wherein the administration is not intratumoral, but instead is extratumoral and is in some cases intramuscular, intradermal, intravenous, intranodal or intralymphatic, intradermal, intravenous or a combination thereof. In certain embodiments, the vaccination step comprising administering the first composition intramuscularly at a site distal to the tumor site.
- In certain embodiments, the vaccination step comprises distally administering the first composition at a site at least about 0.1 mm, at least about 0.2 mm, at least about 0.3 mm, at least about 0.4 mm, at least about 0.5 mm, at least about 0.6 mm, at least about 0.7 mm, at least about 0.8 mm, at least about 0.9 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, at least about 6 mm, at least about 7 mm, at least about 8 mm, at least about 9 mm, at least about 10 mm, at least about 15 mm, at least about 20 mm, at least about 25 mm, at least about 30 mm, at least about 35 mm, at least about 40 mm, at least about 45 mm, at least about 50 mm, at least about 60 mm, at least about 70 mm, at least about 80 mm, at least about 90 mm, at least about 10 cm, at least about 20 cm, at least about 30 cm, at least about 40 cm, at least about 50 cm, 50 cm or more away from the tumor (e.g., the edge of the tumor, or the center of the tumor). In certain embodiments, the vaccination step comprises administering a first composition to the subject at a site distal to a tumor site, therein the site distal to the tumor site is at least about 0.1 mm, at least about 0.2 mm, at least about 0.3 mm, at least about 0.4 mm, at least about 0.5 mm, at least about 0.6 mm, at least about 0.7 mm, at least about 0.8 mm, at least about 0.9 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, at least about 6 mm, at least about 7 mm, at least about 8 mm, at least about 9 mm, at least about 10 mm, at least about 15 mm, at least about 20 mm, at least about 25 mm, at least about 30 mm, at least about 35 mm, at least about 40 mm, at least about 45 mm, at least about 50 mm, at least about 60 mm, at least about 70 mm, at least about 80 mm, at least about 90 mm, at least about 10 cm, at least about 20 cm, at least about 30 cm, at least about 40 cm, at least about 50 cm, 50 cm or more away from the tumor (e.g., the edge of the tumor, or the center of the tumor).
- In certain embodiments, the vaccination step comprises distally administering the first composition at a site in an organ system that is different to the organ system in which the tumor resides. In certain embodiments, the vaccination step comprises administering a first composition into an organ system that is different than the organ system in which the tumor resides. For example, if the tumor resides at or in an ovary (e.g., an epithelial ovarian cancer), the vaccination step comprises distally administering the first composition at a site in an organ system that is not the ovary, e.g., the liver, kidney, etc. The term “organ” or “organ system” as used herein refers to a group of tissues with similar functions. Examples of organ systems include, without limitation, the muscular system, the digestive system (e.g., stomach, small intestine, large intestine, liver, pancreas, etc.), the respiratory system (e.g., lungs), the urinary system (e.g., kidneys, bladder, etc.), the reproductive organs (e.g., male and female reproductive system, ovaries, placenta, prostate, etc.), the endocrine system, the circulatory system, the nervous system (e.g., central and peripheral nervous systems), and the integumentary system (e.g., skin, subcutaneous tissue).
- In certain embodiments, the vaccination step comprises distally administering the first composition at a site contralateral to the tumor site. In certain embodiments, the vaccination comprises administering a first composition at a site contralateral to the tumor (a site in which the tumor resides). For example, if the tumor resides at or in an ovary, the vaccination step comprises distally administering the first composition at or in the contralateral ovary. For example, if the tumor resides at or in the left ovary, the vaccination step comprises distally administering the first composition to the right ovary. For example, if the tumor resides at or in an ovary, the vaccination step comprises administering a first composition at or in the contralateral ovary. For example, if the tumor resides at or in the left ovary, the vaccination step comprises administering a first composition to the right ovary.
- In certain embodiments, a method as described herein comprises one or more vaccination steps. In certain embodiments, a second, a third, a fourth, a fifth, a sixth, a seventh, or more vaccination steps are performed. The skilled artisan will recognize that any, if any, subsequent vaccination steps are performed, the subsequent vaccination steps are envisioned to incorporate any of the embodiments of a vaccination step described herein.
- In certain embodiments, the tumor-marking step comprises intratumorally or peri-tumorally administering the second composition. In certain embodiments, the tumor-marking step comprises administering a second composition to the subject at the tumor site. In certain embodiments, the tumor-marking step comprises administering a second composition into the tumor or proximal to the tumor. Accordingly, use of an antigenic polypeptide described herein prepared for intratumoral delivery as described herein, is provided.
- Also provided is a method for eliciting an immune response against a subject suffering from a tumor, comprising the steps of administering to a subject suffering from a tumor a pharmaceutically effective amount of an antigenic polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery; and administering to said subject a pharmaceutically effective amount of an immunogenic composition comprising said polypeptide as an immunogen, or comprising a nucleic acid encoding said immunogen, and optionally one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents. In certain embodiments, the (i) polypeptide/nucleic acid prepared for intratumoral delivery, (ii) the immunogenic composition, and (iii) the medical use as described herein.
- Such a method may further comprise the step of allowing an MHC peptide antigen complex to be produced from said polypeptide following intratumoral delivery of said polypeptide, or said nucleic acid encoding said polypeptide, prepared for intratumoral delivery.
- In certain embodiments, administration of the first composition and the second composition according to a method as described herein, elicits a T cell mediated immune response against the antigenic polypeptide or the MHC peptide antigen complex.
- Also provided herein is a method for treating a tumor in a subject in need, comprising: (1) a vaccination step comprising distally administering a first composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide. Accordingly, in certain embodiments, provided herein is a method for treating a tumor in a subject in need, comprising: (1) a vaccination step comprising distally administering a first composition comprising a non-tumor antigen or a nucleic acid encoding the non-tumor antigen, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. Also provided herein is a method for treating a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. Accordingly, in certain embodiments, provided herein is a method for treating a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- Also provided herein is a method for generating an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising distally administering a first composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide. Accordingly, in certain embodiments, provided herein is a method for generating an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising distally administering a first composition comprising a non-tumor antigen or a nucleic acid encoding the non-tumor antigen, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. Also provided herein is a method for generating an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. Accordingly, in certain embodiments, provided herein is a method for generating an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- Also provided is a method for eliciting or directing an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising distally administering a first composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising an antigenic polypeptide or a nucleic acid encoding the antigenic polypeptide. Accordingly, in certain embodiments, provided herein is a method for eliciting or directing an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising distally administering a first composition comprising a non-tumor antigen or a nucleic acid encoding the non-tumor antigen, wherein the administration is performed distal to the tumor site; and (2) a tumor-marking step comprising intratumorally or peri-tumorally administering a second composition comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. Also provided is a method for eliciting or directing an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen. Accordingly, in certain embodiments, provided herein is a method for eliciting or directing an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
- In certain embodiments, the antigenic polypeptide of a method as described herein is CRM197. Accordingly, also provided herein is a method for treating a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises CRM197 or a nucleic acid encoding CRM197; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises CRM197 or a nucleic acid encoding CRM197. Also provided herein is a method for generating an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises CRM197 or a nucleic acid encoding CRM197; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises CRM197 or a nucleic acid encoding CRM197. Also provided is a method for eliciting or directing an immune response against a tumor in a subject in need, comprising: (1) a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises CRM197 or a nucleic acid encoding CRM197; and (2) a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises CRM197 or a nucleic acid encoding CRM197.
- In certain embodiments, the vaccination step and the tumor-marking step are temporally separated. Accordingly, in certain embodiments, the vaccination step is performed prior to the tumor-marking step. In certain embodiments, the tumor-marking step is performed subsequent to the vaccination step. In certain embodiments, a certain time has elapsed after the vaccination step before the tumor-marking step is performed. In certain embodiments, the amount of time elapsed after the vaccination step is sufficient for the subject to mount an immune response to the antigenic polypeptide comprised within the administered first composition. In certain embodiments, the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step.
- For example, a primary immune response can be mounted as a result of the vaccination step. In the case of a primary immune response, it may take about 7 days to about 21 days to mount the primary immune response. In another example, a secondary immune response can be mounted as a result of the vaccination step, e.g., in response to an antigenic polypeptide for which the subject has pre-existing immunity against. In the case of a secondary immune response, it may take about 2 days to about 3 days to mount the secondary immune response. Accordingly, in certain embodiments, the time between the vaccination step and the tumor-marking step is from about 1 day to about 21 days, from about 1 day to about 22 days, from about 1 day to about 23 days, from about 1 day to about 24 days, from about 1 day to about 3 weeks, from about 1 day to about 4 weeks, from about 1 day to about 5 weeks, from about 1 day to about 10 weeks, from about 1 day to about 15 weeks, from about 1 day to about 20 weeks, from about 1 day to about 25 weeks, from about 1 day to about 30 weeks, from about 1 day to about 35 weeks, from about 1 day to about 40 weeks, from about 1 day to about 45 weeks, from about 1 day to about 50 weeks, from about 1 day to about 1 year, from about 1 day to about 2 years, from about 1 day to about 3 years, from about 1 day to about 4 years, from about 1 day to about 5 years, from about 1 day to about 10 years, from about 1 day to about 15 years, from about 1 day to about 20 years, from about 1 day to about 25 years, from about 1 day to about 30 years, from about 1 day to more than about 30 years, and any intervening amount of time thereof. In certain embodiments, the time between a vaccination step and the tumor-marking step is about 1 day to about 1 month, 14 days to about 2 months, 1 month to about 3 months, 2 months to about 5 months, 4 months to about 6 months, 5 months to about 7 months, 6 months to about 8 months, 7 months to about 9 months, 8 months to about 10 months, 9 months to about 11 months, 10 months to about 12 months, 11 months to about 13 months, 12 months to about 14 months, 13 months to about 15 months, 14 months to about 16 months, 15 months to about 17 months, 16 months to about 18 months, 17 months to about 19 months, 18 months to about 20 months, 19 months to about 21 months, 20 months to about 22 months, 21 months to about 23 months, 22 months to about 24 months, 3 months to about 1 year, 6 months to about 1 year, 1 year to about 2 years, 1.5 years to about 3 years, 2 years to about 3.5 years, 2.5 years to about 4 years, 3 years to about 4.5 years, 3.5 years to about 5 years, 4 years to about 5.5 years, 4.5 years to about 6 years, 5 years to about 6.5 years, 5.5 years to about 7 years, 6 years to about 7.5 years, 6.5 years to about 8 years, 7 years to about 8.5 years, 7.5 years to about 9 years, 8 years to about 9.5 years, 8.5 years to about 10 years, and any intervening range of time thereof.
- In certain embodiments, the time between the vaccination step and the tumor-marking step is about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks about 50 weeks, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 10 years, about 15 years, about 20 years, about 25 years, about 30 years, or more, and any intervening amount of time thereof. In certain embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days. In certain embodiments, the time between the vaccination step and the tumor-marking step is about 2 days to about 3 days. In certain embodiments, the time between the vaccination step and the tumor-marking step is about 7 days to about 21 days.
- The contents of the documents referred to throughout the present disclosure are each incorporated herein by reference in their entirety.
- For the purpose of clarity and a concise description, features are described herein as part of the same or separate aspects and embodiments thereof. For instance, embodiments relating to polypeptides may also apply to nucleic acids encoding such polypeptides, and vice versa. The same applies for instance to embodiments that relate to medical uses defined in product for use, use and method format. While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. It will be readily apparent to those skilled in the art that other suitable modifications and adaptations of the methods described herein may be made using suitable equivalents without departing from the scope of the embodiments disclosed herein. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. Having now described certain embodiments in detail, the same will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and are not intended to be limiting.
-
-
SEQ ID NO: 1: Diphtheria toxin GADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGI QKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNE NPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKE LGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPF AEGSSSVEYINNWEQAKALSVELEINFETRGKRGQ DAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIR DKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQ YLEEFHQTALEHPELSELKTVTGTNPVFAGANYAA WAVNVAQVIDSETADNLEKTTAALSILPGIGSVMG IADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGEL VDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHK TQPFLHDGYAVSWNTVEDSIIRTGFQGESGHDIKI TAENTPLPIAGVLLPTIPGKLDVNKSKTHISVNGR KIRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHVA FHRSSSEKIHSNEISSDSIGVLGYQKTVDHTKVNS KLSLFFEIKS SEQ ID NO: 2: Receptor-binding domain of diphtheria toxin (amino acids 385-535 of SEQ ID NO: 1) KTQPFLHDGYAVSWNTVEDSIIRTGFQGESGHDIK ITAENTPLPIAGVLLPTIPGKLDVNKSKTHISVNG RKIRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHV AFHRSSSEKIHSNEISSDSIGVLGYQKTVDHTKVN SKLSLFFEIKS SEQ ID NO: 3: Receptor-binding domain of diphtheria toxin (amino acids 387-535 of SEQ ID NO: 1) QPFLHDGYAVSWNTVEDSIIRTGFQGESGHDIKIT AENTPLPIAGVLLPTIPGKLDVNKSKTHISVNGRK IRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHVAF HRSSSEKIHSNEISSDSIGVLGYQKTVDHTKVNSK LSLFFEIKS - Generation of DCOne Mature Dendritic Cells (mDC)
- DCOne progenitors (as deposited with the DSMZ under accession number DSMZ ACC3189 on 15 Nov. 2012) were differentiated and matured according to the procedure described in WO2009019320 A2, the disclosure of which is incorporated by reference herein in its entirety. Cells were counted and phenotypic analysis of DCOne mDC cells was performed using flow cytometry (FACSVerse; BDBiosciences).
- OV90 ovarian cancer cell were cultured in medium199/MCDB105 medium (1:1) containing 15% FBS and 2% P/S) in an incubator at 37° C. with 5% CO2 OV90 cells were obtained from ATCC.
- Uptake by DCOne mDC was assessed for three different foreign antigens at a final concentration of 10 μg/mL for 4 hours and 24 hours during maturation. 750.000 cells were seeded into 6 well plates for each condition. The antigens used were CRM197-Alexa488, subunit KLH-FITC and β-galactosidase-FITC. CRM197-Alexa488 was purchased from Fina Biosolutions. Subunit KLH was purchased from Stellar Biotechnologies Inc. β-galactosidase was purchased from Roche. Subunit KLH and β-galactosidase were conjugated in-house to fluorochrome fluorescein isothiocyanate (FITC) using a FITC labelling kit according to manufacturer's protocol. Uptake of foreign antigens was assessed by flow cytometry. 0.08% Trypan blue was used to quench externally bound protein, to visualize only the internalized protein.
- Labelling of Tumor Cells with Foreign Antigens
- The labelling of OV90 ovarian cancer cells was assessed for three different foreign proteins at a final concentration of 10 μg/mL for 4 hours and 24 hours. 100.000 cells were seeded into 96 well plates for each condition. The proteins used were CRM197-Alexa488, Subunit KLH-FITC and β-galactosidase-FITC. Labelling of tumor cells in vitro was assessed by flow cytometry as mentioned above for DCOne mDC cells.
- Four-week-old immunodeficient female NOD/Shi-scid/IL-2Rynull immunodeficient mouse strain (NCG; Taconic) were engrafted with intravenous (IV) injection of 5e4 cord blood-derived CD34+ hematopoietic stem and progenitor cells (French Blood Bank) two days after chemical myeloablative treatment. Humanized mice were enhanced for dendritic cell populations with a GM-CSF/IL3/1L4 hydrodynamic boost and Flt3L recombinant protein. After 7 days mice were inoculated subcutaneously in the right flank with 1e6 U87-MG glioblastoma cells/mouse (Sigma Aldrich) for tumor engraftment. Approximately 15 days after tumor engraftment mice were randomised and divided into different vaccination groups including 5 mice per group. All mice received 1 intraperitoneal (i.p.) vaccination and one intratumoral (i.t.) injection marking the tumor.
- Mice received 100 μg KLH per i.p. injection or a 100 μl PBS i.p. injection, and were injected with 200.000 KLH-loaded DCOne mDCs i.t. or 100 μg KLH in 50 μl i.t. according to following schedule:
-
- Group 1 (PBS/KLH) received one i.p. PBS vaccination (on
day 1 after randomization), and one i.t. injection with KLH (on day 8 after randomization); - Group 2 (KLH/KLH) received one i.p. KLH vaccination (on
day 1 after randomization), and one i.t. injection with KLH (on day 8 after randomization); - Group 3 (PBS/KLH loaded DCOne) received one i.p. PBS vaccination (on
day 1 after randomization), and one i.t. injection with KLH loaded DCOne mDC (on day 8 after randomization); - Group 4 (KLH/KLH loaded DCOne) received one i.p. KLH vaccination (on
day 1 after randomization), and one i.t. injection with KLH loaded DCOne mDC (on day 8 after randomization).
- Group 1 (PBS/KLH) received one i.p. PBS vaccination (on
- Subunit KLH was purchased from Stellar Biotechnologies Inc. Tumor growth reduction and induction of immune responses were measured.
- After humanization with CD34+ stem cells and hydrodynamic boost with cytokines as described above, mice were inoculated subcutaneously in the right flank with 2e6 A375 melanoma cells/mouse (Sigma Aldrich) for tumor engraftment. Approximately 15 days after tumor engraftment mice were randomized and divided into different vaccination groups including 5 mice per group. The mice received two intraperitoneal (i.p.) vaccinations and thereafter one intratumoral (i.t.) injection for marking the tumor.
- Mice received 100 μg KLH in 100 μl per i.p. injection or a 100 μl PBS i.p. injection, and were injected with 200.000 KLH-loaded DCOne mDCs or 100 μg KLH in 50 μl i.t. according to the following schedule:
-
- Group 1 (PBS/KLH) received two i.p. PBS vaccinations (on
days 1 and 8 after randomization), and one i.t. injection with KLH (onday 15 after randomization); - Group 2 (KLH/KLH) received two i.p. KLH vaccinations (on
days 1 and 8 after randomization), and one i.t. injection with KLH (onday 15 after randomization); - Group 3 (PBS/KLH loaded DCOne) received two i.p. PBS vaccinations (on
days 1 and 8 after randomization), and one i.t. injection with KLH loaded DCOne mDC (onday 15 after randomization); - Group 4 (KLH/KLH loaded DCOne) received two i.p. KLH vaccinations (on
days 1 and 8 after randomization), and one i.t. injection with KLH loaded DCOne mDC (onday 15 after randomization).
- Group 1 (PBS/KLH) received two i.p. PBS vaccinations (on
- Subunit KLH was purchased from Stellar Biotechnologies Inc. Tumor growth reduction and vaccination induced immune responses were measured.
- DCOne mDC cells were loaded with fluorochrome-conjugated subunit KLH during maturation process for 4 hours and 24 hours as described in the material and methods section. The internalization of subunit KLH was analysed using flow cytometer. Trypan blue quenches the cell surface-bound antigen and was used to distinguish between surface-bound antigen and internalized antigen. The observed internalization of subunit KLH-FITC by DCOne mDC after 4 hrs was 54.6±8.8%, and 49.9±9.8% with trypan blue and after 24 hours 86.1±7.0%, and 81.7±8.0% with trypan blue indicating effective antigen uptake by DCOne mDC (
FIG. 1A ). - Labelling of OV90 Tumor Cells with Subunit KLH
- OV90 ovarian carcinoma cells were cultured with subunit KLH-FITC for 4 hours and 24 hours as described in the material and methods section. It was observed that 13.5±2.6%, labelling of OV90 for 4 hours of which 7.5±1.0% of cells with intracellular antigen as demonstrated by quenching of surface-bound subunit KLH-FITC signal with trypan blue, and after 24 hours 16.5±11.5% of OV90 cells were labelled with antigen with 9.5±3.8% of antigen inside the cells (
FIG. 1B ). - DCOne mDCs were incubated with β-galactosidase-FITC for 4 hrs and 24 hrs as described in the materials and methods section. The uptake of β-galactosidase-FITC was measured using flow cytometry in the absence or presence of trypan blue in order to distinguish between extracellularly bound and internalized β-galactosidase-FITC.
FIG. 2A depicts that after 4 hrs incubation 39.7±10.7% of DCOne mDC have internalized β-galactosidase-FITC as the trypan blue quenching hardly affected the signal (34.5±10.2%) indicating intracellular localization of β-galactosidase-FITC in DCOne mDC. The internalisation of β-galactosidase-FITC by DCOne mDC was increased after 24 hours i.e., 57.6±10.2%, and 49.9±13.0% with trypan blue indicating intracellular β-galactosidase-FITC. - The labelling of ovarian cancer cell line OV-90 with β-galactosidase-FITC after 4 hours and 24 hours was 11.3±8.9% (6.0±4.6% with trypan blue) and 10.4±4.2%, (6.5±3.6% with trypan blue) respectively showing both surface-bound and intracellular presence of β-galactosidase-FITC (
FIG. 2B ). - During the maturation process, DCOne mDC cells were cultured with CRM197-Alexa488 for 4 and 24 hours as described in the materials and methods section. After 4 and 24 hours uptake of antigen CRM-197 by DCOne mDCs were analysed using a flow cytometer in the presence and absence of trypan blue as mentioned in above sections. 90.6±5.4% and 99.4±0.1% of DCOne mDC were observed to have had efficiently internalized CRM-197 after 4 and 24 hours, respectively. Trypan blue quenching did not affect these results (87.6±8.0 and 99.5±0.2% respectively;
FIG. 7A ). - Labelling of OV90 Tumor Cells with CRM197
- The percentage of CRM197-Alexa488 uptake after 4 hours by OV90 tumor cells was 82.0±2.5%, and after 24 hours labelling increased up to 98.2±0.1% (
FIG. 3 ). The trypan blue quenching did not affect the signal indicating that CRM-197 is predominantly present inside the cell (72.7±11.9% and 97.6±1.4% with trypan blue after 4 and 24 hours respectively). - The in vitro data of uptake of foreign proteins by DCOne mDCs showed that DCOne mDCs were very efficient in internalizing foreign protein. All foreign proteins tested, CRM197, KLH and β-galactosidase were taken up very well by DCOne mDCs. DCOne cells can thus be used as a carrier for vaccination and/or intratumoral delivery of foreign proteins.
- The data of uptake of foreign proteins by ovarian cancer cells showed that ovarian cancer cells were more specific in internalizing foreign protein as compared to DCOne cells. CRM197 is taken up very efficiently by receptor-mediated endocytosis (Moya et al. J Cell Biol, 101(2):548-59 (1985), the disclosure of which is incorporated by reference herein in its entirety) in tumor cells due to presence of the specific HB-EGF receptor for diphtheria toxin/CRM197 as described in literature (e.g., Miyamoto et al. Cancer Sci, 97(5):341-7 (2006) the disclosure of which is incorporated by reference herein in its entirety), while uptake of KLH and β-galactosidase is lower. These findings show that a tumor can be marked by foreign proteins. This is especially the case for CRM197, which can therefore potentially be used as a carrier for tumor marking with other foreign protein coupled to CRM197.
- The U87-MG mice received one i.p. vaccination of either PBS or KLH and one i.t. injection to mark the tumor either with KLH or KLH-loaded DCOne mDCs. Tumor growth was monitored three times per week using a digital caliper (
FIG. 4A ). Tumor volumes (in mm3) were calculated according to the following formula: Volume=(width×length{circumflex over ( )}2)/2. At day 18, a slowed tumor growth was observed in vaccinated mice as compared to the mice injected with PBS, with i.t. injection of KLH-loaded DCOne having the strongest effect (FIG. 4B ). - The A375 melanoma mice received two i.p. vaccinations of either PBS or KLH and one i.t. injection to mark the tumor either with KLH or KLH-loaded DCOne mDCs. Tumor growth was monitored three times per week using a digital caliper (
FIG. 5A ). Tumor volumes (in mm3) were calculated according to the following formula: Volume=(width×length{circumflex over ( )}2)/2. As with the U87-MG mice, it was observed that the vaccinated group of mice had a slowed tumor growth compared to the groups injected with PBS (FIG. 5B ). This effect was strongest in the mice treated with KLH/KLH loaded DCOne. - These in vivo data in humanized mice show that vaccination followed by intratumoral injection (tumor marking) leads to slowed tumor growth in two separate solid tumor models, particularly when tumor marking was carried out using DCOne mDCs as a carrier. Although not statistically significant, the trend of slowed tumor growth was consistent in two separate solid tumor models.
- Possible antibody responses against KLH resulting from intratumoral injection and/or vaccination were quantified by ELISA (DO, D14 and sacrifice). In both U87-MG and A375 mice, no significant difference was observed regarding anti-KLH IgM concentration between treated groups and the PBS control group over time (
FIG. 6A -FIG. 6B ). However, it was surprisingly observed that mice from the KLH/KLH loaded DCOne group produced significantly more anti-KLH IgG than the PBS control group at sacrifice (FIG. 6C -FIG. 6D ). This indicates a T cell-dependent IgM to IgG switch (Geha et al., NEJM, 330:1008-1009 (1994) the disclosure of which is incorporated by reference herein in its entirety). - Generation of DCOne Mature Dendritic Cells (mDC)
- DCOne progenitor cells (as deposited with the DSMZ under accession number DSMZ ACC3189 on 15 Nov. 2012) were differentiated and matured according to the procedure described in PCT Publication No. WO 2009/019320, incorporated herein by reference in its entirety. Cells were counted and phenotypic analysis of DCOne mDC cells was performed using flow cytometry (FACSVerse; BDBiosciences).
- DCOne AML progenitor cells were cultured in MEMα containing 10% FBS and 2% P/S in an incubator at 37° C. with 5% CO2. OV90 ovarian cancer cells were cultured in medium199/MCDB105 medium (1:1) containing 15% FBS and 2% P/S in an incubator at 37° C. with 5% CO2. OV90 cells were obtained from ATCC. U87MG glioblastoma cancer cells were cultured in EMEM medium containing 10% FBS and 2% P/S in an incubator at 37° C. with 5% CO2. U87MG cells were obtained from Merck.
- Uptake by DCOne mDC cells was assessed for foreign antigen at a final concentration of 10 μg/mL for 4 hours and 24 hours during maturation. 750,000 cells were seeded into 6-well plates for each condition. The foreign antigen used was CRM197-Alexa488 (Fina Biosolutions). Uptake of foreign antigens was assessed by flow cytometry. 0.08% Trypan blue was used to quench externally bound protein, to visualize only the internalized protein.
- Labelling of Tumor Cells with Foreign Antigen CRM197
- The labelling of DCOne progenitor AML cells, OV90 ovarian cancer cells and U87MG glioblastoma cancer cells was assessed at a final concentration of 10 μg/mL for 4 hours and 24 hours. 100,000 cells were seeded into 96 well plates for each condition. The foreign antigen used was CRM197-Alexa488 (Fina Biosolutions). Labelling of tumor cells in vitro was assessed by flow cytometry as mentioned above for DCOne mDCs.
- NSGS were engrafted with intravenous (IV) injection of 5e4 cord blood-derived CD34+ hematopoietic stem and progenitor cells. Mice were inoculated subcutaneously with 5e6 OV90luc ovarian cancer cells expressing luciferase for tumor engraftment. Mice were randomized by tumor volume and divided into different vaccination groups including 5 mice per group. The average tumour size at start of vaccination was 80 mm3. All mice received 2 intraperitoneal (i.p.) vaccinations and one intratumoral (i.t.) injection marking the tumor.
- Mice received 50 μg CRM197 per i.p. injection or a PBS i.p. injection, and were injected with 25 μg CRM197 i.t. according to the following schedule:
-
- Group 1 (PBS/PBS) received two i.p. PBS vaccinations (
week week 4 after randomization). - Group 2 (PBS/CRM197) received two i.p. PBS vaccinations (
week week 4 after randomization). - Group 3 (CRM197/PBS) received two i.p. CRM197 vaccinations (
week week 4 after randomization). - Group 4 (CRM197/CRM197) received two i.p. CRM197 vaccinations (
week week 4 after randomization).
- Group 1 (PBS/PBS) received two i.p. PBS vaccinations (
- CRM197 was purchased from Fina Biosolutions. Tumor growth reduction (caliper measurement and BLI imaging) and induction of immune responses were measured.
- During the maturation process, DCOne mDC cells were cultured with CRM197-Alexa488 for 4 and 24 hours as described in the materials and methods section. After 4 and 24 hours uptake of antigen CRM-197 by DCOne mDC cells were analysed using a flow cytometer in the presence and absence of trypan blue as mentioned in above sections. 90.6±5.4% and 99.4±0.1% of DCOne mDC cells were observed to have had efficiently internalized CRM-197 after 4 and 24 hours, respectively. Trypan blue quenching did not affect these results (87.6±8.0% and 99.5±0.2% respectively;
FIG. 7A ). - Labelling of DCOne Progenitor Cells with CRM197
- The percentage of CRM197-Alexa488 uptake after 4 hours by DCOne progenitor cells was 94.2±3.3%, and after 24 hours labelling increased up to 99.5±0.8%. The trypan blue quenching did not affect the signal indicating that CRM197 is predominantly present inside the cell (90.7±7.3% and 98.8±1.7% with trypan blue after 4 and 24 hours respectively;
FIG. 7B ). - Labelling of OV90 Tumor Cells with CRM197
- The percentage of CRM197-Alexa488 uptake after 4 hours by OV90 tumor cells was 82.0±2.5%, and after 24 hours labelling increased up to 98.2±0.1%. The trypan blue quenching did not affect the signal indicating that CRM197 is predominantly present inside the cell (72.7±11.9% and 97.6±1.4% with trypan blue after 4 and 24 hours respectively;
FIG. 7C ). - Labelling of U87MG Tumor Cells with CRM197
- The percentage of CRM197-Alexa488 uptake after 4 hours by U87MG tumor cells was 95.3±2.6%, and after 24 hours labelling increased up to 99.4±0.4%. The trypan blue quenching did not affect the signal indicating that CRM197 is predominantly present inside the cell (93.9±4.2% and 98.8±0.7% with trypan blue after 4 and 24 hours respectively;
FIG. 7D ). - Tumor growth was monitored by weekly calliper measurements and optical imaging from the beginning of treatment. The OV90luc mice received two i.p. vaccinations of either PBS or CRM197 and one i.t. injection to mark the tumor either with PBS or CRM197. Tumor growth was monitored per week using a digital caliper. Tumor volumes (in mm3) were calculated by the ellipsoid formula (L×W×H)π/6.
- No difference in tumor volume was found in CRM197 vaccinated mice as compared to the mice injected with PBS (
FIG. 8A ). Bioluminescence data showed that CRM197 vaccinated mice followed by i.t. injection of CRM197 exhibited a significantly lower bioluminescence intensity (FIG. 8B andFIG. 9 ). This is indicative of a significant growth arrest of OV90 ovarian cancer cells in this CRM197 vaccinated/CRM197 i.t. group. - These in vivo data in humanized mice show that CRM197 vaccination followed by intratumoral injection (tumor marking) of CRM197 leads to cancer cell growth arrest.
- CRM197 is used to study a tumor antigen-independent prime-boost strategy using CRM197 as a tumor-independent antigen in a humanized tumor mouse model. Goals of this study are: optimization of a vaccination protocol; repetition of an earlier experiment using an optimal mouse model for robust tumor regression; and assessment of tumors using immunohistochemistry for immune activation at the tumor site.
- Intraperitoneal vaccination:
- (week −1, pre-engraftment;
week 1, post-engraftment) - I. Vaccination with saline (6 mice).
- II. Vaccination with saline (6 mice).
- III. Vaccination with CRM197 (6 mice).
- IV. Vaccination with CRM197 (6 mice).
- Intratumoral Injection:
- (
week 3 post-engraftment) - I. Intra-tumoral vaccination with saline (6 mice).
- II. Intra-tumoral vaccination with CRM197 (6 mice).
- III. Intra-tumoral vaccination with saline (6 mice).
- IV. Intra-tumoral vaccination with CRM197 (6 mice).
- The studies are performed in mice with an HB-EGF-expressing tumor using the U87MG glioblastoma cell line. The clinical readout is tumor regression/clearance and survival. Immunohistochemistry of the tumors is assessed to determine tumor infiltration of immune cells. A serum analysis is performed to detect anti-CRM antibodies. The vaccination dose is 50 μg CRM197/mouse. The intratumoral dose is 25 μg CRM197/mouse.
-
TABLE 1 Tabular overview of the CRM197 experiment Tumor Intratumoral # of engraftment Vaccination (i.p.) injection Group mice Week 0 Week − 1&1 Week 3 #1 6 U87MG Saline Saline # 2 6 U87MG Saline CRM197 # 3 6 U87MG CRM197 Saline # 4 6 U87MG CRM197 CRM197
Claims (33)
1. A method for generating an immune response against a tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and
a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen,
wherein the time between the vaccination step and the tumor-marking step is between about one day and about 6 months.
2. The method of claim 1 , optionally wherein:
the method further comprises one or more booster steps each comprising administering a booster composition to the subject, wherein the booster composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen, optionally wherein the one or more booster steps occur prior to the tumor-marking step;
the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor;
the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue;
the vaccination step comprises administering the first composition into an organ system that is different than the organ system in which the tumor resides, or the vaccination step comprises administering the first composition at a site contralateral to the tumor;
the tumor is a solid tumor, optionally wherein the solid tumor is glioblastoma or ovarian cancer;
the first composition comprises a dendritic cell comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen, optionally wherein the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell, optionally wherein the mature dendritic cell is derived from DCOne;
the second composition is prepared for intratumoral administration;
the second composition comprises a dendritic cell comprising the non-tumor antigen or a nucleic acid encoding the non-tumor antigen, optionally wherein the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell, optionally wherein the mature dendritic cell is derived from DCOne;
the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents;
the subject is a non-tumor antigen-naïve subject, or wherein the subject has previously been exposed to the non-tumor antigen, optionally wherein the subject has previously mounted an immune response against the non-tumor antigen; and/or
the subject is a human, or the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
3-5. (canceled)
6. The method of claim 1 , wherein the vaccination step comprises intradermally administering the first composition, optionally wherein the first composition is prepared for intradermal injection, optionally wherein the first composition comprises a diluent or solvent acceptable for intradermal injection.
7-8. (canceled)
9. The method of claim 1 , wherein the vaccination step comprises intramuscularly administering the first composition, optionally wherein the first composition is prepared for intramuscular injection, optionally wherein the first composition comprises a diluent or solvent acceptable for intramuscular injection.
10-13. (canceled)
14. The method of claim 1 , wherein the vaccination step is performed subsequent to the tumor-marking step, or wherein the tumor-marking step is performed subsequent to the vaccination step, optionally wherein:
the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step; and/or
the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
15-23. (canceled)
24. The method of claim 1 , wherein the second composition comprises a tumor targeting component, optionally wherein:
the tumor targeting component is a tumor-specific virus, optionally wherein the tumor-specific virus is an oncolytic virus, optionally wherein the tumor-specific virus comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen; or
the tumor targeting component is a tumor-specific nanoparticle, optionally wherein the tumor-specific nanoparticle comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
25-38. (canceled)
39. A method for generating an immune response against a tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a non-tumor recall antigen or a nucleic acid encoding the non-tumor recall antigen; and
a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises the recall antigen or a nucleic acid encoding the recall antigen.
40. The method of claim 39 , optionally wherein:
the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor;
the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue;
the vaccination step comprises administering the first composition into an organ system that is different than the organ system in which the tumor resides, or the vaccination step comprises administering the first composition at a site contralateral to the tumor;
the tumor is a solid tumor, optionally wherein the solid tumor is glioblastoma or ovarian cancer;
the first composition comprises a dendritic cell comprising the recall antigen or a nucleic acid encoding the recall antigen, optionally wherein the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell, optionally wherein the mature dendritic cell is derived from DCOne;
the second composition is prepared for intratumoral administration;
the second composition comprises a dendritic cell comprising the recall antigen or a nucleic acid encoding the recall antigen, optionally wherein the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell, optionally wherein the mature dendritic cell is derived from DCOne
the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents;
the subject has previously been exposed to the recall antigen, optionally wherein the subject has previously mounted an immune response against the recall antigen; and/or
the subject is a human, or the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
41. (canceled)
42. The method of claim 40 , wherein the vaccination step comprises intradermally administering the first composition, optionally wherein the first composition is prepared for intradermal injection, optionally wherein the first composition comprises a diluent or solvent acceptable for intradermal injection.
43-44. (canceled)
45. The method of claim 40 , wherein the vaccination step comprises intramuscularly administering the first composition, optionally wherein the first composition is prepared for intramuscular injection, optionally wherein the first composition comprises a diluent or solvent acceptable for intramuscular injection.
46-49. (canceled)
50. The method of claim 39 , wherein the vaccination step and the tumor-marking step are temporally separated, wherein the vaccination step is performed subsequent to the tumor-marking step, or the tumor-marking step is performed subsequent to the vaccination step,
optionally wherein the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step,
optionally wherein the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
51-60. (canceled)
61. The method of claim 39 , wherein the second composition comprises a tumor targeting component, optionally wherein:
the tumor targeting component is a tumor-specific virus, optionally wherein the tumor-specific virus is an oncolytic virus, optionally wherein the tumor-specific virus comprises the recall antigen or a nucleic acid encoding the recall antigen;
the tumor targeting component is a tumor-specific nanoparticle, optionally wherein the tumor-specific nanoparticle comprises the recall antigen or a nucleic acid encoding the recall antigen.
62-74. (canceled)
75. A method for generating an immune response against a tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof; and
a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof.
76. The method of claim 75 , optionally wherein:
the method further comprises one or more booster steps each comprising administering a booster composition to the subject, wherein the booster composition comprises the diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof, optionally wherein the one or more booster steps occur prior to the tumor-marking step;
the diphtheria toxin or detoxified variant thereof is CRM197;
the tumor marking-step comprises administering the second composition into the tumor or proximal to the tumor;
the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue;
the vaccination step comprises administering the first composition into an organ system that is different to the organ system in which the tumor resides;
the vaccination step comprises administering the first composition at a site contralateral to the tumor;
the tumor is a solid tumor, optionally wherein the solid tumor is glioblastoma or ovarian cancer;
the first composition comprises a dendritic cell comprising CRM197 or a nucleic acid encoding CRM197, optionally wherein the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell, optionally wherein the mature dendritic cell is derived from DCOne;
the second composition is prepared for intratumoral administration;
the second composition comprises a dendritic cell comprising CRM197 or a nucleic acid encoding CRM197, optionally wherein the dendritic cell is a CD34-positive, CD1a-positive, and CD83-positive mature dendritic cell, optionally wherein the mature dendritic cell is derived from DCOne;
the first and second compositions each optionally comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents; and/or
the subject is a human or the subject is a domesticated animal and/or an animal suitable for veterinary healthcare.
77-80. (canceled)
81. The method of claim 75 , wherein the vaccination step comprises intradermally administering the first composition, optionally wherein the first composition is prepared for intradermal injection, optionally wherein the first composition comprises a diluent or solvent acceptable for intradermal injection.
82-83. (canceled)
84. The method of claim 75 , wherein the vaccination step comprises intramuscularly administering the first composition, optionally wherein the first composition is prepared for intramuscular injection, optionally wherein the first composition comprises a diluent or solvent acceptable for intramuscular injection.
85-88. (canceled)
89. The method of claim 75 , wherein the vaccination step and the tumor-marking step are temporally separated, optionally wherein the vaccination step is performed subsequent to the tumor-marking step, or wherein the tumor-marking step is performed subsequent to the vaccination step,
optionally wherein the time between the vaccination step and the tumor-marking step is sufficient for an immune response to be mounted as a result of the vaccination step,
optionally wherein the time between the vaccination step and the tumor-marking step is about 2 days to about 21 days.
90-99. (canceled)
100. The method of claim 75 , wherein the second composition comprises a tumor targeting component, optionally wherein:
the tumor targeting component is a tumor-specific virus, optionally wherein the tumor-specific virus is an oncolytic virus, optionally wherein the tumor-specific virus comprises CRM197 or a nucleic acid encoding CRM197; or
the tumor targeting component is a tumor-specific nanoparticle, optionally wherein the tumor-specific nanoparticle comprises CRM197 or a nucleic acid encoding CRM197.
101-115. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/342,893 US20210401961A1 (en) | 2019-04-25 | 2021-06-09 | Methods of tumor vaccination |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19170999.7 | 2019-04-25 | ||
EP19170999 | 2019-04-25 | ||
PCT/NL2019/050451 WO2020017962A1 (en) | 2018-07-16 | 2019-07-16 | A combination product for use in tumor vaccination. |
NLPCT/NL19/50451 | 2019-07-16 | ||
US202062961554P | 2020-01-15 | 2020-01-15 | |
US16/857,851 US11052144B2 (en) | 2019-04-25 | 2020-04-24 | Methods of tumor vaccination |
US17/342,893 US20210401961A1 (en) | 2019-04-25 | 2021-06-09 | Methods of tumor vaccination |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/857,851 Continuation US11052144B2 (en) | 2019-04-25 | 2020-04-24 | Methods of tumor vaccination |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210401961A1 true US20210401961A1 (en) | 2021-12-30 |
Family
ID=72941340
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/857,851 Active US11052144B2 (en) | 2019-04-25 | 2020-04-24 | Methods of tumor vaccination |
US17/342,893 Pending US20210401961A1 (en) | 2019-04-25 | 2021-06-09 | Methods of tumor vaccination |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/857,851 Active US11052144B2 (en) | 2019-04-25 | 2020-04-24 | Methods of tumor vaccination |
Country Status (6)
Country | Link |
---|---|
US (2) | US11052144B2 (en) |
EP (1) | EP3958894A1 (en) |
JP (1) | JP2022530044A (en) |
AU (1) | AU2020264083A1 (en) |
CA (1) | CA3133410A1 (en) |
WO (1) | WO2020217226A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3664830A4 (en) | 2017-08-07 | 2020-07-01 | The Regents of the University of California | Platform for generating safe cell therapeutics |
GB201919316D0 (en) * | 2019-12-24 | 2020-02-05 | Queens Univ Of Belfast | Polymeric nanoparticles for enhanced cancer treatment |
US20220168407A1 (en) * | 2020-11-05 | 2022-06-02 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
CN116723854A (en) * | 2021-01-22 | 2023-09-08 | 门德斯有限公司 | Tumor vaccination method |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO180167C (en) | 1994-09-08 | 1997-02-26 | Photocure As | Photochemical method for introducing molecules into the cytosol of cells |
US5667786A (en) | 1995-06-07 | 1997-09-16 | Novavax, Inc. | Method for treating tumors with a toxin |
GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
US6398748B1 (en) | 1999-03-16 | 2002-06-04 | Robert B. Wilson | Splint bandage and method |
WO2001018636A1 (en) | 1999-09-09 | 2001-03-15 | American Express Travel Related Services Company, Inc. | System and method for authenticating a web page |
WO2001049317A2 (en) | 2000-01-05 | 2001-07-12 | Aventis Pasteur Limited | Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen |
US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
KR101180548B1 (en) | 2000-11-29 | 2012-09-06 | 피씨아이 바이오테크 에이에스 | Photochemical Internalization for Virus-Mediated Molecule Delivery into the Cytosol |
KR100980153B1 (en) | 2000-11-29 | 2010-09-03 | 피씨아이 바이오테크 에이에스 | Photochemical Internalization for Delivery of Molecules into the Cytosol |
ES2399386T3 (en) | 2001-04-05 | 2013-04-01 | Novartis Vaccines And Diagnostics, Inc. | Increased mucosal immunity after parenteral sensitization |
GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
US20040057935A1 (en) | 2002-09-20 | 2004-03-25 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
JP2006232761A (en) | 2005-02-25 | 2006-09-07 | Osaka Univ | Anticancer agent |
CA2610281C (en) | 2005-06-21 | 2014-07-29 | The Research Foundation For Microbial Diseases Of Osaka University | Therapeutic agent for cancer |
DK2201100T3 (en) | 2007-09-14 | 2016-05-30 | Univ Bruxelles | IMPROVING THE T-CELL STIMULATING ABILITY OF HUMAN antigen presenting cells AND USE THEREOF IN THE VACCINATION |
US20110110979A1 (en) | 2008-04-16 | 2011-05-12 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
CA2724018C (en) | 2008-05-19 | 2017-01-10 | Dcprime B.V. | Method for inducing and accelerating cells |
GB0914286D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Method |
WO2012031175A2 (en) | 2010-09-02 | 2012-03-08 | The Scripps Research Institute | Nanoparticle-based tumor-targeted drug delivery |
GB201106357D0 (en) | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
NL2009102C2 (en) | 2012-07-02 | 2014-01-06 | Dcprime B V | Method for dc-loading. |
EP2743344A1 (en) | 2012-12-11 | 2014-06-18 | DCPrime B.V. | Therapeutic cancer vaccines derived from a novel dendritic cell line |
US20160000842A1 (en) | 2013-03-05 | 2016-01-07 | Baylor College Of Medicine | Oncolytic virus |
US9974848B2 (en) * | 2013-11-14 | 2018-05-22 | Duke University | Tetanus toxoid and CCL3 improve DC vaccines |
KR20190090775A (en) | 2016-07-21 | 2019-08-02 | 백4올 피티이 리미티드 | Biofusion Proteins as Anti-malaria Vaccines |
EP3823668A1 (en) | 2018-07-16 | 2021-05-26 | DCPrime B.V. | A combination product for use in tumor vaccination |
-
2020
- 2020-04-24 CA CA3133410A patent/CA3133410A1/en active Pending
- 2020-04-24 WO PCT/IB2020/053898 patent/WO2020217226A1/en unknown
- 2020-04-24 EP EP20721813.2A patent/EP3958894A1/en active Pending
- 2020-04-24 AU AU2020264083A patent/AU2020264083A1/en active Pending
- 2020-04-24 JP JP2021562977A patent/JP2022530044A/en active Pending
- 2020-04-24 US US16/857,851 patent/US11052144B2/en active Active
-
2021
- 2021-06-09 US US17/342,893 patent/US20210401961A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020217226A1 (en) | 2020-10-29 |
AU2020264083A1 (en) | 2021-12-02 |
CA3133410A1 (en) | 2020-10-29 |
US11052144B2 (en) | 2021-07-06 |
US20200390876A1 (en) | 2020-12-17 |
JP2022530044A (en) | 2022-06-27 |
EP3958894A1 (en) | 2022-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11052144B2 (en) | Methods of tumor vaccination | |
US11071778B2 (en) | Combination product for use in tumor vaccination | |
JP6903120B2 (en) | Compositions and Methods for Alpha Virus Vaccination | |
RU2631002C2 (en) | Fusion proteins for application as immunogenic amplifying agents to induce antigen-specific t-cell response | |
EA035378B1 (en) | Virus-like particle with efficient epitope display | |
ES2748381T3 (en) | CYAA-borne polypeptide (s) and use to induce prophylactic and therapeutic immune responses | |
JP2016502507A (en) | Compositions and methods for cancer treatment | |
US11560408B2 (en) | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | |
Xu et al. | A DNA-launched nanoparticle vaccine elicits CD8+ T-cell immunity to promote in vivo tumor control | |
KR20140048119A (en) | Dna vaccine | |
Lee et al. | mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization | |
WO2022115471A1 (en) | Vaccination by heterologous boost immunization | |
KR20220103944A (en) | PEGylated kynureninase enzymes and their use for the treatment of cancer | |
KR102654464B1 (en) | Novel vaccine platform based on Reovirus and the use thereof | |
AU2021385555B2 (en) | Dna vaccine for human palillomavirus and method for using the same | |
WO2020260947A1 (en) | Stabilized chimeric synthetic proteins and therapeutic uses thereof | |
EP1257654A1 (en) | M cell directed vaccines | |
Zeng et al. | Soluble Proteins Induce Strong CD8+ T Cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: MENDUS B.V., NETHERLANDS Free format text: CHANGE OF NAME;ASSIGNOR:DCPRIME B.V.;REEL/FRAME:063663/0906 Effective date: 20220623 |